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  In recent years, hydrogen sulfide (H2S) has garnered interest as the third addition 
to the gasotransmitter family. Essential to human physiology, H2S has roles in the 
cardiovascular, nervous, and respiratory systems and perturbations in physiological H2S 
levels have been correlated to a variety of diseases. As a result, there has been significant 
interest in the development of H2S-releasing compounds (H2S donors) that can mimic 
slow, enzymatic production for research and therapeutic applications. While a large 
library of H2S donors exists, several common drawbacks persist, such as: lack of spatial 
and temporal control, poorly understood mechanisms of release, uncontrolled kinetics, 
and low efficiency. These issues significantly limit the biological applications of many 
H2S donors.  
     This dissertation describes recent work to provide biocompatible H2S donors 
with controllable release kinetics using a robust, novel strategy for H2S delivery that 
relies on rapid enzymatic hydrolysis of carbonyl sulfide (COS) to H2S by the ubiquitous 
mammalian enzyme carbonic anhydrase (CA). Self-immolative thiocarbamates can be 
designed to release COS by a variety of stimuli, and in biological milieu this COS is 
rapidly converted to H2S by CA. This strategy has enabled the development of the first 
analyte-replacement fluorescent probe for H2S and has become a popular strategy for H2S 
	 v 
delivery in a variety of applications. Additionally, the unexpected cytotoxicity profile of 
enzyme-activated COS/H2S donors has piqued interest in COS chemical biology, and 
these donors are being used as tools for studying COS itself.  This dissertation includes 
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EMERGING ROLES OF CARBONYL SULFIDE (COS) IN CHEMICAL 
BIOLOGY: SULFIDE TRANSPORTER OR GASOTRANSMITTER? 
 
This chapter includes previously published and coauthored material from Steiger, A.K.; 
Zhao, Y.; Pluth, M.D. “Emerging Roles of Carbonyl Sulfide (COS) in Chemical Biology: 




Small gaseous biomolecules, such as nitric oxide (NO), carbon monoxide (CO), 
and hydrogen sulfide (H2S), have attracted significant attention due to their important 
physiological roles as signaling molecules.1-10 Often referred to as gasotransmitters, these 
gases share several defining characteristics: they are membrane permeable, are generated 
endogenously by enzymes, and exert action on molecular targets at physiologically-
relevant concentrations.11, 12 We note that although commonly referred to as gaseous 
signaling molecules or gasotransmitters, these small gaseous molecules are actually 
solutes rather than gases when they act as signaling agents. In this dissertation, we use the 
terms gaseous signaling molecules and gasotransmitters to refer to the class of molecules 
rather than the physical state of the molecules in a biological environment. Highlighting 
the broad importance of these signaling molecules, gasotransmitter generation and/or 
metabolism has been implicated in diverse biological processes including vascular 
biology, immune functions, metabolism, and stress resistance/response.2, 6, 13-19 In 
addition to the primary gasotransmitter criteria, recent and growing evidence supports a 
complex cross-talk and interconnectivity between NO, CO, and H2S, suggesting that the 
interactions between these molecules play an important role in gasotransmitter 
function.20-25 For example, H2S inhibits CO production through regulation of heme 
oxygenase 1 (HO-1)26, 27 and can either stimulate or inhibit different nitric oxide synthase 
(NOS) isoforms.15-19 Similarly, both NO and CO inhibit H2S production from heme-
containing cystathionine β-synthase (CBS).28, 29 Complementing regulatory interactions 
	 2 
through enzymatic synthesis, NO and H2S also react through different redox pathways to 
generate reactive sulfur, nitrogen, and oxygen species (RSONS), including thionitrous 
acid (HSNO), perthionitrite (SSNO–), and nitroxyl (HNO), which further intertwine these 
gasotransmitters.22-24, 30, 31  
Despite the significant research on the chemical biology of NO, CO, and H2S, 
investigations into other potential gasotransmitters, such as SO2, NH3, or COS, remain 
significantly underdeveloped (Figure 1.1).11, 32 Both sulfur dioxide (SO2) and ammonia 
(NH3) are produced enzymatically in mammalian cells and are interconnected with 
established gasotransmitters, giving credence to the suggestion that they may play 
significant roles in biology. For example, SO2 can be generated from H2S by NADPH 
oxidase or from thiosulfate (S2O32–) by thiosulfate sulfurtransferase.33, 34 Alternatively, 
cysteine oxidation by cysteine dioxygenase (CDO) generates cysteine sulfonate, and 
subsequent transamination by aspartate aminotransferase (AAT) generates β-
sulfinylpyruvate, which spontaneously decomposes to extrude pyruvate and SO2.35, 36 
Although still in its infancy, investigations into the possible biological actions of SO2 
have demonstrated roles as a vasorelaxant and also in providing protection against 
myocardial ischemia-reperfusion injury.34 Additionally, NH3 is formed in many 
pathways, including deamination of amino acids, nucleic acids, nucleotides, and 
nucleosides, as a byproduct of transsulfuration enzymes, including H2S-producing CSE 
and CBS, and from urea recycling.11 Once formed, NH3 may not only provide a viable 
form of nitrogen for DNA and RNA synthesis but also may contribute to acid-base 
buffering capacity. Additionally, NH3 has been demonstrated to increase inducible nitric 
oxide synthase (iNOS) expression in cultured astrocytes 37 and also to increase iNOS and 
neuronal nitric oxide synthase (nNOS) expression in animal models of 
hyperammonenemia.38 
Unlike SO2 or NH3, pathways for enzymatic COS synthesis in mammals have yet 
to be identified, although COS has been detected in various biological tissues and in 
exhaled breath, supporting the presence of pathways for endogenous generation (vide 
infra).39-41 Furthermore, COS shares an interconnection with H2S generation through the 
action of different metalloenzymes, including carbonic anhydrase (CA) activity, which 
rapidly converts COS to H2S.42-44 Although historical investigations on terrestrial COS  
	 3 
 
Figure 1.1 Structures, space filling models, and electrostatic potential maps of NO, CO, 
H2S, NH3, SO2, and COS.   
 
have focused on its atmospheric presence and importance in the global sulfur cycle, 
contemporary chemical investigations have focused primarily on COS-mediated peptide-
bond formation under prebiotic conditions, many of which suggest important roles of 
COS in origin of life chemical ligation.45, 46 When taken together with the potential role 
of  COS in thermophilic origin of life theories, COS detection in tissues, as well as its cell 
permeability and moderate water solubility, suggest that COS may play a much more 
significant role in mammalian chemical biology than initially appreciated. Building on 
these factors, this review focuses on current knowledge on biological COS formation and 
consumption, growing evidence that COS may play roles in sulfide transport and disease 
pathology, emerging chemical tools for investigating COS in biological contexts, and the 
potential role of COS as a new member of the gasotransmitter family.  
 
1.2 Basic Properties  
Carbonyl sulfide (COS, CAS 463-58-1; also referred to carbon oxysulfide, carbon 
monoxide monosulfide, carbon oxide sulfide, OCS) is a colorless and odorless gas in its 
pure form.47 Initially misidentified as a mixture of carbon dioxide (CO2) and H2S due to 
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its rotten egg smell in an impure state, COS was first characterized by Than in 1867 by 
the reaction of CO with elemental sulfur vapor in a glowing porcelain tube (eq. 1).48 
Although removal of CO impurities was not practical from the initial preparations, 
experimental modification allowed for generation and purification of COS by acid-
mediated hydrolysis of thiocyanate salts (eq. 2).48 This reaction can be used to prepare 
COS in the laboratory, but the produced gas requires significant purification due to 
common contamination by gaseous impurities.49 Commercial sources of high purity COS 
(often >97.5%) often contain significant levels of H2S as the main impurity. Although 
only moderately soluble in water, COS is stable in acidic solution but undergoes base-
mediated hydrolysis to generate H2S and CO2.47 As a moderately lipophilic gas (log 
Poct(COS) = 0.79 by comparison to log Poct(NO) =0.70),50 the dipole moment of COS is 
more similar to that of NO, CO, and H2S rather than the significantly more polar SO2 and 
NH3. These properties suggest a sufficient lipid solubility to enable cell membrane 
permeability and also penetration to the central nervous system. Basic properties of COS, 
as well as those of H2S, NO, CO, SO2, and NH3 are provided in Table 1.1. 
 
CO + S  →  COS     (eq 1) 
 
KSCN + 2 H2SO4 + H2O  →  COS + KHSO4 + NH4HSO4  (eq 2) 
 
Table 1.1 Basic physical properties of COS and other biologically-relevant gaseous 
molecules receiving attention as confirmed or potential gasotransmitters. 
Physical property COS H2S NO CO SO2 NH3 
Molecular weight (g/mol) 60.08 34.08 30.01 28.01 64.06 17.03 
Density (g/mL) 1.028 1.36 1.34 1.14 2.63 0.769 
Melting point (°C) -138.8 -82 -164 -205.0 -72 -77.8 
Boiling point (°C) -50.2 -60 -152 -191.5 -10 -33.3 
Dipole moment (D) 0.65 0.97 0 0.12 1.62 1.42 
Solubility (H2O, mol/L, 25 
°C)  




1.2.1 Toxicity and Safety 
Much like H2S, NO, and CO, COS is a flammable gas that is toxic in high 
concentrations. COS is a skin, eye, nose, throat, and lung irritant, matching many of the 
topical toxicity characteristics of H2S. These similarities are likely due to the hydrolysis 
of COS to form H2S upon contact with different mucosal membranes, which typically 
contain CA thus facilitating H2S generation (vide infra). Similarly, in toxicological 
investigations of COS, treatment of rats with the CA inhibitor acetazolamide (AAA) 
reduces measured blood levels of H2S, and also the toxicity of COS, suggesting that at 
least some of the observed COS toxicity is due to CA-mediated metabolism to H2S.42, 51 
Although specific hazardous concentrations of COS are not specified by the US 
Environmental Protection Agency (EPA), different reports have documented irritation in 
the upper respiratory tract at concentrations above 20 mg/L.52 Low to moderate 
concentrations are accepted to elicit lachrymatory effects, photophobia, nausea, increased 
salivation, headache, mental confusion, as well as other characteristics.52 Higher COS 
concentrations can result in decreased vision, tachycardia, and collapse, and continuous 
exposure to COS concentrations of 0.1% (v/v) can result in death within two hours due to 
respiratory paralysis. A limited number of animal studies have investigated acute or 
chronic COS toxicity, but toxicological investigations of 50 ppm levels of COS in rabbits 
for up to 7 weeks did not impact the myocardial ultrastructure significantly.53 Similarly, 
toxicological investigations in rats revealed LC50 of over 2000 mg/m3 with further 
investigations classifying COS as a non-carcinogenic, low-toxicity fumigant.54  
 
1.2.2 Natural Sources 
 COS is the most prevalent sulfur-containing gas in Earth’s atmosphere and is 
produced by both biological and chemical pathways (Figure 1.2).52, 55 Primary abiotic 
COS emissions occur from volcanos, hot springs, and oceans, with biotic sources 
stemming from soils, trees, marshes, plant roots, manure, microorganisms, and biomass 
burning (see section 3 for more detailed information).56 Up to one half of terrestrial COS 
is generated from secondary production in the global sulfur cycle through oxidation of 
atmospheric dimethyl sulfide (Me2S) and carbon disulfide (CS2).56 Anthropogenic 
sources of COS, which include aluminum production, coal and automobile fuel burning, 
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and industrial desulfurization, contribute minimally to global COS production, but more 
recent estimates indicate that industry and manufacturing may produce more COS than 
has been previously reported.57 Measurement of atmospheric COS levels from Antarctic 
ice cores have shown that COS levels have risen over the last 350 years, which has been 
attributed to human sources of industrialization.58 Once produced, COS is more stable in 
the atmosphere than the common sulfur-containing gases Me2S, H2S, and CS2, which 
results in a prolonged atmospheric lifetime of about four years.59 As a result, COS is 
generally transported from the troposphere to the stratosphere, where it undergoes 
photodissociation and oxidation to SO2 and sulfate particles, therefore influencing 
stratospheric ozone concentrations.52, 60 The long atmospheric lifetime, as well as its 
formation from CS2 in the atmosphere, make COS the primary sulfur gas in Earth’s 
atmosphere, with measured concentrations of 0.5 ppb.56  
 
 
Figure 1.2 Simplified overview highlighting the roles of COS in the global sulfur cycle. 
Primary COS emission sources include volcanoes and hot springs, biomass, and open 
ocean emission. Approximately one half of atmospheric COS is generated from the 
oxidation of Me2S and CS2 in the global sulfur cycle. Primary anthropogenic sources 
include aluminum production, coal and automobile fuel burning, and industrial 
desulfurization. Once produced, COS has a longer atmospheric lifetime than Me2S, H2S, 
or CS2 and is typically transported to the stratosphere, where it undergoes 
photodissociation and oxidation to SO2 and sulfate particles. COS uptake also occurs in 
plants, soils, marine algae, and microbes, which often convert COS to CO2.   
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Although oxidation of COS to sulfate occurs in the atmosphere by hydroxyl 
radical, the major sink of atmospheric COS is uptake by many plants, soils, marine algae, 
and microbes, which often convert COS to CO2. This conversion is typically mediated by 
the ubiquitous enzyme CA as well as other COS-metabolism enzymes (vide infra). In 
addition to COS metabolism by CA, some plants are able to convert COS to CS2, as 
demonstrated by increased CS2 release after COS absorption by moist soils.61 These 
observations suggest a link between CS2 and COS not only in the atmosphere, but also in 
soils and vegetation.  
 
1.3 Biological Roles of COS 
Growing evidence supports the importance of reactive sulfur species in biology, 
but surprisingly little attention has focused on the most-prevalent sulfur-containing gas in 
Earth’s atmosphere: COS. Reported investigations into the biological roles of COS 
remain sporadic and our understanding of the potential roles physiological and 
pharmacological roles of COS remain underdeveloped. Despite these limited reports, 
enzymatic COS production and consumption is well documented, and COS generation in 
cell culture and in exhaled breath in human subjects suggests a broader role for this 
important gas in diverse biological processes.  
 
1.3.1 Enzymatic Consumption of COS 
Carbonic anhydrases (CAs) are a family of ubiquitous metalloenzymes that 
catalyzes the reversible hydration of CO2 to bicarbonate (HCO3–).62, 63 CAs are comprised 
of five classes found primarily in vertebrates (α-CAs), higher plants and some 
prokaryotes (β-CAs), archaebacteria (γ-CAs), and diatoms (δ-CAs and ξ-CAs). Although 
not its natural substrate, CA is also able to readily hydrolyze COS to H2S, providing a 
broad enzymatic platform for redox-neutral conversion of COS to H2S. The catalytic 
efficiency (kcat/KM) of CA-mediated COS conversion to H2S is less efficient than the 
canonical CO2 metabolism (~8 x 107 M-1 s-1),64 but still boasts a high catalytic efficiency 
of 2.2 x 104 M-1s-1 for bovine CA-II (Table 1.2).65 Drawing parallels to CA, other 
enzymes are also able to catalyze the hydrolysis of COS even though it is not their natural 
substrate. For example CS2 hydrolase, nitrogenase, CO dehydrogenase, and ribulose-1,5-
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bisphosphate carboxylase oxygenase (RuBisCO), have all been reported to hydrolyze 
COS.66-69 Of these enzymes, CS2 hydrolase, initially isolated from acidophilic and 
thermophilic archaea extremophiles66 exhibits the greatest catalytic efficiency of 
enzymatic COS hydrolysis (Table 1.2). Because the distribution of this enzyme is limited 
to extreme and sulfur-rich environments, such as sulfotaras, it is unlikely that CS2 
hydrolase contributes significantly to global COS consumption. The only known example 
of an enzyme for which COS is the natural substrate is carbonyl sulfide hydrolase 
(COSase), which was recently identified, purified from T thioparus strain THI115, and 
characterized.70, 71 COSase shares both a high sequence homology and shares a similar 
Zn(II) active site with the β-CAs and are structurally similar to enzymes in clade D of the 
β-CA phylogenetic tree.70 Importantly, COSase has a higher efficiency than widely-
distributed enzymes able to catalyze COS hydrolysis, suggesting that it may play an 
important role in the global consumption of atmospheric COS. Although less efficient 
than COSase, other metalloenzymes, such as CO dehydrogenase,68  RuBisCO,69 and 
nitrogenase 67 have been shown to metabolize COS in plants and bacteria with varied 
levels of catalytic efficiency (Table 1.2).  
 
Table 1.2 COS degrading enzymes and associated enzyme kinetic parameters. Modified 
from reference 70.70 







CS2 hydrolase Acidianus sp. Strain A1-3 1800 22 8.2 x 107 66 
COSase T thioparus strain THI115 58 60 9.6 x 105 70 
CO dehydrogenase Rhodospirillum rubrum  
ATCC11170T 
0.52 2.2 2.4 x 105 68 
CA Bos taurus 41 1.9 x 103 2.2 x 104 65 
RuBisCO Spinacia oleracea 3.8 1.8 x 103 2.2 x 103 69 
RuBisCO Rhodospirillum rubrum   6.3 5.6 x 103 1.1 x 103 69 
Nitrogenase Azotobacter vinelandii 0.16 3.1 x 103 5.2 x 101 67 
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1.3.2 Biological Production of COS 
Thiocyanate (SCN–) is a common organic anion found in plants, mammals, and 
natural environments. In plants, SCN– is formed from the hydrolysis of glucosinolates, 
often found in Cruciferae (Brassicaceae) by glucosidases.72 In mammals, SCN– is 
commonly found in saliva, blood, and milk, and derives from ingestion of glucosinolates, 
often derived from broccoli, cauliflower, and other cruciferous vegetables, as well as 
from cyanide (CN–) detoxification by the ubiquitous enzyme rhodanese.73 Although 
mammalian thiocyanate degradation primarily occurs through peroxidation by 
myeloperoxidase and lactoperoxidase,74 at a microbial level, a number of 
chemoorganotrophic bacteria are able to degrade SCN– as a source of nitrogen and sulfur. 
Furthermore, chemolithoautotrophic sulfur bacteria, such as Thiobacillus thioparus, have 
been identified that utilize SCN– as their primary energy source.75 More specifically, the 
enzyme thiocyanate hydrolase (SCNase), which catalyzes the hydrolysis of SCN– to COS 
and NH3 (eq. 3), was initially isolated and identified in T. thioparus strain THI115.76 
SCNase consists of three subunits (α (19 kDa), β (23 kDa), and γ (32 kDa)), which share 
a high sequence homology to bacterial nitrile hydratases, and maintains an unusual 
distorted square pyramidal low-spin Co(III) active site.77 Thiocyanate hydrolase has also 
been identified as the primary enzyme for initiating SCN– hydrolysis in the sulfur-
oxidizing bacterium Thiohalophilus thiocyanoxidans.78  
 
SCN– + 2 H2O  →  COS + NH3 + OH–   (eq 3) 
 
In addition to SCNase, COS can also be formed from archaeal CS2 hydrolase, 
which converts CS2 to H2S and CO2, but proceeds through intermediate generation of 
COS.66 CS2 hydrolase, isolated from Acidianus A1-3, which is a hyperthermophilic 
Archaea that lives in volcanic solfataras, has a structure that is similar to typical β-CAs, 
but does not hydrolyze CO2. Instead, this enzyme has evolved a highly hydrophobic 
tunnel that serves as a filter by blocking the entrance of CO2 into the active site, which is 
otherwise identical to that of CA.79 Similarly, in mammalian systems, CS2 can be 
metabolized to COS by the mixed-function oxidase enzyme system. Liver damage, as 
well as a measureable decrease in the concentration of cytochrome P450, is observed 
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when rats are treated with CS2.80-82 This damage has been attributed to the binding of 
reactive sulfur species that are released during the hydrolysis of CS2 to COS. Once 
released, the COS is further metabolized to H2S, most likely by hepatic CA. 
Alternatively, COS can function as a suicide substrate for cytochrome P450, generating 
CO2 but also reactive sulfur species that react with and inhibit the P450.81 
 
1.3.3 Abiotic COS generation 
In addition to enzymatic COS generation, abiotic COS production of has also 
been demonstrated. Because much of the COS in the atmosphere derives from open 
waters, a number of studies have investigated possible mechanisms of COS formation, 
such as the reaction of carbonyl groups of dissolved organic compounds with thiyl 
radicals.83 Interestingly, and possibly of more direct biological relevance, is the direct 
reaction of polysulfides with CO to generate COS.84 Inorganic polysulfides play an 
important role in the global sulfur cycle and such polysulfides, as well as their organic 
counterparts, are now understood to be of increasing importance in the biological action 
of H2S.85-89 By using inorganic polysulfides and CO, both of which are abundant in 
aquatic systems, mechanistic investigations revealed that the rate of COS generation had 
a first-order dependence in both CO and the molar sum of polysulfide species in 
solution.84 Although further investigations are needed to determine whether the reaction 
kinetics, pH, and temperature dependence make such mechanisms of COS formation 
viable under physiological conditions, these observations highlighted the interconnected 
role of COS with CO and polysulfides. 
 
1.3.4 COS Detection in Mammalian Systems  
Although the precise mechanisms of COS biosynthesis in eukaryotes remain 
unknown, two primary pathways for COS genesis have been postulated in investigations 
of COS in the body: metabolism (or impaired metabolism) of sulfur containing 
precursors, and direct generation by cohabitating bacteria. COS has also been detected as 
a metabolite of different sulfur-containing drugs, supporting that abnormal metabolism of 
sulfur-containing compounds may, in part, contribute to COS generation. One simple 
example of such is disulfiram (tetraethylthiuram disulfide), which functions as an 
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acetaldehyde dehydrogenase inhibitor and is commonly used for treatment of chronic 
alcoholism.50 Reduction of the dithiocarbamate disulfide in disulfuram, followed by 
partial hydrolysis to form diethylthiocarbamate, may provide a path for COS extrusion, 
although it is also possible that initial CS2 release generates COS as a metabolic 
byproduct. Additionally, metabolism of the commonly-used dithiocarbamate pesticides 
has also been demonstrated to release COS. Although such systems provide convenient 
examples of COS in biological contexts, the high concentrations of such sulfur-
containing molecules significantly simplifies COS detection. By contrast, detection of 
endogenous COS remains significantly more challenging. These challenges arise 
primarily from the likely low levels of COS as well as the efficient metabolism of COS 
by CA to form H2S, which has so far necessitated detection of COS from only gaseous 
biological samples or from the headspace of samples, where COS can be isolated outside 
of a CA-rich environment. Despite these challenges, observation of COS in mammalian 
cell culture, ex vivo tissues, and exhaled breath has provided compelling evidence for the 
importance of COS in biology and implications for COS involvement in various 
pathologies. 
One strategy for COS detection is to monitor the gas content of the headspace 
over cell culture or ex vivo tissues. One benefit of this approach is that analysis of the 
headspace is readily accessible through standard GC-MS techniques or by various 
spectroscopic techniques.90 In one such example, headspace analysis of porcine coronary 
artery (PCA) and cardiac muscle tissue in vitro demonstrated COS formation by GC-MS 
analysis.41 In addition, COS was found to induce arterial dilation. Moreover, stimulation 
of PCA with acetylcholine and calcium ionophore A23187 resulted in increased COS 
levels, suggesting that muscarinic acetylcholine receptors (mAChRs), which have already 
been shown to be involved in production of CO, NO, and H2S leading to 
vasorelaxation,91-96 may also be involved in COS genesis. Although a simple example, 
these experiments may suggest a promising starting point for future COS investigations.  
In addition to detection of COS in the headspace of tissue culture experiments, 
COS has also been detected in exhaled breath, providing evidence for the role of COS as 
a potential gaseous biomarker for various disease states. For example, investigations into 
the presence of sulfur gases in patients with cystic fibrosis (CF) revealed measurable 
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differences between COS levels in inhaled and exhaled breath.39 As a whole, CF patients 
had a reduced uptake of atmospheric COS by comparison with healthy patients. 
Furthermore, CF patients with reduced pulmonary function exhibited greater COS levels 
in exhaled breath than normal patients, with a strong inverse correlation between COS 
concentration and all four indices of pulmonary function in CF patients, with no 
correlation observed in normal patients. Prior research has also demonstrated an inverse 
correlation between pulmonary function and respiratory bacterial load,97-99 which when 
taken together, provide support for the hypothesis that cohabitating bacteria may play an 
important role in biological COS generation. Consistent with this hypothesis, recent 
studies have reported that CA distribution and activity may be altered in CF patients,100-
102 suggesting a lower potential for COS metabolism. One hypothesis, which is consistent 
with the experimental data, is that impairment of CA function/expression in CF patients 
may reduce COS metabolism in the lungs which, when coupled with increased bacterial 
load and COS production in the respiratory tract, may result in higher COS levels 
observed in exhaled gas. On the basis of these observations, these studies suggest that 
exhaled COS may provide a potential non-invasive biomarker for bacterial colonization 
of the respiratory tract of CF patients.  
Furthering the potential role of COS as a biomarker for lung pathologies in 
exhaled breath, COS has also been investigated as a potential marker of acute rejection 
(AR) after organ transplant. AR after lung allograft is a major risk factor for bronchiolitis 
obliterans (BO), which is one of the primary causes of death in lung transplant patients. 
Early detection and diagnosis of AR typically requires routine biopsies, which are 
invasive and associated with pulmonary complications. In a study investigating the 
efficacy of non-invasive breath testing for AR monitoring, comparisons between healthy, 
non-rejection patients and AR patients did not provide significant differences in exhaled 
ethane, isoprene, acetone, or H2S, all compounds that are potential organ transplant 
related biomarkers. Only exhaled COS levels were demonstrated to provide a biomarker 
for AR, with elevated COS levels observed for AR patients by contrast to non-rejection 
patients. Furthermore, individual patient tracking documented examples of COS levels 
increasing with worsening AR and decreasing with AR resolution. Although the direct 
COS origin was not identified, the authors hypothesized that abnormal metabolism of 
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sulfur-containing compounds in AR patients may be responsible for the observed 
increase in exhaled COS. 
In addition to direct lung pathologies, COS levels in exhaled breath have also 
been characterized in various stages of liver disease.40 When compared to patients with 
normal liver function, patients with hepatocellular injury (grouped to include: alcoholic 
cirrhosis, autoimmune cirrhosis, cryptogenic cirrhosis, fulminant hepatitis, hepatitis B, 
hepatitis C, 1-antitrypsin deficiency, and steatohepatitis) exhibited elevated COS levels in 
exhaled breath. Additionally, COS, but not CS2 or Me2S, was found to correlate with the 
severity of disease, resulting in increasing COS levels in early, mid, and end stage liver 
disease, potentially providing a diagnostic tool for early detection. By contrast, patients 
with bile duct injury diseases (grouped to include: cystic fibrosis, primary biliary 
cirrhosis, sclerosing cholangitis, and biliary obstruction) exhibited reduced COS levels in 
exhaled breath. These human studies are consistent with previous observations in isolated 
rat hepatocytes and liver microsomes, which have been observed to generate COS, 
possibly from CS2 metabolism or metabolism of other sulfur-containing compounds.51 
These data are also consistent with previous experiments where COS has been observed 
in exhaled breath of rats exposed to CS2, suggesting that the observed COS may be due to 
metabolism of CS2 or, by analogy, the incomplete metabolism of other sulfur-containing 
compounds.80  
The above examples provide key demonstrations of COS generation from 
metabolic abnormalities or bacterial colonization associated with disease, but also 
provide compelling evidence for the necessity of further exploration into potential 
metabolic pathways of COS in biology. Although mammalian COS production from 
natural sources remains poorly understood, one possible route for COS synthesis is SCN– 
hydrolysis by SCNase, although the presence of this enzyme has yet to be reported in 
mammals. Given that COS has been detected in biological samples, particularly in non-
diseased tissues, elucidation of possible enzymatic pathways for COS production remains 
an important area of investigation. Importantly, these studies additionally suggest a key 
role of bacterial colonization in COS generation in mammalian systems. In the cases of 
exhaled breath analysis, a distinct interplay between the host, mammalian tissues, and 
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bacterial colonization not only suggests a complex landscape in COS generation, but also 
may provide access to a convenient method of detection for a variety of disease states. 
 
1.4 COS Chemistry 
The most simple reactions of COS, including hydrolysis, oxidation, reduction, and 
dissociation, have been known for many years and are the main subject of a thorough 
COS review published in 1957.47 Since then, COS chemistry has expanded to address 
environmental concerns associated with COS contaminants in industrial settings, and 
catalysts for the low temperature rapid hydrolysis of COS have been developed. 
Although the most basic chemical reactions are well researched, more complex and 
biologically-relevant COS-related reactions remain less understood, even though 
contemporary investigations suggest important biological roles for COS stemming from 
initial thermophilic origin of life chemistry.  
 
1.4.1 Simple Reactions of COS 
Shortly after the initial synthesis of COS, early reactivity studies demonstrated 
that COS reacts with primary amines (1), such as excess aniline to generate diphenylurea 
and H2S.48 In such reactions, COS initially reacts with the amine to generate a stable, 
often isolable monothiocarbamate (2), which subsequently extrudes HS– to furnish an 
electrophilic isocyanate (3). In the presence of excess amine, the isocyanate intermediate 
is trapped by the amine to generate the urea product (4) (Figure 1.3). By tuning the 
reaction conditions, the generated isocyanate can also react with other nucleophiles, such 
as thiols, to furnish thiocarbamate esters (5). Although challenging to control the reaction 
conditions and stoichiometries on laboratory scale syntheses, these reactions are 
commonly used industrially in the manufacture ureas and thiocarbamates for use as 
herbicides and pesticides. Because COS is also known to a be a sulfur contaminant in 
natural gas and hydrocarbon streams, the chemistry detailed above can be utilized for 
COS removal through the addition of primary amines during the purification process.103 
	 15 
 
Figure 1.3 Amines react reversibly with COS to generate thiocarbamates, which can 
release H2S to afford electrophilic isocyanates. These isocyanates can be trapped in 
synthetically-useful reactions to generate ureas and thiocarbamate esters.  
 
1.4.2 Implications in Origins of Life and Prebiotic Bond Formation 
In addition to the role of COS in laboratory scale and industrial syntheses, 
contemporary investigations have focused on the potential role of COS in nascent bond-
forming reactions under prebiotic conditions. Perhaps unsurprisingly, the volcanic and 
geothermal generation of COS, as well as its bond forming potential with simple 
nucleophiles, appears consistent with the thermophilic origin of life requirements. Much 
of this work stems from studies by Hirschmann and co-workers in 1971 focused on 
peptide formation from 2,5-thiazolidinediones, in which a footnote comments that traces 
of dipeptides were formed from phenylalanine thiocarbamate– a known reaction product 
of amines with COS.104  
Over 30 years later, more detailed investigations into origin of life peptide 
synthesis were performed by mimicking volcanic or hydrothermal environments. Using 
prebiotic building blocks such as CO, nickel and iron sulfides ((Ni,Fe)S), and a reducing 
atmosphere of H2S or CH3SH at elevated temperatures (Figure 1.4a), amino acids (6) 
combined successfully to form dipeptides (7). Amino acid chirality was lost, however, 
likely due to the presence of metal sulfides that may promote racemization of the 
stereocenter of the anhydride intermediate under the harsh conditions investigated. Trace 
amounts of COS were detected during the course of the dipeptide-forming reactions, 
which was consistent with a proposed mechanistic explanation that involved COS as a 
key intermediate required to generate the thioanhydride (9) prior to dipeptide (10) 
formation (Figure 1.4b). Supporting the necessity of COS in these reactions, dipeptides 
were still formed if CO and H2S were replaced with COS, although removal of (Ni,Fe)S 
abolished dipeptide formation. Highlighting the feasibility of metal-mediated formation 
of COS, a recent report demonstrated the ability of Mo(II) complexes to function as pre-
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Figure 1.4 (a) Hydrothermal generation of dipeptides in the presence of (Ni,Fe)S, 
H2S/MeSH, and CO. (b) The proposed mechanism for this conversion generates COS as 
a key intermediate.   
 
Furthering investigations into the role of COS in primordial amino acid chemistry, 
an elegant study by Ghadiri and co-workers demonstrated that COS can facilitate the 
direct formation of small peptides from amino acids in water under mild conditions in the 
absence of metal sulfides (Figure 1.5).46 Remarkably, even the simplest conditions, such 
as addition of excess COS gas to an aqueous buffered solution of phenylalanine resulted 
in 7% dipeptide formation after 2 days at 25 ºC. Further investigations revealed 
quantitative formation of thiocarbamate (8) upon addition of COS to a pH 8.9 buffered 
solution. Importantly, this intermediate showed good hydrolytic stability, and studies 
using analytically pure phenylalanine thiocarbamate showed it to be a competent 
intermediate in the peptide bond formation. Such reactions are proposed to occur through 
formation of a cyclic N-carboxyanhydride (Leuchs’ anhydride, 11), which functions as a 
versatile platform for subsequent reactions with different nucleophiles. Formation of this 
anhydride, however, requires extrusion of HS– from the thiocarbamate intermediate, 
which is hindered both by the stability of the thiocarbamate intermediate as well as by the 
poor leaving group ability of hydrosulfide anion. In further optimization of peptide bond 
formation, significant rate enhancements were observed in the presence of metal ions, 
oxidizing agents, and electrophilic alkylating agents, suggesting that such species (or 
Lewis acids in general) may facilitate decomposition of the monothiocarbamate 
intermediate and subsequent H2S release. 
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In addition to simple peptide forming reactions, the activation of amino acids by 
COS has been demonstrated to be a more general pathway to biologically-relevant 
peptide functionalization. For example, under mild aqueous conditions, COS facilitates 
the formation of aminoacyl phosphates (13) from amino acids and inorganic phosphate. 
Under identical conditions, no aminoacyl phosphates are observed in the absence of COS. 
Similarly, when inorganic phosphate is replaced with adenylic acid (5’-AMP), several 
amino acids produced aminoacyl adenylates (15), which are important for protein 
biosynthesis. Furthermore, in the presence of Ca(II) and an amino acid, COS was also 
found to facilitate pyrophosphate (14) formation through intermediate generation of an 
aminoacyl-phosphate anhydride. Combined with the above evidence that COS mediates 
peptide formation, this work suggests that both prebiotic peptide synthesis and  
 
 
Figure 1.5 Prebiotic chemistry mediated directly by COS including formation of 
peptides, aminoacyl phosphates, and inorganic phosphates. Each pathway proceeds 
through COS-mediated formation of thiocarbamate 8, followed by sulfide extrusion to 
generate electrophilic intermediate 11 (Leuchs’ anhydride), which functions as a versatile 
platform for subsequent reactions with different biologically-relevant nucleophiles.  
 
phosphoryl transfer reactions might have relied on a common, COS-activated 
precursor.106  
Although the atmospheric levels of COS are unlikely to generate suitable 
concentrations of the required thiocarbamate intermediates to facilitate efficient peptide 
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coupling under global prebiotic conditions, the higher temperatures and COS levels near 
geothermal locales of COS generation could likely facilitate access to the reaction 
manifolds associated with these important prebiotic bond forming reactions. More 
importantly, these studies set the stage for establishing the potential role of COS in 
biologically-relevant reactions and intermediate generation, paving the way for future 
applications of COS chemistry. 
 
1.5 Emerging Tools for COS Investigations 
Both chemical and biological tools are needed to expand our understanding of the 
potential roles of COS in biology. Because direct knockout, overexpression, and blockage 
of the enzymes associated with production of the currently identified gasotransmitters 
have proven essential in studying the chemical biology of these gases, the definitive 
identification of COS-producing enzymes or pathways will be equally important. Prior to 
such information, downregulation of biological COS will remain a significant challenge. 
In the interim, one potential strategy to increase COS bioavailability is to shunt pathways 
associated with COS metabolism. For example, because of the wide distribution of CA 
and its high activity toward COS hydrolysis, the use of CA inhibitors and/or enzymatic 
knockout could potentially be used to increase COS accumulation. Inhibition of CA by 
small molecules is a well-researched field,107-112 and a variety of methods are available 
for strong inhibition of a variety of CA isoforms. Unfortunately, such inhibition studies 
would also alter the normal CO2 / HCO3– equilibrium, and thus normal buffering 
capacities and cellular pH levels, likely leading to complicating effects. Additionally, 
even small changes in pH would also alter the distribution of H2S and HS–, likely leading 
to confounding results.  
Prior to insights gleaned from such investigations, the development of small 
molecule chemical tools for COS research may offer an attractive platform for expanding 
our understanding of COS in biology. Chemical tools for detection and delivery of the 
canonical gasotransmitters NO, CO, and H2S have been invaluable for investigating the 
multifaceted roles of these important biological molecules,113-130 suggesting that similar 
constructs may find utility for COS investigations. Reaction-based fluorescent probe 
development for COS is likely to remain a significant challenge based on the inherent 
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reactivity of COS. Because COS is a weaker electrophile than CO2, strategies to intercept 
COS by nucleophilic trapping are likely to be plagued by unwanted side reactivity 
leading to significant selectivity challenges. By contrast to reaction-based detection 
motifs, small molecules that release COS may offer a more attractive first line of tools for 
investigating COS in different biological contexts.  
 
1.5.1 General Strategies to Develop COS Donors.  
Because of the structural similarities between COS and CO2, many 
decarboxylation reactions can be engineered to release COS rather than CO2 by simple 
replacement of an oxygen atom with a sulfur in the parent scaffold. This basic design 
concept enables structurally-diverse COS donors that provide access to both triggered- / 
active-release donors, such as those that respond to specific biological or biorthogonal 
stimuli, as well as slow- / passive-release donors, such as those activated by hydrolysis or 
reaction with ubiquitous cellular enzymes and nucleophiles. Additionally, easily-
accessible control compounds are available through synthesis of analogous carbamate 
compounds, which release CO2 rather than COS. Access to such control compounds are 
instrumental in differentiating the biological effects of the donor scaffolds themselves 
from the released COS. Recognizing the potential powerful utility of engineered COS 
release, our lab was the first to harness such motifs to develop COS-releasing small 
molecules.131 Since this initial report, we have been delighted that other researchers are 
using related strategies to broaden the palette of COS-releasing motifs available for future 
biological investigations.  
The key breakthrough in our initial design was recognizing that self-immolative 
benzyl carbamates (Figure 1.6a),132, 133 often used as delivery platforms for prodrugs, 
fluorophores, and other small-molecules,134-137 could be modified to release COS rather 
than CO2 by exchanging the canonical carbamate linker with a thiocarbamate (Figure 
1.6b). In a proof-of-concept demonstration of this approach, we established the utility of 
on-demand COS-extrusion as a strategy to access both analyte replacement fluorescent 
probes and triggered COS/H2S donors (See Chapter II).131 The early motivation of this 
work was to address a major challenge in reaction-based probes for small molecule 
analytes, especially RSONS. Activation of these reporter scaffolds results in analyte 
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consumption, thus perturbing homeostasis. Exploitation of the self-immolative 
decomposition of thiocarbamates to release COS enabled the generation of the first 
examples of analyte replacement fluorescent probes, which react with (and consume) H2S 
to produce a turn-on fluorescent response, concomitant with the release one equivalent of 
caged H2S in the form of COS, thus providing progress toward analyte homeostasis in 
reaction-based detection systems (Figure 1.6c). By using an H2S-reactive azide trigger, 
which is reduced to an amine upon reduction by H2S, we established that the subsequent 
self-immolative cascade reaction extrudes COS, which is quickly hydrolyzed to H2S by 
CA. Importantly, this donor motif was found to be stable in whole mouse blood prior to 
trigger activation, thus highlighting the biological stability of these platforms. Control 
experiments on thiocarbamate motifs lacking a latent fluorophore demonstrated that 
triggered reductive cleavage by tris(2-carboxyethyl)phosphine (TCEP) in mouse blood 
resulted in COS donation with nearly 50% efficiency and conversion to H2S by CA. 
Additionally, addition of the CA inhibitor AAA abrogated H2S production in vitro, 
confirming that H2S release is a result of CA-mediated COS hydrolysis. Although this 
initial report provided an important contribution toward H2S detection technology, the 
broader impact is providing a viable and highly tunable COS donating strategy for 
accessing chemical tools for expanding our understanding of the chemical biology of 
COS.  
 
1.5.2 Triggered/Active Release of COS 
Furthering the strategies outlined above, simple changes to the general self-
immolative thiocarbamate scaffold can provide access to new donor motifs with more 
specific functions. Notably, incorporation of protecting groups that selectively respond to 
specific stimuli and result in on-demand COS release may provide access to highly 
targeted COS donors with utility in investigating the chemical biology of COS, as well as 
for site-selective COS/H2S donation. Such triggerable donors can be expected to be 
useful in therapeutic applications where COS delivery is targeted to a specific location as 





Figure 1.6 (a) Established strategy of using protected benzylcarbamates to deliver a 
payload after trigger activation. (b) Translation of this delivery technique by using 
protected benzylthiocarbamates enables access to COS releasing motifs. (c) Initial 
application of caged COS release to develop analyte replacement fluorescent probes for 
H2S based on azide reduction.  
 
ROS Triggered COS Donors. A powerful application of such responsive donors is the 
judicious choice of triggering analytes associated with contexts in which H2S can exert 
beneficial action. For example, because H2S has been demonstrated to provide protection 
against increased oxidative stress, a system in which COS release is triggered by reactive 
oxygen species (ROS) should not only provide access to actively-triggered COS donors, 
but also provide a platform with high pharmacological potential. Using an ROS-cleavable 
aryl boronate as the protecting group,138, 139 we developed a class of COS donors that 
respond to increased ROS levels (Figure 1.7a).140 Highlighting the responsive nature of 
this design platform, COS is released from PeroxyTCM-1 in a dose-dependent manner 
upon addition of H2O2 as well as other ROS and is quickly converted to H2S by CA.  
Supporting in vitro investigations, stimulation of endogenous ROS production in 
Raw. 264.7 cells by addition of phorbol 12-myristate 13-acetate (PMA) resulted in 
COS/H2S release from PeroxyTCM-1, as evidenced by an increase in fluorescence when 
imaged with the H2S-responsive probe HSN2.141 Providing early insights into the 
potential of such donors to impart cellular protections under conditions of increased 
oxidative stress, PeroxyTCM-1 exhibited a dose-dependent increase in cell viability in 
HeLa cells treated with exogenous H2O2, which is consistent with ROS protection.  
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Figure 1.7 (a) Strategy for using ROS-responsive aryl boronates to access ROS-triggered 
COS/H2S donors. (b) Structure of ROS-triggered COS donor PeroxyTCM-1 and control 
compounds PeroxyCM-1, which releases CO2, and TCM-1, which lacks the ROS-
activated trigger.  
 
Importantly, the use of carbamate control compound PeroxyCM-1 or triggerless TCM-1 
(Figure 1.7b) did not recapitulate the cytoprotective effects, suggesting that the observed 
cytoprotection was indeed due to the COS/H2S release rather than from the organic 
scaffold or reaction byproducts. In addition, in vitro investigations also demonstrated that 
H2O2 can react directly with COS to generate H2S, thus decreasing the need for CA and 
also highlighting the importance of COS as a potential ROS scavenger.  
 
Bio-orthogonal COS Release (See Chapter III). COS donors triggered through bio-
orthogonal methods have also been reported. One advantage of this approach is that the 
donor constructs are stable until exposure to a benign external stimulus and release COS 
without the need for a detrimental cellular trigger. Additionally, bio-orthogonal methods 
allow for the potential of high spatial and temporal resolution, as evidenced by the utility 
of such strategies for targeted drug delivery.142, 143 For example, incorporation of a COS-
releasing thiocarbamate into the cyclooctene reaction partner of the inverse-electron 
demand Diels-Alder (IEDDA) click reaction between cyclooctenes and tetrazines144-146 
enabled access to “click-and-release” COS donors (Figure 1.8).147 The initial 
cyclooctene-tetrazine click reaction generates a thiocarbamate-functionalized 
dihydropyridazine (26), which after spontaneous tautomerization, deprotonation, and 
rearomatization releases the cyclooctylpyridazine product (29), benzylamine, and COS. 
Direct COS release was confirmed by GC-MS, and H2S production was observed after 
incubation with CA. Although preliminary biological compatibility was demonstrated in 
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whole blood and plasma, further biological investigations and applications are needed to 
establish the fidelity of this platform in more complex contexts and to improve on the 
efficiency and rate of COS release.  
 
Figure 1.8 Bio-orthogonal COS donors based on the IEDDA click reaction. 
 
1.5.3 Continuous/Passive Release of COS 
A complementary approach to access caged COS donors is to develop continuous 
release COS donors, which are activated by ubiquitous cellular nucleophiles or enzymes. 
Such donors would result in continuous, rather than triggered, COS release, thus 
increasing basal COS levels in an otherwise normal physiological environment. Similar 
to well-known hydrolytically-activated donors for NO and H2S,148, 149 these compounds 
are likely to contribute to an important class of tools for investigating COS chemical 
biology. 
 
Nucleophile activation. Matson and co-workers recently investigated N-
thiocarboxyanhydrides (NTAs, Figure 1.9a) as COS-releasing molecules.150 These 
electrophiles release COS upon reaction with nucleophiles, and are analogous to the 
thiocarboxyanhydrides proposed by Hirschmann in studies of peptide couplings (9, 
Figure 1.4).104 In these scaffolds, COS release likely occurs through initial formation of 
an thiocarbamate intermediate (30) akin to those observed by Ghadiri and co-workers in 
COS-mediated peptide forming reactions (Figure 1.9b).46 After preparing small molecule 
(NTA1) and polymeric (polyNTA1) derivatives (Figure 1.9a), GC-MS experiments 
confirmed that the NTA derivatives release COS in the presence of mild biological 
nucleophiles, such as glycine. As further evidence of COS formation, the addition of CA 
resulted in H2S formation, which was confirmed using an H2S-responsive electrode. 
Because alkylthiocarbamates similar to 30 have been used previously as efficacious CA 
inhibitors,151 fine tuning of the structure of NTA derivatives and the resultant 
thiocarbamate intermediates may enable further tuning of rates of COS hydrolysis to H2S. 
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Cell culture investigations demonstrated the ability of NTA1, but not polyNTA1, to 
promote cell proliferation in brain-derived endothelial cells at levels akin to that observed 
by treatment with NaSH. As a whole, these continuous release NTA platforms provide a 
simple scaffold for further modifications based on the simplicity of the COS-releasing 
core and offer the benefit of innocuous peptide byproducts after COS release. 
 
Ubiquitous enzyme activation. Complementing COS donors that function by reaction 
with bioavailable nucleophiles, Chakrapani and co-workers recently reported 
thiocarbamate (32) and thiocarbonate (33) containing COS-donor motifs responsive to 
ubiquitous cellular esterases.152 Leveraging the design strategies outlined in sections 5.1-
2, installation of an ester functional group, which is cleaved by intracellular esterases,153 
generates a phenolic intermediate (34) that initiates the subsequent self-immolative 
collapse to extrude COS (Figure 1.9c). Esterase-mediated release of COS and subsequent 
conversion to H2S by CA was confirmed in vitro using both the methylene blue (MB) 
assay and also an H2S-responsive electrode. COS/H2S release was also confirmed in 
MCF-7 cells using the H2S-responsive probe NBD-fluorescein.154 One difference of these 
platforms from those outlined in sections 5.1-2 is the use of an S-alkylthiocarbamate 
rather than an O-alkylthiocarbamate, as well as investigation into COS/H2S release from 
thiocarbonates in addition to thiocarbamates. Preliminary mechanistic investigations 
suggest that the choice of thiocarbamate versus thiocarbonate may impact the rate 
limiting step of COS extrusion, thus providing a pathway for further control and tuning of 
reaction kinetics and release profiles.  
 
1.5.4 Outstanding Questions  
Although the recent introduction of a variety of COS donor compounds provides 
simple ways to introduce exogenous COS into biological samples, the direct CA-
mediated metabolism of COS to H2S represents a significant challenge in differentiating 
the biological actions of COS from those associated with H2S. Additionally, because 
COS metabolism by CA generates CO2/HCO3– in addition to H2S, it is important to 
consider the total amount of COS metabolized in a system to ensure buffering capacities 
are not exceeded by these otherwise innocuous products. Answers to such questions will  
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Figure 1.9 Continuous-release COS donors including (a) N-thiocarboxyanhydride (NTA) 
COS-releasing molecules NTA1 and polyNTA1. (b) Proposed mechanism of COS 
release from NTA-based donors. (c) Esterase-cleaved COS donors and associated 
mechanism of COS release. 
 
likely require thoughtful and careful applications of available H2S and COS donors used 
in concert to investigate specific biomolecular questions. Whether available COS donors 
function merely as clever sources of biological H2S, or whether the released COS imparts 
different outcomes in biological contexts remains to be determined. If realized, COS-
releasing molecules that provide outcomes distinct from those attributed to available H2S 
donors will likely play a significant role in assessing the and advancing not only the role 
of COS as a potential gasotransmitter, but also its role in potential therapeutic 
applications associated with human health.  
 
1.6 Conclusions 
Key challenges remain in further elucidating the chemical biology of COS, but 
our current, albeit limited, understanding of the biological production and consumption of 
COS suggests that it may play diverse roles. Could COS be poised to be the next on the 
list of established gasotransmitters? This distinction will first require identification of 
enzymatic COS production in higher organisms and evidence that COS and H2S function 
independently. It is also possible that COS functions primarily as a source of ‘caged’ H2S 
that is liberated by CA metabolism. Such a pathway is intriguing because it would 
provide a source of reduced sulfur that is not ionizable through acid-base equilibria at 
physiological pH, and that is less susceptible to ambient or enzymatic oxidation through 
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direct action of oxidases or sulfur:quinone oxidoreductase (SQR),155 thus bypassing 
interaction with the sulfane-sulfur pool.156 Additionally, the neutral state of COS could 
enable distribution to locales that would otherwise be challenging for H2S/HS– alone.  
Finally, there is compelling evidence that COS stems from bacterial generation, 
especially in certain disease pathologies. In these cases, COS could provide a transport 
mechanism from pathogen to host. Even if eukaryotic COS synthesis is not a major 
source of endogenous COS, a thorough understanding of the role that COS plays in these 
diseases will likely be beneficial in early detection and treatment. When viewed more 
broadly, the absence of well-established metabolic pathways for COS formation in 
eukaryotic systems paired with the presence of COS-producing pathways from simple 
and abundant sulfur sources by a variety of bacteria may paint a broader, yet 
fundamentally underexplored picture of the COS functions in sulfur biology and 
transport.  
In this dissertation, I report novel chemical tools for studying COS and H2S 
chemical biology through the development of self-immolative thiocarbamates that can be 
triggered to release COS by a variety of stimuli. In Chapter II, I describe the first report 
of this strategy, initially established to address a significant problem in reaction-based 
detection of H2S: consumption of the analyte. In Chapters III and IV, I expand the library 
of thiocarbamate-based, COS-releasing scaffolds and report two novel H2S donation 
strategies: bioorthogonally-activated and cysteine-selective. In Chapters V and VI, I 
adapt this COS-releasing motif to develop H2S donors that are activated by ubiquitous 
enzymes, and in the process reveal unexplored physiological properties of COS itself. 
Finally, in Chapter VII, I survey a wide-range of scaffolds that could be used as COS-
releasing core motifs for cytotoxicity and CA inhibition and suggest ideal structures for 
researchers developing COS donors. Chapters II through VII contain both unpublished 









SELF-IMMOLATIVE THIOCARBAMATES PROVIDE ACCESS TO 
TRIGGERED H2S DONORS AND ANALYTE REPLACEMENT FLUORESCENT 
PROBES 
 
This chapter includes previously published and coauthored material from Steiger, A.K.; 
Pardue, S.; Kevil, C.G.; Pluth, M.D. “Self-Immolative Thiocarbamates Provide Access to 
Triggered H2S Donors and Analyte Replacement Fluorescent Probes” J. Am. Chem. Soc. 
2016, 138, 7256-7259.  
 
2.1 Introduction 
The advent of chemical tools to probe and manipulate biochemical processes has 
revolutionized how biological processes are investigated.157-159 Spawning from initial 
investigations into fluorescent proteins,160, 161 small molecule fluorescent reporters now 
comprise a key pillar of investigative chemical biology with a remarkable diversity of 
fluorescent tagging and measurement technologies.162, 163 Recent years have witnessed a 
significant expansion of sensor development to include chemical tools for imaging 
different transition metal, alkali, and alkali earth ions.164-166 Many of these sensors 
provide real-time, quantitative measurements of ion fluxes due to the reversible 
interaction of the sensor with the analyte, thus providing methods for imaging the 
dynamic process of metal ion trafficking associated with signaling events ranging from 
Ca2+ sparks during muscle contraction167 to Zn2+ fluxes during mammalian egg 
fertilization.168 Complementing such investigative tools are small molecule donors that 
release caged analytes at controllable rates.124, 169-171 Such platforms provide powerful 
methods to control levels of specific analytes, which often include pro-drugs, metal ions, 
or small reactive sulfur, oxygen, and nitrogen species (RSONS), in different biological 
contexts.  
In the last two decades, RSONS have emerged as important bioinorganic 
molecules involved in myriad biological processes, many of which have been elucidated 
by utilizing chemical tools for small molecule detection and delivery. RSONS are 
	 28 
involved in the complex cellular redox landscape and are often involved in oxidative 
stress responses, immune responses and signaling pathways, as well as other emerging 
roles.172 For example, NO, HNO, and ONOO– play important roles ranging from smooth 
muscle relaxation to immune response173 and are largely intertwined with reactive 
oxygen species, such as O2– and H2O2, which are critical in oxidative stress responses and 
have been implicated in various aging mechanisms.174 Similarly, reactive sulfur species, 
such as H2S, hydropolysulfides (HSn>1–), and persulfides (RSSH) have recently garnered 
interest as important signaling molecules with roles in long term potentiation and 
cardiovascular health.2 By contrast to their metal ion counterparts, RSONS are often 
fleeting nature and often react irreversibly with cellular targets. This heightened reactivity 
has provided chemists with significant challenges in developing constructs that can 
release these molecules under controlled conditions, but have also provided different 
strategies to devise chemical tools for their detection by engineering reactive groups onto 
sensing platforms that react selectively albeit irreversibly with the analyte of interest.175  
Although small molecule donors and reaction-based probes have provided 
significant insights into the roles of RSONS in biology, key needs remain. For example, 
engineering donors with precise but modifiable triggers to enable analyte release in 
response to specific stimuli and developing reaction-based probes that do not irreversibly 
consume the analyte would enable new insights into RSONS biology. Motivated by these 
needs, as well as our interest H2S chemistry, we report here a new caged H2S releasing 
strategy and provide proof-of-concept applications in both small-molecule donor and 
reaction-based probe design. By leveraging triggerable self-immolative thiocarbamates, 
we demonstrate access to easily-modifiable H2S donors that can be triggered by external 
stimuli (Figure 2.1a), and address common issues of analyte consumption in reaction-
based fluorescent probes (Figure 2.1b) by developing analyte-replacement reaction-based 
platforms (Figure 2.1c). 
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Figure 2.1 (a) Caged donors triggered by different stimuli. (b) Reaction-based probes 
typically consume the target analyte. (c) Analyte-replacement reaction-based probes 
enabled by incorporation of caged analytes into reaction-based motifs. 
 
2.2 Results and Discussion 
Development of analyte-replacement sensing platforms requires two important 
components: a versatile H2S donation motif that releases H2S in response to a specific 
triggering event and a method to couple this caged donor to a reaction-based sensing 
platform with an optical output. As a proof-of-concept design toward this objective, we 
chose to use H2S-mediated azide reduction for our sensing platform, which has emerged 
as the most common method for H2S detection and exhibits high selectivity for H2S over 
other RSONs (Figure 2.2a).176 Although a number of H2S-donating motifs have been 
reported and have found utility as important research tools,122-124 none of these fit the 
design requirement of our approach. To develop an H2S donating motif compatible with 
our design requirements, we reasoned that common strategies in drug and fluorophore 
release, namely the self-immolative cascade decomposition of para-functionalized benzyl 
carbamates (Figure 2.2b),132, 133, 177 could be modified to enable triggered H2S release. 
Because self-immolative carbamates release an amine-containing payload and extrude 
CO2 as a byproduct, we reasoned that replacing the carbonyl oxygen with a sulfur atom to 
generate a thiocarbamate would result in carbonyl sulfide (COS) rather than CO2 release 
(Figure 2.2c). In a biological environment, COS is quickly hydrolyzed to H2S and CO2 by 
carbonic anhydrase (CA), which is a ubiquitous enzyme present in plant and mammalian 
cells.42, 110 The second byproduct of the thiocarbamate self-immolation is a reactive 
quinone methide, which rapidly rearomatizes upon reaction with available nucleophiles, 
such as water or nucleophilic amino acids such as cysteine.178, 179  On the basis of the 
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requirements outlined above, we expected that a quenched fluorophore could be 
functionalized with a p-azidobenzylthiocarbamate to enable H2S-mediated azide 
reduction to form the transient aryl amine intermediate, which would subsequently 
undergo the self-immolative cascade reaction to extrude COS/H2S and liberate the 
fluorophore to access an analyte-replacement sensing motif (Figure 2.2d).  
 
 
Figure 2.2 Established strategies for (a) H2S-mediated azide reduction and (b) self-
immolative carbamates to deliver an amine-bound fluorophore. Incorporation of self-
immolative thiocarbamates enables access to (c) triggered H2S donors, and (d) analyte 
replacement probes. 
 
To confirm that the COS could serve as a potential source of H2S donation, we 
first established that independently prepared COS could be efficiently hydrolyzed to H2S 
by CA. Upon addition of COS gas to deoxygenated aqueous buffer (PBS, 1 mM CTAB, 
pH 7.4) containing CA from bovine erythrocytes, we observed rapid H2S production 
using an H2S-responsive electrode. In the absence of CA, negligible current was observed 
from COS alone, which is consistent with slow and pH-dependent, nonenzymatic 
hydrolysis in water (Figure A4).180 We also observed a dose-dependent reduction in H2S 
production upon addition of the CA inhibitor acetazolamide (AAA),108 which confirmed 
the enzymatic hydrolysis of COS by CA (Figure 2.3).  
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Figure 2.3 Conversion of COS to H2S by carbonic anhydrase (CA) with varying 
concentrations of CA inhibitor acetazolamide (AAA) in PBS buffer, pH 7.4. 
 
We next prepared model thiocarbamates to confirm that the proposed 
decomposition cascade to release COS occurs efficiently and to demonstrate the 
biological compatibility of this donor motif. We incorporated an azide in the para 
position of the benzylthiocarbamate to function as the H2S-responsive trigger for self-
immolation and COS release. To facilitate NMR identification of the products, we first 
prepared azidobenzylthiocarbamate 1 with a p-fluoroaniline payload, and the 
corresponding carbamate 2 as a control compound (Figure 2.4a-c). Although 2 should 
undergo the same self-immolative decomposition upon azide reduction, it releases CO2 
rather than COS, and thus should not donate H2S upon reaction with CA. To monitor the 
reactivity of the model compounds under controlled reaction conditions, we used tris(2-
carboxyethyl)phosphine (TCEP), an azide-reducing agent, to trigger self-immolation, due 
to its near-instantaneous reduction of azides. In each case, 1H, 13C{1H}, and 19F NMR 
spectroscopy was used to monitor the reaction after reduction of the model complexes by 
TCEP. Consistent with our design hypothesis, we observed the disappearance of the 
benzylic peak, loss of the thiocarbonyl carbon peak, and formation of new resonances 
upon self-immolation by NMR spectroscopy (Figure A1-A3). All such changes were 
observed within 5 minutes of TCEP addition, confirming the rapid self-immolation of the 
scaffold upon reduction, and were consistent with COS release from the thiocarbamate 
scaffold upon azide reduction.   
Having confirmed that CA rapidly catalyzes COS hydrolysis, we next 
investigated the H2S-donating ability of model compounds 1 and 2 under identical 
conditions. Monitoring thiocarbamate 1 in buffer containing CA did not result in H2S 
formation, confirming that the thiocarbamates do not react directly with CA and that aryl 
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azides are stable in the presence of CA (Figure A5). Upon injection of TCEP, however, 
rapid release of H2S was observed, indicating that azide reduction to an amine is essential 
to trigger self-immolation and COS release. Additionally, repeating the experiment with 
added AAA significantly reduced the rate of H2S production, confirming that uninhibited 
CA is required for significant H2S production from the triggered thiocarbamate scaffold 
(Figure 2.4d). Finally, the analogous carbamate (2) was investigated under identical 
conditions, and as expected no H2S was produced upon addition of TCEP, confirming 
that the sulfur-containing thiocarbamate is required for H2S formation. In total, these 
experiments demonstrate the validity of using thiocarbamates as a triggerable source of 
H2S release in aqueous solution, which we expect will prove fruitful for researchers 
interested in the pharmacological and physiological roles of sulfide donating 
molecules.122, 123 
 
Figure 2.4 (a,b) Synthesis of model thiocarbamates and carbamates. (c) Model 
compounds. (d) H2S release from 1 after reduction by TCEP in the presence of CA, under 
identical conditions with the addition of AAA (2.5 µM,), and from carbamate 2. (e) 
Quantification of total sulfide in whole mouse blood after treatment 25 µM 3 and 4 after 
30 min of incubation time in the presence of excess TCEP.  
 
Expanding on our cuvette-based studies, we also investigated H2S release from 
model thiocarbamates in whole mouse blood to expand on the efficacy of H2S release 
from thiocarbamates in biologically-relevant contexts. Although murine systems provide 
	 33 
a convenient model, mice have among the lowest CA levels in mammals, with murine 
blood only containing about 15% of the CA present in human blood,181 and thus represent 
a challenging target for sulfide release mediated by CA. To quantify total sulfide levels, 
we used the monobromobimane (mBB) method which allows for the analytical 
measurement of different sulfide pools and is compatible with many types of biological 
samples.182 Measurement of the total sulfide, which includes free sulfide as well as bound 
sulfane-sulfur, revealed background levels of 8 µM, which are higher than total sulfide 
levels commonly observed and reported in plasma, but are consistent with the high 
sulfane-sulfur content in red blood cells.183, 182 We prepared thiocarbamate 3, which lacks 
the azide trigger, to confirm that the thiocarbamate group was stable in whole blood and 
did not release COS without activation of the trigger group, and compared results 
obtained with this model compound with azide-functionalized 4. Total sulfide levels were 
measured for each compound, as well as the control, after 30 minutes of incubation with 
excess TCEP (Figure 2.4e). Consistent with our expected results, only samples containing 
donor 4 with the azide trigger increased total sulfide levels in blood (p ≤ 0.0001). These 
results establish the stability of the thiocarbamate in biological milieu and confirm that 
endogenous CA in murine blood, even though significantly lower than in most other 
biological environments,181 is sufficient to hydrolyze the COS released from 
thiocarbamates after the self-immolation cascade is triggered, highlighting the efficacy of 
this H2S-releasing strategy in biological environments.  
Having confirmed the viability of triggered H2S release with the model 
compounds, we next applied this design to incorporate a fluorophore to access an H2S-
responsive fluorescent probe that releases H2S upon H2S detection. Our primary goal was 
to demonstrate that the thiocarbamate group could be appended to common fluorophore 
motifs and efficiently quench the fluorescence. We chose to use the methylrhodol 
(MeRho)184 fluorophore due to its high quantum yield and single fluorogenic amine, 
which could be readily converted into the desired thiocarbamate. Since the azide-
functionalized scaffold would be triggered by H2S to release both MeRho and COS, this 
would function as a fluorescent H2S probe that would replenish sulfide through the 
release of COS. To access the desired scaffold, we treated MeRho with 
thiocarbonyldiimidazole (TCDI) and NEt3 in DMF to afford methylrhodol isothiocyanate 
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(MeRho-NCS) in 60% yield. Subsequent treatment with 4-azidobenzyl alcohol and NaH 
afforded the methylrhodol thiocarbamate azide (MeRho-TCA) in 35% yield (Figure 
2.5a). We note that one benefit of this simple synthetic route is that almost any 
fluorophore containing a fluorogenic nitrogen can be functionalized with the benzylazide 
thiocarbamate group, thus providing access to a diverse library of fluorophores. 
 
 
Figure 2.5 (a) Synthesis of MeRho-TCA. (b) Fluorescence response of MeRho-TCA to 
H2S. Inset shows integrated fluorescence over time by comparison to MeRho-TCA in the 
absence of NaSH. (c) Selectivity of MeRho-TCA for H2S over other RSONs. Conditions: 
5 µM probe, 250 µM RSONs unless noted otherwise, in PBS buffer, 1 mM CTAB, pH 
7.4, 37 °C. λex = 476 nm, λem = 480-650 nm. 
 
With a sulfide-replenishing H2S probe in hand, we investigated the fluorescence 
response upon addition of sulfide. Treatment of MeRho-TCA with 50 equiv. of NaSH in 
aqueous buffer (PBS, 1 mM CTAB, pH 7.4) resulted in a 65-fold fluorescence turn-on 
over 90 minutes (Figure 2.5b). Additionally, we confirmed that the MeRho-TCA scaffold 
was selective for HS– over other RSONs, by measuring the fluorescence response to Cys, 
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GSH, Hcy, S2O32–, SO32–, SO42–, H2O2, and NO (Figure 2.5c). As expected, the MeRho-
TCA scaffold exhibited excellent selectivity for sulfide over other RSONs, demonstrating 
that the thiocarbamate linker group did not erode the selectivity of the azide trigger, and 
also establishing that the MeRho-TCA scaffold can function as a viable H2S reporter. 
Because MeRho-TCA releases H2S upon reaction with H2S, we note that one 
consequence of this analyte replacement approach is that the resultant fluorescence 
response is not directly proportional to the initial H2S concentration. Additionally, in 
isolated systems, two equiv. of HS– are required for complete azide reduction, suggesting 
that the first-generation analyte-replacement scaffolds only replace one half of the 
consumed sulfide.185 It is also possible, however, that in biological media one equiv. of a 
thiol may play a role in H2S-mediated azide reduction, which remains a question for 
future investigations.  In the present system, preliminary mechanistic investigations 
indicate that H2S-mediated azide reduction is the rate-limiting step of the self-immolative 
process, and that the subsequent release of COS and hydrolysis by CA to form H2S is 
rapid. Taken together, these data highlight the potential of this strategy to access analyte-
replacement, reaction-based fluorescent scaffolds.  
 
2.3 Conclusions 
In summary, we have outlined and demonstrated a new strategy for triggered H2S 
release based on self-immolative thiocarbamates. Importantly, this strategy provides 
solutions to key challenges associated with both H2S delivery and detection. 
Thiocarbamate-based H2S donors provide a new, versatile, and readily modifiable 
platform for developing new H2S donor motifs that can be triggered by endogenous or 
biorthogonal triggers. Similarly, this same H2S donation strategy can be coupled to 
fluorescent probe development to access reaction-based fluorescence reporters that 
replace the analyte that has been consumed by the detection event. In a broader context, 
we expect that the self-immolative thiocarbamate donors will find significant utility as a 
potential platform for academic and potentially therapeutic H2S donors. The following 
Chapters will show numerous examples of self-immolative thiocarbamates as triggerable 
COS/H2S donors activated by a variety of stimuli. In Chapter III, we report the first 
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example of a bio-orthogonal H2S donor using a self-immolative thiocarbamate to release 
COS upon activation. 
 
2.4 Experimental Details 
2.4.1 Materials and Methods 
Reagents were purchased from Sigma-Aldrich or Tokyo Chemical Industry (TCI) and 
used as received. p-Azidobenzylalcohol,186 O-(4-azidobenzyl)-N-tolylthiocarbamate,187 
methylrhodol,184 and COS gas49 were synthesized as previously reported. Spectroscopic 
grade, inhibitor-free THF was deoxygenated by sparging with argon followed by passage 
through a Pure Process Technologies solvent purification system to remove water and 
then stored over 4Å molecular sieves in an inert atmosphere glove box. Deuterated 
solvents were purchased from Cambridge Isotope Laboratories and used as received. 
Silica gel (SiliaFlash F60, Silicycle, 230-400 mesh) was used for column 
chromatography. Preparatory chromatography was performed on Silicycle SiliaPlates (1 
mm thickness). 1H, 13C{1H}, and 19F NMR spectra were recorded on a Bruker 600 MHz 
instrument. Chemical shifts are reported in ppm relative to residual protic solvent 
resonances. H2S electrode data were acquired with a World Precision Instruments (WPI) 
ISO-H2S-2 sensor connected to a TBR4100 Free Radical Analyzer. Fluorescence spectra 
were obtained on a Quanta Master 40 spectrofluorometer (Photon Technology 
International) equipped with a Quantum Northwest TLC-50 temperature controller at 
37.0 ± 0.05 °C. UV-visible spectra were acquired on a Cary 100 spectrometer equipped 
with a Quantum Northwest TLC-42 dual cuvette temperature controller at 37.00 ± 0.05 
°C. All air-free manipulations were performed under an inert atmosphere using standard 
Schlenk techniques or an Innovative Atmospheres N2-filled glove box. 
 
Spectroscopic Materials and Methods. Phosphate buffered saline (PBS) tablets (1X, 
CalBioChem) and cetyl trimethylammonium bromide (CTAB) were used to make 
buffered solutions (PBS, 140 mM NaCl, 3 mM KCl, 10 mM phosphate, 1 mM CTAB, 
pH 7.4) in Millipore water. Buffer solutions were sparged with N2 to remove dissolved 
oxygen and stored in an N2-filled glovebox. Anhydrous sodium hydrosulfide (NaSH) was 
purchased from Strem Chemicals and handled under nitrogen. Aqueous stock solutions of 
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NaSH were prepared in buffer in an N2-filled glovebox immediately prior to use.  Stock 
solutions of MeRho-TCA were prepared in an N2-filled glovebox in DMSO and stored at 
-25 °C until immediately before use. Septum-sealed cuvettes from Starna Scientific were 
used to obtain spectroscopic measurements under anaerobic conditions.  
 
H2S Electrode Materials and Methods. Phosphate buffered saline (PBS) tablets (1X, 
CalBioChem) and cetyl trimethylammonium bromide (CTAB) were used to make 
buffered solutions (PBS, 140 mM NaCl, 3 mM KCl, 10 mM phosphate, 1 mM CTAB, 
pH 7.4) in Millipore water. Buffer solutions were sparged with N2 to remove dissolved 
oxygen and stored in an N2-filled glovebox. Carbonic anhydrase (CA) from bovine 
erythrocytes (≥3,500 W/A units/mg) was obtained from Sigma Aldrich and a 1% CA 
stock solution was prepared in deoxygenated buffer (50 mM PIPES, 100 mM KCl, pH 
7.4) in a glovebox, and the absorbance at 280 nm (1 cm path length cuvette) at 37 °C was 
measured to be 3.825. The concentration of the stock solution was calculated to be 67 µM 
using 𝜀!"#!% = 19 for CA.
188 The stock solution was stored under nitrogen at 4 °C and 
warmed to room temperature immediately before use. Stock solutions of tris(2-
carboxyethyl)phosphine (TCEP) and acetazolamide (AAA) were prepared under N2 with 
degassed buffer (PBS, pH 7.4) immediately prior to use. Thiocarbamate and carbamate 
stock solutions were prepared in an N2-filled glovebox in DMSO and stored at -25 °C 
until immediately before use.  
 
General Procedure for H2S Electrode Experiments. Scintillation vials containing 20.00 
mL of phosphate buffer (140 mM NaCl, 3 mM KCl, 10 mM phosphate, 1 mM CTAB, pH 
7.4) were prepared in an N2-filled glovebox. A split-top septum cap was placed on the 
vial after probe insertion and the headspace was sparged with N2. The WPI electrode was 
then inserted into the vial and the measured current was allowed to equilibrate before 
starting the experiment. With moderate stirring, the CA stock solution (50 µL, 67 µM) 
was injected, followed by subsequent injections of acetazolamide (10-50 µL of a 10 mM 
stock solution in PBS buffer), COS gas (10 µL, 0.345 µmol), TCA stock solution (10 
mM in DMSO), or TCEP stock solution (10 mM in PBS buffer).  
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General Procedure for Fluorescence Measurements. In an N2-filled glovebox, a septum-
sealed cuvette was charged with 3.00 mL of buffer (140 mM NaCl, 3 mM KCl, 10 mM 
phosphate, 1 mM CTAB, pH 7.4). The cuvette was removed from the glovebox and 
MeRho-TCA (60 µL of a 1 mM stock solution) was injected into the vial, after which a 
background spectrum was recorded. The desired analytes were then introduced, and the 
fluorescence spectrum was measured at designated time points.  
 
General Procedure for Measurement of Total Sulfide in Mouse Blood. Mice were 
maintained at the association for  assessment  and  accreditation  of  laboratory  animal  
care  international-accredited  Louisiana State  University  Health  Science  Center -
Shreveport  animal  resource  facility  and  maintained  in accordance with the National 
Research Council’s guide for care and use of laboratory animals. All  animal  studies  
were  approved  by  the  institutional  animal  care  and  use  committee  (protocol P-12-
011) and conformed to the guide for the care and use of laboratory animals published by 
the National Institutes of Health. Mice were anesthetized by IP injection with 150 mg/kg 
ketamine and 10 mg/ kg xylazine. Mouse whole blood was collected from the retroorbital 
capillary plexus from three C57BL/6J male mice and diluted 1:50 in PBS (phosphate 
buffered saline pH 7.4) or red blood cell lysing buffer (Sigma, St Louis). Samples were 
treated with either 3 or 4 at a final concentration of 25 µM.  A separate set of blood 
samples were left untreated and used for baseline sulfide measurements.  Once mixed 
with either compound 3 or 4, half of each sample was treated with 10 mM TCEP (tris(2-
carboxyethyl)phosphine hydrochloride) for 30 minutes while the other half remained 
untreated. Sulfide bioavailability was subsequently measured in all samples using the 
MBB method as previously reported.182, 189, 190 
 
2.4.2 Syntheses 
General procedure for the preparation of thiocarbamates. Sodium hydride (60% in oil, 
1.25 mmol) was added to a solution of the isothiocyanate (1 mmol) and the benzyl 
alcohol (1 mmol) in anhydrous THF (6-12 mL). The reaction mixture was stirred at room 
temperature under nitrogen for 18 hours. After the solvent was removed under reduced 
pressure, CH2Cl2 was added, and the resulting solution was washed with water and brine. 
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The organic layer was dried over sodium sulfate and filtered. The solvent was removed 
by rotary evaporation and the crude product was purified using either column 
chromatography (hexanes:EtOAc gradient) or silica gel preparatory thin layer 
chromatography (3:2 hexanes:EtOAc). 
 
O-(4-Azidobenzyl)-N-(4-fluorophenyl)thiocarbamate (1). Purification via preparatory 
TLC (3:2 hexanes/EtOAc) yielded the product as a pure white solid (107.9 mg, 35% 
yield). 1H NMR (600 MHz, DMSO-d6) δ (ppm): 7.23-7.50 (m, 4H), 7.06-7.13 (m, 4H), 
7.44-7.48 (br s, 2H). Two rotomers were observable by 13C{1H} and 19F NMR: 13C{1H} 
NMR (150 MHz, DMSO) δ (ppm): 189.4 (187.9 minor), 161.3 (159.7 minor), 140.6 (d, 
J=15.4 Hz), 135.4 (134.3 minor), 133.7 (133.0 minor), 126.8 (125.5 minor), 120.1 (130.9 
minor), 116.5 (m), 71.0 (72.7 minor). 19F NMR (470 MHz, DMSO-d6) δ (ppm): -115.9 (-
116.4 minor). FTIR (ATR, cm-1): 3199, 3039, 2109, 1607, 1543, 1503, 1404, 1339, 1280, 
1220, 1168, 1014, 857, 787, 658. 
 
O-(4-Azidobenzyl)-N-(4-fluorophenyl)carbamate (2). p-Azidobenzyl alcohol (57.5 mg, 
0.386 mmol) and NEt3 (54 mL, 0.39 mmol) were combined in dry THF (2 mL), and 4-
fluorophenylisocyanate (44 mL, 0.39 mmol) was added dropwise. The reaction mixture 
was stirred under nitrogen at room temperature and shielded from light for 24 hours. The 
solvent was evaporated under reduced pressure, and the crude product was purified by 
preparatory TLC (2:1 hexanes/EtOAc) to yield the pure product as a white solid (61.8 
mg, 56%). 1H NMR (600 MHz, DMSO-d6) δ (ppm): 9.79 (s, 1H), 7.48-7.44 (m, 4H), 
7.10-7.15 (m, 4H), 5.12 (s, 2H). 13C{1H} NMR (150 MHz, DMSO-d6) δ (ppm): 158.4, 
156.9, 153.4, 139.2, 135.4, 133.5, 130.0, 119.2, 115.4 (d, J= 22.2 Hz), 65.2. 19F NMR 
(470 MHz, DMSO-d6) δ (ppm): -120.82. HRMS (m/z): [M + Na]+ calcd for 
[C14H11FN4O2Na]+ 309.0764, found 309.0601. 
 
O-(4-Benzyl)-N-tolylthiocarbamate (3). Purification via column chromatography 
(hexanes/EtOAc gradient) yielded the product as a pure white solid (173.7 mg, 68%). 1H 
NMR (600 MHz, DMSO-d6) δ (ppm): 11.11 (s, 1H), 7.57-7.44 (m, 2H), 7.43-7.32 (m, 
4H), 7.23-7.06 (m, 3H), 5.49-5.58 (br s, 2H), 2.26 (s, 3H). 13C{1H} NMR (150 MHz, 
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DMSO-d6) δ (ppm): 187.4, 186.8, 136.0, 135.6, 135.1, 134.4, 134.0, 129.2, 128.8, 128.4, 
128.3, 128.2, 128, 122.9, 121.2, 72.0, 70.3, 20.4. HRMS (m/z): [M + H]+ calcd for 
[C15H16NOS]+ 258.0953, found 258.0948. 
 
Methylrhodol-isothiocyanate (MeRho-NCS). Methylrhodol (200 mg, 0.577 mmol) and 
NEt3 (480 µL, 3.46 mmol) were combined in dry DMF (2 mL) in oven-dried glassware. 
Thiocarbonyldiimidazole (TCDI, 211 mg, 1.16 mmol) was dissolved in dry DMF (6 mL) 
and added dropwise to the solution. The reaction mixture was stirred under nitrogen at 
room temperature for 24 hours then quenched with water. The organic layer was 
extracted with EtOAc, washed three times with aqueous LiCl (5%, 20 mL), dried over 
MgSO4, and the solvent was evaporated under reduced pressure. The crude product was 
purified using preparatory TLC on an oven-dried prep plate using dry hexanes:EtOAc 
(1:1) and isolated as a white solid (134 mg, 60%). 1H NMR (600 MHz, CDCl3) δ (ppm): 
8.03 (d, J=7.5 Hz, 1H), 7.68 (t, J=7.4 Hz, 1H), 7.63 (t, J=7.5 Hz, 1H), 7.15-7.12 (m, 2H), 
6.89 (dd, J1= 8.5, J2=2.1 Hz, 1H), 6.80-6.76 (m, 2H), 6.70 (d, J=8.8 Hz, 1H), 6.64 (dd, 
J1= 8.9, J2=2.5 Hz, 1H), 3.84 (s, 3H). 13C{1H} NMR (150 MHz, CDCl3) δ (ppm): 169.3, 
161.7, 153.0, 152.1, 151.9, 137.8, 135.4, 133.4, 130.2, 129.5, 129.2, 126.5, 125.4, 123.9, 
121.4, 118.5, 114.2, 112.4, 110.8, 101.1, 82.2, 55.8. FTIR (ATR, cm-1): 2922, 2852, 
2017, 1761, 1607, 1563, 1495, 1416, 1324, 1247, 1099, 1079, 941. HRMS (m/z): [M + 
H]+ calcd for [C22H13NO4SH]+ 388.0644, found 388.0471. 
 
O-(4-Azidobenzyl)-N-methylrhodolthiocarbamate (MeRho-TCA). In oven-dried 
glassware, MeRho-NCS (134 mg, 0.346 mmol) was dissolved in dry THF (5 mL). p-
Azidobenzylalcohol (150 mg, 1.00 mmol) was dissolved in dry THF (5 mL) and added to 
the solution of MeRho-NCS. Sodium hydride (60% in mineral oil, 18 mg, 0.45 mmol) 
was added and the reaction mixture was stirred at room temperature under nitrogen and 
protected from light for 24 hours. The solvent was evaporated under reduced pressure and 
the crude product was dissolved in EtOAc. The organic layer was washed with water and 
brine and dried over sodium sulfate. The product was purified by preparatory TLC (5% 
MeOH in DCM) while protected from light, to yield the pure product as a pale yellow 
solid (65 mg, 35%). 1H NMR (600 MHz, CDCl3) δ (ppm): 8.26 (br s, 1H), 8.02 (d, J=7.6 
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Hz, 1H), 7.67 (td, J1=7.5, J2=1.3 Hz, 1H), 7.62 (td, J1=7.5, J2=1.0 Hz, 1H), 7.43 (d, J=8.4 
Hz, 2H), 7.14 (d, J=7.5 Hz, 1H), 7.05 (d, J=8.4 Hz, 2H), 6.78 (d, J=2.5 Hz, 1H), 6.73 (d, 
J=8.2 Hz, 1H), 6.69 (d, J=8.8 Hz, 1H), 6.62 (dd, J1=8.8, J2=2.5 Hz, 1H), 5.59 (br s, 2H), 
3.84 (s, 3H). 13C{1H} NMR (150 MHz, CDCl3) δ (ppm): 206.9, 169.3, 161.5, 152.9, 
152.3, 151.7, 140.6, 135.1, 130.3, 129.9, 129.0, 128.8, 126.6, 125.1, 123.9, 119.3, 116.9, 
115.9, 112.0, 110.9, 109.2, 100.9, 82.5, 55.6, 53.5, 30.9, 29.7, 29.3. HRMS (m/z): [M + 




























BIO-ORTHOGONAL “CLICK-AND-RELEASE” DONATION OF CAGED 
CARBONYL SULFIDE (COS) AND HYDROGEN SULFIDE (H2S) 
 
This chapter includes previously published and coauthored material from Steiger, A.K; 
Yang, Y.; Royzen, M.; Pluth, M.D. “Bio-orthogonal “Click-and-Release” Donation of 




With the recent addition of hydrogen sulfide (H2S) to the list of biologically-
relevant gasotransmitters,2 significant efforts have focused on developing H2S donors as 
powerful research, and potentially therapeutic, tools.122, 124 Available synthetic slow-
release donors have already made major impacts in H2S research, and several small 
molecule H2S donors have already entered clinical trials.123 Despite this promise, 
providing temporal control over H2S release remains a major challenge, and there is 
significant interest in developing synthetic H2S donors that are activated by well-defined 
triggering mechanisms that enable on-demand H2S release.  
 Aligned with this need, we recently pioneered the use of carbonyl sulfide (COS)-
releasing molecules as a strategy to access responsive H2S donors. We demonstrated that 
self-immolative thiocarbamates can be triggered to decompose and release COS, which is 
rapidly converted to H2S by the ubiquitous enzyme carbonic anhydrase (CA).131 
Analogous to the broad applications of self-immolative carbamates as delivery platforms 
for prodrugs, fluorophores, and other biologically-relevant payloads, thiocarbamates 
provide a highly tunable platform on which the triggering mechanism can be engineered 
to initiate self-immolation and COS release by specific analytes of interest. Since our 
initial report on caged COS/H2S release, passive H2S donation from small molecule and 
polymeric N-thiocarboxyanhydrides150 as well as responsive ROS-triggered donors that 
provide protection against cellular oxidative stress have been reported.140 Missing from 
current COS/H2S donor technologies are platforms activated by bio-orthogonal triggers to 
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allow precise temporal control for H2S release. Motivated by this need, we report here the 
first example of bio-orthogonal activation of COS/H2S release through adaptation of the 
well-developed inverse-electron demand Diels-Alder (IEDDA) click reaction to release 
COS/H2S (Scheme 3.1). 
 
Scheme 3.1 IEDDA reaction of thiocarbamate-functionalized TCO 1 with tetrazine to 
generate COS/H2S. 
 
3.2 Results and Discussion 
 The IEDDA reaction between a trans-cyclooctene (TCO) and a tetrazine is a 
proven platform for bio-orthogonal click reactions in living systems.144-146 In addition to 
providing an important biocompatible bond-forming tool, the IEDDA reaction has also 
been adapted for targeted drug release by using functionalized benzylic carbamates, 
which can be triggered to undergo self-immolative decomposition following the click 
reaction and subsequently release the attached drug, as well as CO2 as a byproduct.142, 191, 
192 We envisioned that a similar strategy could be leveraged to develop a fully bio-
orthogonal COS/H2S releasing platform by using a benzylic thiocarbamate-functionalized 
TCO (Scheme 3.1). The initial IEDDA click reaction would generate the thiocarbamate-
functionalized dihydropyridazine, which after tautomerization, deprotonation, and 
rearomatization can extrude COS, BnNH2, and the cyclooctylpyridazine product. To test 
this hypothesis, we prepared TCO 1 by treating (E)-cyclooct-2-enol with benzyl 
isothiocyanate in the presence of NaH.142 In parallel, we prepared the analogous 
carbamate-functionalized TCO 2, which undergoes the same IEDDA reaction but 
releases CO2 rather than COS (Scheme 3.2). Both TCO 1 and 2 are isolated as the axial 
isomer, which is estimated to be significantly more reactive than the analogous equatorial 
isomer.193 Importantly, this design strategy provides simple synthetic access to both the 
thiocarbamate donor and key carbamate control compounds. Additionally, click-and-
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release CO donors were recently reported utilizing an intramolecular Diels-Alder 




Scheme 3.2 Synthesis of thiocarbamate-functionalized COS/H2S donor TCO 1 and the 
associated carbamate-functionalized control compound TCO 2.  
 
 To confirm that the IEDDA reaction would initiate self-immolative 
decomposition of the thiocarbamate moiety, we monitored the reaction of 1 and 2 equiv. 
of bis-isopropyl-1,2,4,5-tetrazine in wet methanol-d4 by 1H NMR spectroscopy (Figure 
3.1a). Within 5 minutes of tetrazine addition, we observed disappearance of the alkene 
peaks (5.3-5.7 ppm), indicative of cycloaddition. New resonances corresponding to 
BnNH2 were subsequently observed at 4.25 ppm, while 1 continues to decompose over 
24 hours. Due to the complexity of this reaction and the different potential intermediates 
that could be formed en-route to COS extrusion, we also monitored product formation by 
mass spectrometry. Consistent with our design hypothesis we observed the re-aromatized 
IEDDA product (M+H+ 247.239), BnNH2 (M+H+ 108.091), and COS (M+H+ 61.044) 
(Figure 3.1b,c) using direct analysis in real time mass spectrometry (DART-MS). Taken 
together, these data indicate that addition of the tetrazine to 1 results in the expected click 
reaction and initiates self-immolation of the thiocarbamate moiety, thus producing COS.  
 Having confirmed the fidelity of the IEDDA reaction, we next investigated click-
and-release H2S-donation from this system in aqueous buffer at physiological pH (PBS, 
pH 7.4) using an H2S-selective electrode (Figure 3.2). Non-enzymatic background  
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Figure 3.1 (a) 1H NMR spectra of the reaction of 1 and tetrazine. (b) ESI-MS of reaction 
products, confirming self-immolation. (c) MS confirmation of COS formation. 
  
hydrolysis of COS to H2S is very slow at physiological pH, but is rapid in the presence of 
carbonic anhydrase (CA). Using biologically-relevant CA concentrations (25 µg/mL) we 
first monitored TCO 1 alone and confirmed that H2S is not released spontaneously in the 
presence of CA. As anticipated, the bis-isopropyl-1,2,4,5-tetrazine alone also failed to 
produce an H2S response. We next monitored H2S release from TCO 1 (50 µM) with 
varying concentrations of tetrazine (5 – 25 equiv.) and observed increased H2S 
production in the presence of excess tetrazine. Using a calibration curve, we measured 12 
µM H2S release from 50 µM TCO 1 with 25 equiv. of tetrazine, resulting in an H2S 
release efficiency of approximately 25%. As additional confirmation of the importance of 
CA for H2S formation, we performed identical reactions in the presence of acetazolamide 
(AAA, 2.5 µM), a known CA inhibitor. Furthermore, use of the control compound TCO 2 
in the presence of excess tetrazine failed to generate COS/H2S. Together, these data 
confirm that the IEDDA click reaction is necessary to generate COS, and that uninhibited 




Figure 3.2 H2S release profiles from TCO 1 (50 µM) with 5-25 equiv of tetrazine in the 
presence of CA (25 µg/mL) in buffer (PBS, pH 7.4). 
 
 To demonstrate the basic biological compatibility of the reaction, we also 
investigated H2S release from TCO 1 (50 µM) with the tetrazine (500 µM) in complex 
media (Figure 3.3). For these experiments, we chose to use whole sheep and bovine 
blood due to the presence of CA. Using sheep blood and plasma, diluted 1:1 in PBS (pH 
7.4) with no additional CA added, a similar H2S release profile was observed using an 
H2S-selective electrode. Additionally, H2S production was also observed in diluted whole 
bovine blood, although the process was slower. These experiments confirm that bio-
orthogonal click-and-release strategy has significant potential within a biological 
environment and endogenous CA levels are sufficient to allow for H2S donation from the 
released COS. Additionally, we confirmed the cellular compatibility of TCO 1 using the 
CCK-8 cell viability assay, which indicated that concentrations up to 100 µM of TCO 1 
are not cytotoxic in N2A neuroblastoma cells (Figure B1). 
 In an effort to expand this strategy to a cellular environment, we attempted to 
obtain cell images using a variety of fluorescent probes for H2S, including HSN2, WSP-
5, and SF7-AM.141, 195, 196 Unfortunately, we found that the click-and-release reaction was 
not compatible with these current fluorescent detection strategies for H2S. This 
observation was confirmed in cuvette-based fluorimetry studies as well, in which no 
fluorescent turn-on was observed after several hours despite the production of H2S, as 
confirmed by H2S-electrode experiments. Although unexpected, this outcome may be due 
to slower and/or less-efficient COS/H2S release from this first-generation IEDDA 
platform than from previously reported COS/H2S donors. In a closed system, it is also 
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possible that the tetrazine may also scavenge the generated H2S, as evidenced by a recent 
report demonstrating that H2S can partially reduce dialkoxy tetrazines to the 
dihydrotetrazine.197 Therefore, future investigations into the differential reactivity of H2S 
with substituted tetrazines appears warranted, both to increase the biocompatibility in this 
system and also to increase the initial efficiency of the IEDDA click reaction.198 For 
example, demonstrated recent report highlighted that the efficiency of the IEDDA 
reaction can be improved through strategic choice of the tetrazine. These, as well as other 
modifications to the thiocarbamate scaffold are expected to provide much more efficient 
H2S release from future click and release scaffolds. 
 
 
Figure 3.3 H2S release profiles from TCO 1 (50 µM) with 10 equiv of tetrazine in whole 
bovine blood (red), whole sheep blood (blue), and sheep plasma (grey), diluted 1:1 with 
buffer (PBS, pH 7.4).  
 
3.3 Conclusions 
 In summary, we have reported the first example of COS/H2S donors activated by 
a bio-orthogonal trigger, which provides a significant step toward developing controllable 
H2S donors with high temporal resolution. Given the novelty of this bio-orthogonal 
reaction in the field of sulfide donation, as well as the significant impact that similar click 
strategies have provided to adjacent fields in chemical biology, we anticipate that future 
optimization of this system will result in fast and highly targeted method for H2S 
donation. In Chapter IV, we design a more generalized scaffold for COS/H2S delivery 
using a self-immolative thiocarbamate activated by cysteine, a ubiquitous biothiol. 
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3.4 Experimental Details 
3.4.1 Materials and Methods  
All organic chemicals were purchased from Krackeler Scientific and used without 
further purification. Chromatographic purifications were conducted using SiliaSphere™ 
spherical silica gel 5µm, 60 Å silica gel (Silicycle). Thin layer chromatography (TLC) 
was performed on SiliaPlate™ silica gel TLC plates (250 µm thickness) purchased from 
Silicycle. 1H and 13C{1H} NMR spectra were acquired a Bruker NMR instrument at 400 
MHz (1H) and 100 (13C) MHz. Mass spectra were acquired using a DART-SVP ion 
source (IonSense, Saugus, MA, USA) coupled to a JEOL AccuTOF time-of-flight mass 
spectrometer (JEOL USA, Peabody, MA, USA) in positive ion mode. The DART ion 
source parameters were: grid voltage, 250 V; gas heater temperature, 350 °C. The mass 
spectrometer settings were: ring lens voltage, 5 V; orifice 1 voltage, 20 V; orifice 2 
voltage, 5 V; peak voltage 600 V. Spectra were obtained at 1 scan per second. The 
helium flow rate for the DART source was 2.0 L s−1.  
 
H2S Electrode Materials and Methods. Phosphate buffered saline (PBS) tablets (1X, 
CalBioChem) were used to make buffered solutions (PBS, 140 mM NaCl, 3 mM KCl, 10 
mM phosphate, pH 7.4) in Millipore water. Buffer solutions were sparged with N2 to 
remove dissolved oxygen and stored in an N2-filled glovebox. Whole bovine blood, 
whole sheep blood, and sheep serum were obtained from Carolina Biological Supply 
Company, stored at 4 °C, and warmed to room temperature immediately before use. 
Carbonic anhydrase (CA) from bovine erythrocytes (≥3,500 W/A units/mg) was obtained 
from Sigma Aldrich and a 1% CA stock solution was prepared in deoxygenated buffer 
(PBS, 140 mM NaCl, 3 mM KCl, 10 mM phosphate, pH 7.4) in a glovebox, and stored 
under nitrogen at 4 °C and warmed to room temperature immediately before use. Stock 
solutions of TCO 1 (10 mM) and tetrazine 2 (100 mM) were prepared in the dark in an 
N2-filled glovebox in DMSO and stored, shielded from light, at -25 °C. Stock solutions 
were thawed at room temperature immediately before use.  
 
General Procedure for H2S Electrode Experiments. Scintillation vials containing 20.00 
mL of degassed phosphate buffer (PBS, 140 mM NaCl, 3 mM KCl, 10 mM phosphate, 
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pH 7.4) were prepared in an N2-filled glovebox. A split-top septum cap was placed on the 
vial after probe insertion and the headspace was sparged with Ar. For electrode 
experiments in complex media, whole blood or serum (2.50 mL) was pipetted into a 10 
mL vial with phosphate buffer (PBS, 140 mM NaCl, 3 mM KCl, 10 mM phosphate, pH 
7.4) and stirred prior to the start of the experiment. The WPI electrode was then inserted 
into the vial and the measured voltage was allowed to equilibrate before starting the 
experiment, and the vial was wrapped in foil to shield the reaction from light. With 
moderate stirring, CA stock solution (50 µL, 2.5 µg/mL) was injected when applicable, 
followed by subsequent injections of acetazolamide (10 µL, 2.5 µM, 10 mM stock 
solution in PBS buffer), TCO stock (10 mM in DMSO), or tetrazine stock solutions (100 
mM in DMSO).  
 
3.4.2 Syntheses 
(E)-Cyclooct-2-enyl benzylcarbamate (1). A solution of (E)-cyclooct-2-enyl 4-
nitrophenyl carbonate (500 mg, 1.7 mmol) in CH2Cl2 (5 mL) was added to a solution 
containing benzylamine (370 µL, 3.4 mmol) and N,N-diisopropylethylamine (880 µL, 5.1 
mmol) in CH2Cl2 (5 mL). The reaction mixture was stirred at room temperature under a 
nitrogen atmosphere for 18 h. The reaction mixture was diluted with CH2Cl2 (50 mL) and 
washed with water (20 mL). The organic layer was dried over Na2SO4 and concentrated. 
The title product was purified by flash chromatography using a 9:1 mixture of 
hexanes:ethyl acetate to provide the product as a white powder (260 mg, 58%). 1H NMR 
(CDCl3, 400 MHz) δ: 7.36-7.26 (m, 5H), 5.83 (t, J = 12.3 Hz, 1H), 5.54 (d, J = 17.8 Hz, 
1H), 5.37 (s, 1H), 5.16 (bs, 1H), 4.38 (d, J = 5.5 Hz, 2H), 2.47 (d, J = 10.9 Hz, 1H), 2.09-
1.82 (m, 5H), 1.72-1.45 (m, 3H), 1.11-1.03 (m, 1H), 0.84-0.76 (m, 1H), which matches 
the previously-reported 1H NMR spectrum: Versteegen, R. M.; Rossin, R.; ten Hoeve, 
W.; Janssen, H. M.; Robillard, M. S. Angew. Chem. Int. Ed. 2013, 52, 14112-14116.  
 
O-(E)-Cyclooct-2-enyl N-benzylcarbamothioate (2). A solution of (E)-cyclooct-2-enol 
(120 mg, 0.95 mmol) in 1 mL THF was added dropwise to a suspension of NaH (45 mg, 
1.13 mmol, 60% in mineral oil) in 1 mL THF. The resulting suspension was stirred at 0 
ºC for 1 h under a nitrogen atmosphere. A solution of benzyl isothiocyanate (150 mg, 1.0 
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mmol) in 1 mL THF was added dropwise, and the mixture was stirred for an additional 
hour at 0 ºC. The reaction was quenched by addition of saturated aqueous NaHCO3 (2 
mL). The aqueous layer was extracted with ethyl acetate (3 x 10 mL), and the combined 
organic phases were dried with MgSO4. The title product was isolated as a white powder 
by flash chromatography using a 3:1 solution of hexanes:ether as a mobile phase (199 
mg, 76%). Note: Slow rotation around the thiocarbamate group results in the observation 
of rotational isomers on the NMR timescale, which results in a doubling of peaks in the 
NMR spectrum. This phenomenon has been observed previously in for thiocarbmates. 1H 
NMR (CDCl3, 400 MHz) δ: 7.58 (br s, 1H), 7.34-7.28 (m, 10H), 6.68 (br s, 1H), 5.92 (d, 
J = 10.9 Hz, 2H), 5.83-5.78 (m, 1H), 5.60-5.43 (m, 3H), 4.76 (d, J = 5.5 Hz, 2H), 4.47 (d, 
J = 6.8 Hz, 2H), 2.47 (d, J = 5.5 Hz, 1H), 2.37 (d, J = 9.6 Hz, 1H), 2.20-2.06 (m, 2H), 
2.05-1.32 (m, 13H), 1.11-1.09 (m, 1H), 0.87-0.77 (m, 3H). 13C{1H} NMR (CDCl3, 100 
MHz) δ: 189.45, 188.63, 136.88, 136.74, 132.61, 132.18, 130.92, 130.19, 128.61, 128.58, 
127.86, 127.68, 127.52, 127.20, 80.81, 79.17, 49.05, 47.02, 40.38, 40.37, 35.84, 35.83, 
35.79, 35.67, 28.90, 28.80, 24.34, 24.20. HRMS (ESI) m/z:  calcd. for C16H22NOS 
[M+H]+ 276.1422; found 276.1444 
 
Bis-isopropyl-1,2,4,5-tetrazine. Isobutyronitrile (691 mg, 10 mmol) and zinc triflate (182 
mg, 0.5 mmol) were combined with anhydrous hydrazine (1.6 mL) and stirred at 60 ºC 
for 24 h under nitrogen atmosphere. The reaction mixture was diluted with DMF (2 mL). 
An aqueous solution of NaNO2 (3.5 g in 50 mL) was slowly added. Inside a thoroughly 
ventilated fume hood, an aqueous 2M solution of HCl was added slowly until reaching 
pH~3. (Caution! The last step generates highly toxic fumes, containing reactive nitrogen 
species.) The product was extracted with CH2Cl2 (3x100 mL), dried with Na2SO4 and 
concentrated. The title product was obtained by chromatography using 1% Et2O in 
pentane (1.2 g, 72%). 1H NMR (CDCl3, 400 MHz) δ: 3.62 (sep, J = 6.8 Hz, 2H), 1.51 (d, 
J = 6.9 Hz, 12H). 13C{1H} NMR (CDCl3, 100 MHz) δ: 173.69, 34.14, 21.22. HRMS 







CYSTEINE-ACTIVATED HYDROGEN SULFIDE (H2S) DELIVERY THROUGH 
CAGED CARBONYL SULFIDE (COS) DONOR MOTIFS 
 
This chapter includes previously published and coauthored material from Zhao, Y.; 
Steiger, A.K; Pluth, M.D. “Cysteine-Activated Hydrogen Sulfide (H2S) Delivery through 
Caged Carbonyl Sulfide (COS) Donor Motifs” Chem. Commun. 2018, 54, 4951-4954.  
 
4.1 Introduction 
Hydrogen sulfide (H2S) has joined the gasotransmitter family since its first 
recognition as an endogenous neuromodulator in 1996.199 Four main enzymes, including 
cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE), are responsible for 
endogenous H2S production, converting cysteine (Cys) and homocysteine (Hcy) to H2S.2, 
200, 201 Significant efforts have been contributed to develop H2S releasing agents (H2S 
donors) because the regulation of H2S levels has been found to mediate a wide variety of 
physiological processes, including anti-inflammation, oxidative stress reduction, and 
vasorelaxation.124, 129, 202-204 Although sulfide salts, such as sodium hydrosulfide (NaHS) 
and sodium sulfide (Na2S), have been widely used in the field, they are far from ideal 
donors because they release H2S spontaneously, resulting in a concentrated bolus of 
sulfide that oxidizes rapidly and does not mimic well-regulated endogenous H2S 
production. The use of these inorganic sulfide sources has even led to contradictory 
results,124 demonstrating the need for improved sources of H2S. These limitations suggest 
that controllable H2S donors, which are stable, only release H2S upon activation by 
certain stimuli, and have slower and controllable kinetics of sulfide release, are key 
research tools for H2S investigations. 
 Aligned with this need, our group recently reported the use of caged-carbonyl 
sulfide (COS) molecules as new H2S donors.131, 205 Unlike other known H2S donors, 
which directly release H2S as the activation product, COS-based donors are activated to 
release COS, which is quickly converted to H2S by the ubiquitous enzyme carbonic 
anhydrase (CA). We have demonstrated that caged-thiocarbamates and thiocarbonates 
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can serve as promising COS donors and can be activated to release COS through a self-
immolative cascade reaction.206 One important advantage of this strategy is that COS-
releasing scaffolds can be designed to deliver H2S under well-defined conditions. For 
example, H2S delivery from these caged-COS donors can be modulated by judicious 
trigger selection, and the rate of release can be manipulated through modification of the 
donor structure.206 Following our initial report, we, as well as others, have expended this 
strategy to include donors activated by different triggers, such as reactive oxygen species 
(ROS),140, 206 esterases,152, 207 nucleophiles,150 click chemistry,147 and light208, 209 (Figure 
4.1). 
 
Figure 4.1 Examples of currently available COS-based H2S donors that are activated by 
different triggering stimuli. 
 
 Cellular nucleophiles play crucial roles in biological systems. Among these, thiol 
species, such as Cys and reduced glutathione (GSH), attract the most attention due to 
their cellular abundance and potent reactivity. Cys and GSH have been widely used to 
trigger biologically active molecules and prodrugs to release caged compounds, including 
sulfur dioxide (SO2),210, 211 nitroxyl (HNO),212 and anti-cancer drugs.213 Importantly, thiol 
activation strategies have been adopted in H2S donor development and several thiol labile 
H2S donors exhibit promising protections in animal models with some of them currently 
in clinical trials.124, 202, 204 Motivated by these findings, we report here the first example of 
a Cys-activated COS/H2S donor through functionalization of a thiocarbamate with a Cys-
reactive acrylate moiety. We envision that such thiocarbamate compounds will expand 
the current COS-based H2S donor family and serve as promising research tools for H2S 
studies.  
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The reactions of Cys with acrylates in the preparation of substituted 1,4-
thiazepines have been known for decades.214, 215 The initial attack by Cys on the acrylate 
generates a thioether, which then undergoes an intramolecular cyclization to yield 1,4-
thiazepines. This cyclization strategy has been leveraged by Strongin,216 as well as 
others,217-220 to design a series of acrylate-based fluorescent probes for Cys detection. 
Similarly, the Berreau group has recently used a similar approach to develop a class of 
Cys-responsive CO donors.221 Building from these approaches, we adopt the Cys-acrylate 
reaction as a triggering mechanism to access new COS/H2S donors in which an aryl 
acrylate-functionalized thiocarbamate is activated through a Cys-mediated 
addition/cyclization sequence. The resultant phenolic intermediate then undergoes a 1,6-
elimination to release COS, which is quickly converted to H2S by CA (Scheme 4.1). 
 
Scheme 4.1 General design of Cys-triggered COS/H2S release from caged-thiocarbamate 
donors. 
 
4.2 Results and Discussion 
 To test our hypothesis that acrylate-functionalized thiocarbamates could serve as 
Cys-triggered COS/H2S donors, we prepared O-alkyl cysteine-sensitive thiocarbamate 
(OA-CysTCM-1) with an aryl acrylate trigger and an aniline payload by reacting 4-
(hydroxymethyl)phenyl acrylate and phenyl isothiocyanate. Upon activation, OA-
CysTCM-1 releases COS, which is quickly hydrolyzed to H2S by CA. In addition to OA-
CysTCM-1, we also prepared the corresponding carbamate (OA-CysCM-1) and 
triggerless thiocarbamate (OA-TCM-1)222 control compounds. OA-CysCM-1, obtained 
from the reaction between 4-(hydroxymethyl)phenyl acrylate and phenyl isocyanate, is 
expected to undergo the same Cys activation but would release CO2 instead of COS. OA-
TCM-1, on the other hand, maintains the thiocarbamate scaffold but lacks the acrylate 
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trigger, and thus is not expected to react with Cys or decompose to otherwise release 
COS (Scheme 4.2).  
 
Scheme 4.2 Synthesis of OA-CysTCM-1, OA-CysCM-1, and OA-TCM-1.  
 
 To evaluate Cys-activated H2S release from the donor motif, we used the 
methylene blue (MB) assay to monitor H2S release from OA-CysTCM-1 (50 µM) in the 
presence of Cys (0 – 500 µM) in PBS buffer (pH 7.4, 10 mM) containing cellularly-
relevant concentrations of CA (25 µg/mL). The MB assay was chosen to measure H2S 
production since it has been widely used to detect H2S from previously developed Cys-
activated H2S donors. In the absence of Cys, OA-CysTCM-1 was stable in aqueous 
buffer and did not release COS/H2S spontaneously. By contrast, the addition of Cys led to 
a dose-dependent COS/H2S release from OA-CysTCM-1 (Figure 4.2). These results 
demonstrate that OA-CysTCM-1 can be activated by Cys and the resultant COS is 
quickly converted to H2S in the presence of CA. 
 To further demonstrate that the observed H2S release is due to Cys activation via 
the proposed mechanism, we pretreated Cys with N-ethylmaleimide (NEM), a Cys 
scavenger, for 20 min, followed by the addition of OA-CysTCM-1. When compared to 
the regular activation conditions (Figure 4.3, bar 1), NEM pretreatment significantly 
diminished H2S release from OA-CysTCM-1, confirming that Cys was required for 
donor activation (Figure 4.3, bar 2). No H2S release was observed in the absence of CA, 
and, similarly, pretreatment of CA with acetazolamide (AAA), a CA inhibitor, also failed 
to provide H2S, confirming that H2S release from OA-CysTCM-1 proceeds through a 
COS-dependent pathway (Figure 4.3, bars 3 and 4).  
 In addition to Cys, other biologically relevant nucleophiles, such as GSH, 
oxidized glutathione (GSSG), Hcy, N-acetylcysteine (NAC), serine (Ser), and lysine  
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Figure 4.2 COS/H2S Release from OA-CysTCM-1 (50 µM) in the presence of 0 µM 
(black), 50 µM (red), 250 µM (blue), and 500 µM (green) Cys. The experiments were 
performed in triplicate and results are expressed as mean ± SD (n = 3). 
 
(Lys), were evaluated towards donor activation. As expected, none of these species 
triggered OA-CysTCM-1, and no COS/H2S release was observed due to the lack of the 
addition/cyclization activation sequence (Figure 4.3, bars 5-10). We also evaluated Cys-
triggered COS/H2S release from OA-CysTCM-1 in the presence of GSH. In these 
experiments, OA-CysTCM-1 (50 µM) was co-incubated with Cys (500 µM) and GSH (0 
– 1000 µM) and COS/H2S release was monitored by MB assay (Figure C2). A decrease 
of H2S release was observed as GSH concentration increased, indicating a potential GSH-
induced donor consumption. Although the effects of GSH were not significant in aqueous 
buffer, it should be taken into consideration when applying donors in biological systems. 
Since the acrylate trigger may be prone to esterase-catalyzed hydrolysis, we also 
incubated OA-CysTCM-1 with porcine liver esterase (PLE) to determine whether 
common esterases could generate COS/H2S release. Although we did observe H2S 
release, it was significantly less efficient than Cys activation (Figure 4.3, bar 11). As 
expected, treatment of control compounds OA-CysCM-1 and OA-TCM-1 with Cys in 
the presence of CA failed to generate H2S, demonstrating that both the aryl-acrylate 
trigger and the caged COS-containing thiocarbamate scaffold are crucial for COS release 
from this scaffold (Figure 4.3, bars 12 and 13). Taken together, these selectivity studies 
	 56 
demonstrate that OA-CysTCM-1 is highly sensitive towards Cys activation to release 
COS/H2S and inert to activation by other biomolecules, such as GSH, GSSG, Hcy, NAC, 
Ser, and Lys.  
 
Figure 4.3 COS/H2S Release from OA-CysTCM-1 (50 µM) in the presence of cellular 
nucleophiles (500 µM): (1) Cys, (2) Cys + NEM (10 mM), (3) Cys - CA, (4) Cys + AAA 
(10 µM), (5) Hcy, (6) NAC, (7) GSH (5.0 mM), (8) Ser, (9) Lys, (10) GSSG, and (11) 
PLE (1 U/mL). Cys (500 µM) effects on OA-CysCM-1 (12), and OA-TCM-1 (13) 
toward COS/H2S release. H2S concentration was measured after 3-h incubation. The 
experiments were performed in triplicate and the results were expressed as mean ± SD (n 
= 3). 
 
 We next sought to confirm that OA-CysTCM-1 would release COS/H2S upon 
reaction with Cys in a cellular environment. We incubated bEnd.3 cells with OA-
CysTCM-1 in the presence of Cys and visualized H2S-release using SF7-AM, a cell-
trappable H2S-responsive fluorescent probe.196 In the absence of OA-CysTCM-1, 
negligible SF7-AM fluorescence was observed, suggesting a minimum amount of 
endogenous H2S present in bEnd.3 cells. By contrast, addition of OA-CysTCM-1 
resulted in a significant increase in SF7-AM fluorescence, confirming that OA-
CysTCM-1 can be activated by Cys to release H2S in a cellular environment (Figure 4.4). 
These results demonstrate that OA-CysTCM-1 is a potent COS/H2S donor and Cys-
triggered H2S delivery can be visualized in complex biological systems, indicating 
applications of OA-CysTCM-1 as a potential H2S-related therapeutic or research tool.  
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Figure 4.4 H2S Release from OA-CysTCM-1 in bEnd.3 cells. Top: DIC (left) and GFP 
(right) channels with cysteine (250 µM) and SF7-AM (5 µM). Bottom: DIC (left) and 
GFP (right) channels with cysteine (250 µM), OA-CysTCM-1 (100 µM), and SF7-AM 
(5 µM). Scale bar represents 100 µM. 
 
4.3 Conclusions 
 In summary, we prepared and evaluated OA-CysTCM-1 as a Cys-triggered 
COS/H2S donor. Our studies demonstrate that OA-CysTCM-1 is stable in aqueous media 
and does not release COS/H2S until being activated by Cys. Importantly, H2S delivery 
from OA-CysTCM-1 is observed in a cellular environment, indicating OA-CysTCM-1 
can be used as a new efficacious Cys labile COS/H2S donor in complex biological 
systems. Taken together, our investigations demonstrate that H2S delivery from OA-
CysTCM-1 can be controlled and regulated through a COS-dependent pathway, making 
OA-CysTCM-1 a new member of COS-based H2S donor family with potential 
applications in the study of both H2S and COS chemical biology, especially when used in 
combination with available Cys-activated H2S donors. Activation of the donors 
developed in this chapter still results in consumption of biological thiols, however, and 
Chapter V addresses this limitation through the design of a COS/H2S donor activated by a 
ubiquitous intracellular enzyme. 
 
4.4 Experimental Details 
4.4.1 Materials and Methods 
Reagents were purchased from Sigma-Aldrich, Tokyo Chemical Industry (TCI), 
Fisher Scientific, or VWR and used directly as received. SF7-Am was synthesized as 
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previously reported.196 Silica gel (SiliaFlash F60, Silicycle, 230−400 mesh) was used for 
column chromatography. Deuterated solvents were purchased from Cambridge Isotope 
Laboratories (Tewksbury, Massachusetts, USA). 1H and 13C{1H}. NMR spectra were 
recorded on Varian 300 MHz, Bruker 500 MHz or Bruker 600 MHz NMR instruments at 
the indicated frequencies. Chemical shifts are reported in ppm relative to residual protic 
solvent resonances. Methylene blue (MB) absorbances were measured using an Agilent 
Cary 100 UV-Vis spectrometer. b.End3 cells were purchased from ATCC (Manassas, 
Virginia, USA). Cell imaging experiments were performed on a Leica DMi8 fluorescence 
microscope, equipped with an Andor Zyla 4.2+ sCMOS detector. 
 
H2S Release from OA-CysTCM-1 in PBS. An OA-CysTCM-1 stock solution (0.100 mL, 
10.0 mM in DMSO) was added to 20.0 mL of PBS (pH 7.40, 10.0 mM) containing CA 
(25.0 µg/mL) in a 25-mL scintillation vial. A Cys stock solution (0.100 M in H2O) was 
then added to generate the desired Cys working concentrations as shown in Figure 3. 
Next, 0.300 mL aliquots of the reaction mixture were transferred to UV cuvettes 
containing 0.300 mL of MB cocktail (0.0600 mL zinc acetate (1.00% w/v), 0.120 mL 
FeCl3 (30.0 mM in 1.20 M HCl), and 0.120 mL N,N-dimethyl-p-phenylene diamine (20.0 
mM in 7.20 M HCl) at different time points. The absorbance at 670 nm was then 
measured after 1 hour and was converted to H2S concentration by using the H2S 
calibration curve as shown in Figure C1. 
 
Selectivity Evaluation of H2S Release from OA-CysTCM-1 (Figure 3). All experiments 
were completed in 2.00 mL of PBS containing CA (25.0 µg/mL). After 3 hours of 
incubation at room temperature, 0.300 mL of the reaction aliquot was transferred to a UV 
cuvette containing 0.300 mL of the MB cocktail. The absorbance at 670 nm was then 
measured after 1 hour by the MB assay.  
 
Bar 1: Added Cys (10.0 µL, 0.100 M in H2O), followed by the addition of OA-   
CysTCM-1 (10.0 µL, 10.0 mM in DMSO).  
Bar 2: Added Cys (10.0 µL, 0.100 M in H2O), followed by the addition of NEM (2.50 
mg). After 20 min, OA-CysTCM-1 (10.0 µL, 10.0 mM in DMSO) was added.  
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Bar 3: Added Cys (10.0 µL, 0.100 M in H2O), followed by the addition of OA-
CysTCM-1 (10.0 µL, 10.0 mM in DMSO).  
Bar 4: Added Cys (10.0 µL, 0.100 M in H2O), followed by the addition of AAA (2.00 
µL, 10.0 mM in DMSO). After 20 min, OA-CysTCM-1 (10.0 µL, 10.0 mM in DMSO) 
was added.  
Bar 5: Added Hcy (10.0 µL, 0.100 M in H2O), followed by the addition of OA-
CysTCM-1 (10.0 µL, 10.0 mM in DMSO).  
Bar 6: Added NAC (10.0 µL, 0.100 M in H2O), followed by the addition of OA-
CysTCM-1 (10.0 µL, 10.0 mM in DMSO).  
Bar 7: Added GSH (10.0 µL, 0.100 M in H2O), followed by the addition of OA-
CysTCM-1 (10.0 µL, 10.0 mM in DMSO).  
Bar 8: Added Ser (10.0 µL, 0.100 M in H2O), followed by the addition of OA-CysTCM-
1 (10.0 µL, 10.0 mM in DMSO). 
Bar 9: Added Lys (10.0 µL, 0.100 M in H2O), followed by the addition of OA-
CysTCM-1 (10.0 µL, 10.0 mM in DMSO).  
Bar 10: Added GSSG (10.0 µL, 0.100 M in H2O), followed by the addition of OA-
CysTCM-1 (10.0 µL, 10.0 mM in DMSO).  
Bar 11: Added PLE (20.0 µL, 1.00 U/µL), followed by the addition of OA-CysTCM-1 
(0.100 mL, 10.0 mM in DMSO).  
Bar 12: Added Cys (10.0 µL, 0.100 M in H2O), followed by the addition of OA-CysCM-
1 (10.0 µL, 10.0 mM in DMSO).  
Bar 13: Added Cys (10.0 µL, 0.100 M in H2O), followed by the addition of OA-TCM-1 
(10.0 µL, 10.0 mM in DMSO).  
 
Cellular Imaging of H2S Release from OA-CysTCM-1. b.End 3 cells were plated in poly-
D-lysine coated plates (MatTek) containing 2 mL of DMEM and incubated at 37 °C 
under 5% CO2 for 24 h. The confluent cells were washed with PBS and then incubated 
with SF7-AM (5.00 µM) for 30 min. The cells were then washed with PBS and incubated 
with either OA-CysTCM-1 (100 µM) and cysteine (250 µM) or cysteine (250 µM) alone 
for 30 min. Prior to imaging, cells were washed with PBS and bathed in 2 mL of PBS. 
Cell imaging was performed on a Leica DMi8 fluorescent microscope using DIC for 
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brightfield and a standard GFP filter cube for fluorescence imaging and 100 ms and 50 
ms exposure times, respectively. The scale bar represents 100 µm. 
 
4.4.2 Syntheses 
S1. The benzyl alcohol compound S1 was prepared using a known procedure.223 Briefly, 
K2CO3 (207 mg, 1.50 mmol) was dissolved in acetone/H2O (25.0 mL, v/v 4:1), followed 
by the addition of acryloyl chloride (90.5 mg, 1.00 mmol) at 0 oC. To this reaction 
mixture, a solution of 4-hydroxybenzyl alcohol (124 mg, 1.00 mmol) was added 
dropwise and the reaction solution was stirred at 0 °C for 4 h. Brine was then added, and 
the reaction mixture was extracted with DCM (3 x 25.0 mL). The organic layers were 
collected, dried over MgSO4, and concentrated under vacuum. The product S1 was 
isolated as a clear oil (42.0%) after purification by column chromatography. 1H NMR 
(500 MHz, CDCl3) δ (ppm): 7.43 (d, J = 5.0 Hz, 2H), 7.16 (d, J = 5.0 Hz, 2H), 6.64 (d, J 
= 15.0 Hz, 1H), 6.36 (m, 1H), 6.05 (d, J = 10.0 Hz, 1H), 4.73 (s, 2H), 1.75 (br, 1H). 
13C{1H} NMR (125 MHz, CDCl3) δ (ppm): 164.6, 150.0, 138.5, 132.7, 128.1, 127.9, 
121.6, 64.8. 
 
OA-CysTCM-1. S1 (178 mg, 1.00 mmol) and phenyl isothiocyanate (135 mg, 1.00 
mmol) were dissolved in THF (15.0 mL) and cooled to 0 oC. DBU (152 mg, 1.00 mmol) 
was then added, and the reaction solution was stirred at 0 °C for 4 h. The reaction mixture 
was then quenched by adding brine, and the aqueous solution was extracted with DCM (3 
x 25.0 mL). The organic layers were collected, dried over MgSO4, and concentrated 
under vacuum. OA-CysTCM-1 was isolated as white solid (35.4%) after purification by 
column chromatography. Two sets of NMR resonances showed up due to slow rotation 
around the thiocarbamate functional group at room temperature. 1H NMR (500 MHz, 
DMSO-d6) δ (ppm): 11.24 (s, 1H), 7.68 (br, 1H), 7.52 (br, 2H), 7.34 (br, 3H), 7.22 (br, 
3H), 6.54 (d, J = 15.0 Hz, 1H), 6.42 (dd, J = 15.0, 5.0 Hz, 1H), 6.17 (d, J = 10.0 Hz, 1H), 
5.55 (d, J = 50.0 Hz, 2H). 13C{1H} NMR (150 MHz, DMSO-d6) δ (ppm): 187.8, 187.4, 
164.6, 150.5, 134.2, 130.3, 129.9, 129.3, 128.9, 128.1, 125.6, 123.3, 122.3, 72.0, 70.3. IR 
(cm-1): 3228, 3039, 2919, 1734, 1592, 1547, 1494, 1446, 1402, 1335, 1293, 1146, 1018, 
968. HRMS m/z [M + Na]+ calcd. for [C17H15NNaO3S]+ 336.0670; found 336.0673. 
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OA-CysCM-1. S1 (178 mg, 1.00 mmol) and phenyl isocyanate (119 mg, 1.00 mmol) 
were dissolved in THF (15.0 mL) and cooled to 0 oC. TEA (101 mg, 1.00 mmol) was 
then added, and the reaction solution was heated to 65 °C and stirred for 5 h. The reaction 
mixture was then quenched by adding brine and the aqueous solution was extracted with 
DCM (3 x 25.0 mL). The organic layers were collected, dried over MgSO4, and 
concentrated under vacuum. OA-CysCM-1 was isolated as white solid (47.0%) after 
purification by column chromatography. 1H NMR (300 MHz, CDCl3) δ (ppm): 7.43 (t, J 
= 9.0 Hz, 4H), 7.32 (t, J = 9.0 Hz, 2H), 7.15 (d, J = 9.0 Hz, , 2H), 7.09 (t, J = 9.0 Hz, 
1H), 6.91 (br, 1H), 6.64 (dd, J = 15.0, 3.0 Hz, 1H), 6.35 (dd, J = 18.0, 9.0 Hz, 1H), 6.04 
(dd, J = 12.0, 3.0 Hz, 1H), 5.20 (s, 2H). 13C{1H} NMR (125 MHz, CDCl3) δ (ppm): 
164.6, 153.4, 150.5, 137.8, 133.8, 132.8, 129.6, 129.1, 127.8, 123.5, 121.7, 118.8, 66.3. 
IR (cm-1): 3367, 3064, 1735, 1709, 1634, 1598, 1532, 1502, 1447, 1407, 1318, 1298, 
1234, 1198, 1167, 1071, 982, 901, 819. HRMS m/z [M + Na]+ calcd. for [C17H15NNaO4]+ 




















INHIBITION OF MITOCHONDRIAL BIOENERGETICS BY ESTERASE-
TRIGGERED COS/H2S DONORS 
 
This chapter includes previously published and coauthored material from Steiger, A.K.; 
Marcatti, M.; Szabo, C.; Szczesny, B.; Pluth, M.D. “Inhibition of Mitochondrial 




Hydrogen sulfide (H2S) is an endogenously-produced signaling molecule that 
plays critical roles in mammalian biology. Physiological sulfide levels are tightly 
regulated, and enzymatic production derives primarily from cysteine and homocysteine 
metabolism by cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-
mercaptopyruvate transferase (3-MST).2 Continually broadening in scope, H2S plays 
important roles in cardioprotection,224 inflammation,225 vasodilation,226 as well as other 
processes. Because of this diversity, there is significant interest in developing both 
research and therapeutic strategies for regulating sulfide levels in different biological 
contexts.129 At the biological level, inhibition, knockout, and/or overexpression of H2S-
producing enzymes can be used to modulate endogenous H2S levels. Alternatively, 
chemical approaches using exogenous H2S donation often provide a more convenient and 
broader approach. For example, inorganic sulfide salts, such as NaSH and Na2S provide a 
convenient source of sulfide, however, the large and instantaneous bolus of sulfide 
released from such salts is often rapidly oxidized and fails to mimic the continuous H2S 
release associated with enzymatic synthesis, thus limiting the utility of these exogenous 
H2S sources.227 Because of these limitations, developing small molecules that undergo 
specific reactions to release H2S in a controlled manner to more closely mimic well-
regulated enzymatic production remains an important goal.122, 124 Aligned with these 
needs, naturally-occurring polysulfides such as diallyl trisulfide (DATS), which releases 
sulfide upon reaction with thiols,89, 228 hydrolysis-based H2S donors such as GYY4137 
and ADT-OH,229, 230 which slowly produce H2S in water, and a palette of thiol-activated 
donors, have all been developed.124, 170 Although such donors have been used in 
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applications ranging from probe development to in vivo studies, key challenges include 
low H2S donation efficiencies from hydrolysis-based donors and thiol consumption and 
redox perturbation from polysulfides and thiol-activated donors.  
As a step toward addressing these challenges, our group recently developed a new 
H2S donation strategy based on the intermediate release of carbonyl sulfide (COS), which 
is rapidly hydrolyzed to H2S by the ubiquitous enzyme carbonic anhydrase (CA).131 By 
leveraging well-established work on the triggered decomposition of benzylic carbamates 
commonly used in pro-drug and fluorophore release strategies,132, 231, 232 we demonstrated 
that self-immolative thiocarbamates can be readily engineered to respond to different 
stimuli and release COS/H2S. Specifically, cleavage of an analyte-specific protecting 
group unmasks a phenol, which then undergoes a self-immolative decomposition to 
release COS. Importantly, this strategy enables significant control over H2S donation 
depending on the trigger and provides access to important carbamate control compounds, 
which release CO2/H2O rather than COS/H2S. Furthermore, although COS hydrolysis by 
CA is rapid, some evidence suggests that COS may have unique roles in chemical 
biology, as evidenced by COS detection in the headspace above ex vivo porcine coronary 
arteries and by increased COS levels in exhaled breath from patients with cystic fibrosis, 
organ rejection, or liver disease.39-41, 233 Therefore, although self-immolative 
thiocarbamates have recently been shown to be useful as responsive H2S donors, they 
may also provide a platform for future studies of COS chemical biology. Following our 
initial report of caged COS/H2S release, we have expanded this approach to include 
COS/H2S donors activated by reactive oxygen species (ROS)140 and to access bio-
orthogonal “click-and-release”131 donors based on trans-cyclooctene / tetrazine click 
chemistry. Related COS-based donors based on nucleophilic addition to small molecule 
and polymeric cyclic N-thiocarboxyanhydrides resulting in the release of COS have also 
emerged recently.150 Although the nucleophile-based donors provide slow H2S release 
akin to enzymatic synthesis, the required consumption of cellular nucleophiles, such as 
thiols, to release COS/H2S is similar to other thiol-activated donors.  
To address these limitations, we viewed that installation of an ester as the 
triggering group to thiocarbamate-based platforms would provide access to slow-release 
COS/H2S donors upon ester cleavage by intracellular esterases that do not require 
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consumption of cellular nucleophiles for activation (Scheme 5.1). The strategy of using 
intracellular esterases to cleave esterified moieties on small molecules is a well-
established method used extensively to impart cellular trappability, improve membrane 
permeability, and in the activation of caged pro-drugs and other biological payloads.153, 
234-236 Additionally, activation by intracellular esterases eliminates the consumption of 
cellular nucleophiles for activation. Consistent with this design strategy, the Wang group 
recently reported esterase-triggered H2S donors utilizing a trimethyl lock unmasking of 
caged thioacids and demonstrated their anti-inflammatory effects.171 Similarly, during the 
preparation of this manuscript an esterase-activated S-alkyl thiocarbamate COS/H2S 
donor was reported, but detailed biological applications were not investigated.152 Here, 
we report the design, evaluation, and application of esterase-activated COS/H2S donors 
and provide further insights into the influence of COS donors on cellular bioenergetics.  
 
 
Scheme 5.1 Design of esterase-triggered self-immolative COS/H2S donors and proposed 
COS/H2S release mechanism.  
 
5.2 Results and Discussion 
Triggered COS/H2S donors benefit from a high degree of modularity and facile 
introduction of different triggering functionalities. To access an esterase-functionalized 
thiocarbamate, we first prepared 4-pivaloyl benzyl alcohol in one step,237 which was then 
treated with p-tolylisothiocyanate in the presence of DBU to afford donor 1 in moderate 
yield (Scheme 5.2). The analogous carbamate control 2 was prepared in good yield by 
treating 4-pivaloyl benzyl alcohol with p-tolylisocyanate and DBU. Carbamate 2 
provides an important control compound that undergoes the same self-immolative 
decomposition as 1, but releases CO2 instead of COS, thus enabling separation of the 



















Additionally, we also prepared triggerless thiocarbamate 3 as a control compound to test 
the thiocarbamate stability toward esterases. 
 
 
Scheme 5.2 (a) Synthesis of H2S donor 1, CO2-releasing analogue 2, and triggerless 
thiocarbamate 3. 
 
The mechanism of the cascade decomposition of similar benzyl carbamates has 
established previously to release CO2, the amine payload, and a quinone methide 
intermediate.132, 135, 231, 232 The final fate of the electrophilic quinone methide is dependent 
on which nucleophiles are present in the system, and is often scavenged by water to form 
4-hydroxy benzylalcohol, or can be scavenged by biological nucleophiles to afford thiol 
or amine-derived conjugates.238, 239 To confirm similar reactivity in the present system, 
we first demonstrated that the addition of porcine liver esterase (PLE) initiated a self-
immolative decomposition reaction as anticipated. After stirring 1 (14 mM) with PLE (28 
U/mL) in PBS (pH 7.4) with 10% DMSO for 48 hours, the organic layer was extracted 
and analyzed by NMR spectroscopy and mass spectrometry (Figure 1). Loss of the 
benzylic and thiocarbamate N-H protons at ~5.5 ppm and 11.1 ppm, respectively, in the 
1H NMR spectrum of the reaction mixture confirmed self-immolation (Figure 3.1a). As 
further evidence of the triggered cascade decomposition, the broad NMR resonances 
characteristic of O-alkyl thiocarbamates, which is due to the slow rotation around the 
thiocarbamte moiety on the NMR time scale, sharpen significantly upon ester cleavage 
with PLE. Additionally, the 13C{1H} NMR spectrum after treatment with PLE (Figure 
3.1b), clearly showed the loss of the C=S and benzylic carbon resonances at 185 and 70 
ppm, respectively. Both the 1H and 13C{1H} NMR spectra also show the formation of 
new aromatic species corresponding to several products, which were further 
characterized using mass spectrometry. Because the generated p-quinone methide is 
electrophilic, we expect that it would be scavenged by biological nucleophiles, such as 
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thiols, amines, or water, under physiological conditions. The mass spectrum acquired of 
the reaction mixture after treatment with PLE clearly showed formation of p-toluidine 
(m/z: 107.0) and the product corresponding to p-toluidine trapping of the o-quinone 
methide intermediate (m/z: 214.1) as expected (Figure D1). Taken together, the NMR 
spectroscopy and mass spectrometry studies confirm self-immolation of the scaffold as 
described in Scheme 5.1. 
 
 
Figure 5.1 (a) 1H NMR spectrum of 1 before (top) and after (bottom) treatment with 
PLE. (b) 13C{1H} NMR spectrum of 1 before (top) and after (bottom) stirring with PLE. 
(c) Mass spectrum of the products resulting from the decomposition of 1 upon reaction 
with PLE. 
 
With esterase-triggered donors in hand, we first confirmed that 1 was stable in 
aqueous solution in the absence of esterase. We next verified that addition of 1 to pH 7.4 
PBS buffer containing physiologically relevant levels of CA (25 µg/mL) did not result in 
H2S generation when monitored using an H2S-selective electrode, confirming that the 
esterase does not cleave thiocarbamates directly (Figure 5.2a). Further control 
experiments using the parent benzyl thiocarbamate 3, which lacks the ester trigger, 
confirmed that the benzyl thiocarbamate moiety is not cleaved directly by PLE. Having 
confirmed the stability of the donor platform prior to activation, we next treated 1 with 1 
U/mL PLE in the presence of CA and observed immediate H2S release (Figure 5.2a). As 
expected, increasing the PLE concentration to 20 U/mL under otherwise identical 
conditions resulted in significantly faster H2S release. Additionally, treatment of 1 with 
acetazolamide (AAA), a known CA inhibitor, significantly reduced the rate of H2S 
production, confirming that CA is necessary for COS conversion to H2S under the 
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reaction conditions. Supplementing the H2S electrode measurements, we also confirmed 
H2S release from 1 using an H2S-responsive fluorescent probe (Figure 5.2b). Consistent 
with the electrode data, incubation of 50 µM 1 with 5 µM MeRho-Az184 in the presence 
of CA and 1 U/mL PLE resulted in a fluorescence turn-on consistent with H2S release. 
We also attempted to obtain fluorescent live cell images by incubating 1 in BEAS 2B 
cells with MeRho-Az, but the high cytotoxicity of 1 and limited permeability of MeRhoAz 
in BEAS 2B cells limited our ability to obtain high quality images. Taken together, these 
data demonstrate that the thiocarbamate donors are stable until activated by esterases and 
release H2S in a COS-dependent manner. 
 
 
Figure 5.2 (a) H2S release from 1 in PBS (pH 7.4) in the presence of CA (25 µg/mL) 
with 1 U/mL (green trace) or 20 U/mL (blue trace) PLE. Addition of CA inhibitor AAA 
(2.5 µM) significantly reduces H2S release (black trace). No H2S release was observed 
from 1 in the absence of esterase (grey trace) or from thiocarbamate 3 lacking an ester 
trigger (brown trace). (b) Detection of H2S released from 1 with the H2S-responsive 
probe MeRho-Az. Conditions: 50 µM 1, 5 µM MeRho-Az, 25 µg/mL CA, 1 unit/mL 
PLE, 3 mL PBS (pH 7.4). 37 °C, λex= 476 nm, λem= 480-650 nm. 
  
We next investigated the cytotoxicity of 1-3 on BEAS 2B cells by measuring the 
reduction of a tetrazolium compound (MTT) to formazan by metabolically active cells, 
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and by measuring the release of lactate dehydrogenase (LDH) due to permeability of the 
plasma membrane, which is a sign of necrotic cell death. BEAS 2B human lung epithelial 
cells exhibit low expression of all three canonical H2S-producing enzymes, CBS, CSE, 
and 3-MST.240 To provide suitable comparisons with commonly-used synthetic donors, 
we first obtained comparable cytotoxicity data for known H2S donors GYY4137 and 
mitochondrially-targeted AP39 (Figure 5.3a,b).241 When compared to the DMSO vehicle, 
GYY4137 showed no significant cytotoxicity up to 30 µM using either the MTT or LDH 
assay. Similarly, AP39 showed minimal cytotoxicity at 30 µM and none at lower 
concentrations, indicating that neither of these H2S donors are significantly cytotoxic. By 
contrast, 10 µM of 1 resulted a significant decrease cell viability and increase in LDH 
levels, which was not observed for control compounds 2 or 3 (Figure 5.3c,d). The lack of 
cytotoxicity of control compound 2 suggests that the mechanism of cytotoxicity does not 
result from the formation of the electrophilic p-quinone methide intermediate242 because 
this species is formed upon activation of both donor 1 and control compound 2. Similarly, 
compound 3 does not reduce cell viability, confirming that the observed cytotoxicity of 1 
relies on triggering by cellular esterases and is not a result of the thiocarbamate scaffold 
itself. Importantly, the esterase-triggered COS/H2S donor 1 provides a significantly 
different toxicological profile from other commonly-used H2S donors. 
To investigate the underpinnings of the increased cytotoxicity of 1, and because 
H2S is a well-known inhibitor of mitochondrial cytochrome c oxidase,243 we analyzed the 
mitochondrial respiration of BEAS 2B cells treated with 1-3 using an Extracellular Flux 
Analyzer.244 As expected, incubation of BEAS 2B cells with increasing concentrations of 
1 for 24 hours negatively affected all major bioenergetics parameters, namely oxygen 
consumption linked with basal respiration, maximal respiration, and ATP synthesis 
(Figure 5.4a-f). These reductions are consistent with known inhibitory effects of H2S on 
cellular bioenergetics, primarily through inhibition of mitochondrial cytochrome c 
oxidase (Complex IV). By contrast, control compound 2 did not negatively impact the 
measured bioenergetics parameters, but rather resulted in increases in basal respiration 
and ATP synthesis. Compound 3 had no effect on basal respiration or ATP synthesis, and 
only slightly decreased maximal respiration at 10 µM. To better compare these results 
with known H2S donors, we also analyzed the mitochondrial respiration of BEAS 2B  
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Figure 5.3 Cell viability studies of AP39, GYY4137, and 1-3 in BEAS 2B using the (a,c) 
MTT and (b,d) LDH cell viability assays. 
 
cells incubated with AP39 and GYY4137 under the same conditions (Figure 5.4g-i). We 
failed to observe significant inhibition of cellular bioenergetics at the observed 
concentrations, raising the possibility that the inhibitory effects of 1 may not be from H2S 
release alone, but could also be due to direct COS inhibition of cytochrome c oxidase,245, 
246 which has been reported previously but received less scrutiny than direct H2S 
inhibition. Our previous investigations with ROS-activated140 and “click-and-release”131 
COS/H2S donors did not reveal donor cytotoxicity below 100 µM, suggesting that the 
observed cytotoxicity from 1 may be amplified by specific localization of the esterase-
activated 1 or efficient release H2S in local environments associated with the 
mitochondrial respiratory chain. 
 
5.3 Conclusions 
In conclusion, we have designed an easy-to-access, esterase-triggered COS/H2S 
donor and shown that it is rapidly activated by esterases to generate H2S in vitro using 
isolated PLE. Using toxicity assays and bioenergetics measurements, we demonstrated  
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Figure 5.4 Cellular bioenergetics analysis including (a) basal respiration, (b) maximal 
respiration, and (c) ATP synthesis in BEAS 2B cells upon addition of 1-10 µM of 1-3 as 
well as full bioenergetics data at (d) 1 µM, (e) 3 µM, and (f) 10 µM. For comparison, data 
was additionally collected for (g) basal respiration, (h) maximal respiration, and (i) ATP 
synthesis of BEAS 2B cells incubated with AP39 and GYY4137. Abbreviations: oligo: 
oligomycin, FCCP: carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, AA/Rot: 
antimycin A and rotenone. Values represent the means ± SEMs from three independent 
biological experiments each with five replicates. The values that are significantly 
different by Student's t test are indicated by asterisks as follows: **, P < 0.01; *, P < 
0.05. 
 
that the increased cytotoxicity of 1 is due inhibition of mitochondrial respiration, whereas 
carbamate control compound 2 and triggerless thiocarbamate 3 failed to negatively 
perturb normal bioenergetics. Using AP39 and GYY4137, we confirmed that the 
disruption of cellular bioenergetics observed from 1 is significantly different than is seen 
with other H2S donors, potentially suggesting that either the amount of produced H2S, 
specific localization of the esterase-triggered scaffold, or direct inhibition of 
mitochondrial respiration by COS itself is responsible for the observed cytotoxicity. As a 
whole, the esterase-cleaved donor reported here provides a slow-release method of 
COS/H2S release in cellular environments. Further work investigating the relationship 
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between the kinetics of COS release and the cytotoxicity of esterase-activated donors is 

































TUNABLE ESTERASE-TRIGGERED SELF-IMMOLATIVE 
THIOCARBAMATES PROVIDE INSIGHTS INTO COS CYTOTOXICITY 
 
This chapter includes unpublished, coauthored material written by myself and C.M 
Levinn with editorial assistance by M.D. Pluth. The experimental work was performed by 
either myself or C.M Levinn. 
 
6.1 Introduction 
Hydrogen sulfide (H2S), the most recent addition to the gasotransmitter family,199 
plays important physiological roles in the cardiovascular,247 respiratory, as well as other 
organ systems.2 Significant interest in both research and therapeutic strategies for H2S 
delivery has led to the development of a library of synthetic small molecules that release 
H2S (H2S donors) by using different strategies.122, 129, 248-250 In one recently-developed 
approach, our group, as well as others, has reported H2S donors based on the triggerable, 
self-immolative decomposition of thiocarbamates to release carbonyl sulfide (COS), 
which is rapidly hydrolyzed to H2S by the ubiquitous mammalian enzyme carbonic 
anhydrase (CA).131 This COS-dependent H2S-releasing strategy is highly tunable and 
allows for triggering of H2S release by a variety of stimuli, including ROS,140, 208 
nucleophiles,150 cysteine,251 and light.208, 209, 252 
 In addition to functioning as a precursor for CA-mediated H2S release, COS is the 
most prevalent sulfur-containing gas in Earth’s atmosphere, and plays important roles in 
the global sulfur cycle. Despite this significance, few studies have investigated the 
physiological properties of COS directly.205 Currently, there are no known mechanisms 
of eukaryotic COS biosynthesis, although it has been shown that acetylcholine 
stimulation of porcine coronary artery (PCA) leads to an observed increase in COS, 
indicating that muscarinic acetylcholine receptors (mAChRs) could play a role in 
regulating COS synthesis.41 Additionally, it has been detected in the headspace of porcine 
coronary artery and cardiac muscle,41 suggesting potential endogenous production. COS 
has also been recognized COS as an exhaled breath biomarker for a variety of diseases, 
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including cystic fibrosis39 and liver disease and rejection,40, 233 which suggests a possible 
role in disease physiology. The consumption of COS by CA is well established and COS 
toxicity closely resembles that of H2S, which is likely due to CA-mediated hydrolysis 
within mucous membranes upon exposure. The rapid conversion of COS to H2S, with an 
associated rate constant of 2.2x104 M-1s-1 (for bovine carbonic anhydrase II), makes COS 
a convenient source of sulfide, but also makes disentangling the chemical biology of COS 
from H2S more challenging.65  
We recently reported an esterase-triggered COS-mediated H2S donor,207 wherein 
ester cleavage reveals an intermediate phenol that undergoes a 1,4-self-immolation 
cascade to release COS, followed by rapid hydrolysis to H2S. Contrary to previous 
reports of similar donors, however, these compounds exhibit significant cytotoxicity and 
fully inhibited major mitochondrial bioenergetic pathways in bronchial epithelium 
BEAS2B cells. Similar cytotoxicity profiles were not observed for other H2S donors, 
including NaSH, GYY4137, or AP39, at similar concentrations. Furthermore, analogous 
CO2-releasing carbamate control compound were non-cytotoxic, confirming that the 
observed cytotoxicity or bioenergetics impacts were not due to organic byproducts of 
donor activation. Taken together, these results led to the hypothesis that the observed 
effects could be due to a buildup of COS. Supporting this hypothesis, the rate of small 
ester cleavage by mammalian esterases is likely faster (around 5.1x104 – 5.8x105 M-1s-1) 
than the rate of CA-mediated COS hydrolysis to H2S,65, 253 which would result in a 
buildup of intracellular COS. Here we extend this hypothesis by preparing a library of 
esterase-cleaved COS-releasing donors in which the steric bulk of the ester and the 
electronic properties of the aniline payload are modified, and demonstrate that the 
differential cytotoxicity of these donors maps to the COS release rates, thus furthering the 
hypothesis that COS may exert different biological effects than H2S alone (Figure 6.1).  
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Figure 6.1 Esterase-triggered thiocarbamate-based H2S donors exhibit increased 
cytotoxicity, potentially due to the buildup of intracellular COS.  
 
6.2 Results and Discussion 
To further investigate whether the cytotoxicity of these esterase-activated 
COS/H2S donor could be related to COS directly, we chose to probe the relationship 
between COS release rates and the corresponding cytotoxicity. We hypothesized that if 
COS buildup was responsible for the observed cytotoxicity, then esters cleaved more 
quickly should result in increased cell death, whereas esters cleaved more slowly should 
have a diminished effect. In the esterase-activated donors, the rate of COS release 
depends not only on the rate of ester cleavage (“triggering”), but also on the rate of self-
immolative decomposition. There have been a number of reports demonstrating that rate 
of esterase activity varies directly with the steric bulk of the ester being cleaved,254, 255 
providing a rational strategy for manipulating the rate of triggering by intracellular 
esterases. Similarly, recent work has demonstrated that the electronics of the amine 
payload can affect the rate of thiocarbamate self-immolation.152, 206 To probe the 
relationship between rate of ester cleavage, self-immolative decomposition, and 
cytotoxicity, a suite of esterase-activated COS donors with varying ester sizes and 
payloads were prepared to shed some light on the assumed innocence of COS.  
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Figure 6.2 (a) Synthetic scheme for the development of a library of esterase-activated 
thiocarbamate COS/H2S donors (TCM1-14) and (b) table showing all compounds used in 
this study (TCM1-14 and CM1-14) with yields. 
 
 To probe the effects of steric bulk on the rate of COS release and cytotoxicity of 
esterase-triggered COS donors, we prepared a library of thiocarbamates functionalized 
with different esters. To prepare the donors, we first treated 4-hydroxy benzyl alcohol 
with different alkyl and aryl carbonyl chlorides to afford the corresponding esters. 
Reaction with p-tolyl isothiocyanate furnished the desired thiocarbamates (TCM1 to 
TCM9) in 14-90% yield (Figure 6.2a). In parallel, we also prepared the carbamate 
control compounds, which release CO2 rather than COS, by treatment of the carbonyl 
chloride intermediates with p-tolyl isocyanate (Figure 6.2b). To investigate the role of 
electronic modulation of the aniline payload on the rate of self-immolation and 


















































































esterase-triggered COS donors with electron-rich and electron-deficient amine payloads, 
(TCM10 to TCM14).  
With the library of esterase-activated COS/H2S donors in hand, we next measured 
the H2S release from these compounds in the presence of CA and porcine liver esterase 
(PLE). Direct detection of H2S using a sulfide-selective electrode is simple and fast, but 
analogous methods for rapid COS detection directly in solution. For this reason, we 
added excess CA to these experiments to ensure no buildup of COS and used the 
detection of H2S as an indirect measurement of COS release. We treated compounds 
TCM1 – TCM9 (Figure 6.2b, left) and TCM10 – TCM14 (Figure 6.2b, right) with 5 
U/mL PLE in the presence of CA (25 µg/mL) in PBS buffer (pH 7.4) and observed H2S 
release from each of compounds using a H2S-sensitive electrode. This data confirms that 
physiologically relevant amounts of CA and PLE are sufficient to result in H2S release 
from each of these donors. Consistent with our expectation that steric changes to the 
esters would results in different cleavage rates, we observed significantly different H2S 
release rates and efficiencies from the donor compounds containing a variety of different 
ester groups (Figure 3a). For example, donors with bulkier esters (cyclohexyl (TCM7), 
adamantyl (TCM8), or naphthyl (TCM9), yellow, orange, and light blue, respectively) 
generated H2S more slowly than those with smaller esters (methyl (TCM1), t-butyl 
(TCM5), or methyl cyclopropyl (TCM4), dark green, grey, and magenta, respectively). 
This qualitatively confirms that donors containing larger ester groups produce COS/H2S 
more slowly, consistent with slower hydrolysis by PLE.  
H2S release kinetics were also compared for a library of t-butyl ester 
functionalized donors containing a variety of electronically modulated amine payloads. 
We hoped to systematically decrease the rate of COS release through the introduction of 
electron-donating groups, although acidification of the N-H proton of the thiocarbamate 
has been reported to decrease the rate of COS release from similar donors functionalized 
with electron-withdrawing groups as well.206 Consistent with this hypothesis, the 
introduction of either strongly electron-withdrawing (NO2 (TCM14), CF3 (TCM13), pink 
and purple, respectively) or electron-donating (Ph (TCM10), black) groups decreased the 
rate and efficiency of the donors, indicating that both electron-withdrawing and electron-
donating groups slow down the rate of self-immolation following esterase hydrolysis. 
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The donors containing weakly electronically modified amine payloads TCM5, TCM11, 
and TCM12) appear to have very similar initial rates (Figure 6.3b).  
 
Figure 6.3 H2S release curves for compounds (a) TCM1 – TCM9 and (b) TCM5, TCM 
10-TCM14) in the presence of PLE (5 U/mL) and CA (25 µg/mL) at pH 7.4. (b and c)  
Cytotoxicity of compounds in HeLa cells. Data for donors (TCM1 – TCM14) is shown 
for 10 – 100 µM and compared to the cytotoxicity of the carbamate control compounds 
(CM1 – CM14) at 100 µM. (b) Cytotoxicity data for donors containing varying ester 
groups (TCM1 – TCM9), with steric bulk of the ester group decreasing from left to right. 
(c) Cytotoxicity data for donors containing varying amine payloads (TCM5, TCM10 – 
TCM14), with electronic donating-ability of the payload decreasing from left to right. 
Results are expressed as mean ± SD (n=6). The values that are significantly different by 
Student's t test are indicated by asterisks as follows: ***, p < 0.001 **, p < 0.01; *, p < 
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     We next sought to determine whether the observed differences in COS/H2S release 
rates translated to differences in cytotoxicities of compounds TCM1 – TCM14. To probe 
these effects, we incubated HeLa cells with the COS donor compounds at 10, 25, 50, and 
100 µM for 90 minutes and measured the resultant cell viability against the vehicle using 
the formazan dye-based CCK-8 cytotoxicity assay. We found that the cytotoxicity of the 
donors increased as the size of the ester decreased (Figure 6.3c), with the smallest ester 
(Me, TCM1) resulting in about 70% cell death at 100 µM. No significant cell death was 
observed, however, when cells were incubated with 100 µM of TCM9, which requires 
hydrolysis of a much larger naphthyl ester and has a much slower rate of COS/H2S 
release. To confirm that the observed cytotoxicity was not due to the organic byproducts 
of the donor constructs after activation, we also investigated the cytotoxicity of the 
corresponding carbamate control compounds (CM1 – CM14) using the same conditions. 
Overall, we found significantly less cytotoxicity of all of the carbamates up to 100 µM. 
No significant trend was observed in the cytotoxicity of the donors as the electronics of 
the payload were changed. While many of these donors (TCM5, TCM11 – TCM14) 
were cytotoxic, even as low as 25 µM, we did not find any correlation between 
cytotoxicity and the electronics of the amine payload (Figure 6.3d). Since the mechanism 
of decomposition of these donors may change due to acidification of the N-H proton, the 
cytotoxicity likely does not correspond to the rate of COS production.  
 This work provides evidence that cellular accumulation of COS is cytotoxic. 
Importantly, the cytotoxicity observed from many of these COS donors was completely 
eliminated when HeLa cells were incubated with the analogous, CO2-releasing 
carbamates, which control for all other byproducts, suggesting that COS directly for the 
observed effects. Cell death is dose-dependent for all of the cytotoxic COS-releasing 
compounds, and in general, the most cytotoxic donors were also found the have the most 
rapid kinetics of H2S release in the presence of CA. Overall, the hypothesis that the 
inclusion of a larger ester on these donors would decrease the rate of hydrolysis and 
prevent the build-up of COS was found to hold true. We were not able to systematically 
decrease the rate of COS release through electronic modulation of the amine payloads, 
but did find that both strongly electron-withdrawing and electron-donating groups 
diminished COS/H2S release, consistent with two previously suggested effects: that 
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electron-donating groups decrease the rate of self-immolation, and electron-withdrawing 
groups can result in a change in the mechanism of H2S release due to acidification of the 
N-H proton on the thiocarbamate.206 Due to a potential change in mechanism supported 
by a decrease in H2S production from donors containing electron-withdrawing payloads, 
it is impossible to correlate the cytotoxicity of these particular donors with their rate of 
COS/H2S release.  
In addition to providing new insights into the differential impacts of COS and 
H2S, this work also increases the tools available for increasing basal H2S concentrations 
without the need for external triggering mechanisms or consumption of cellular 
nucleophiles. To confirm that these donors release COS/H2S in a cellular environment, 
we incubated 100 µM Cy-TCM (TCM7) with SF7-AM in HeLa cells and observed an 
increase in fluorescence corresponding to H2S donation from the scaffold (Figure 6.4). 
This confirms the basic cellular viability of this compound as an H2S donor. Although the 
faster donors are too cytotoxic for use, the slower donors form library of enzyme-
activated COS/H2S donors viable for use in vivo. 
 
Figure 6.4 Live-cell imaging of H2S release from TCM7in HeLa cells. HeLa cells were 
treated with SF7-AM (5 µM) and Hoescht (5 µg/mL) for 30 min, washed, and incubated 
with FBS-free DMEM containing TCM7 (100 µM, top) or DMSO (0.5%, bottom) for 













6.3 Conclusions  
In conclusion, this work supports the hypothesis that rapid accumulation of COS 
likely results in cytotoxicity.207 Conclusively disentangling the effects of COS delivery 
from the physiological effects of H2S will require a systematic study of COS, the various 
CA isoforms, and the potential for subcellular localization of COS delivery from various 
donors. The work reported here suggests the likely role of COS in the cytotoxicity of 
many of these compounds, and provides is an important piece of early evidence that COS 
delivery may produce a cellular response that is different than that observed from H2S 
alone.  In Chapter VII, a variety of potential COS donor scaffolds are investigated for 
their cytotoxicity and CA inhibition properties to inform researchers on the best donor 
scaffolds for studying COS and H2S chemical biology. 
 
6.4 Experimental Details 
6.4.1 Materials and Methods 
Reagents were purchased from Sigma-Aldrich or Tokyo Chemical Industry (TCI) 
and used as received. SF7-AM was synthesized as previously reported.196 Spectroscopic 
grade, inhibitor-free THF was deoxygenated by sparging with argon followed by passage 
through a Pure Process Technologies solvent purification system to remove water. 
Deuterated solvents were purchased from Cambridge Isotope Laboratories and used as 
received. Silica gel (SiliaFlash F60, Silicycle, 230-400 mesh) was used for column 
chromatography. 1H, 13C{1H}, and 19F NMR spectra were recorded on a Bruker 500 or 
600 MHz instrument (as indicated). Chemical shifts are reported in ppm relative to 
residual protic solvent resonances. Mass spectrometric measurements were performed on 
a Xevo Waters ESI LC/MS instrument or by the University of Illinois, Urbana 
Champaign MS facility. H2S electrode data were acquired with a Unisense H2S 
Microsensor Sulf-100 connected to a Unisense Microsensor Multimeter. All air-free 
manipulations were performed under an inert atmosphere using standard Schlenk 
techniques or an Innovative Atmospheres N2-filled glove box. HeLa cells were purchased 
from ATCC (Manassas, Virginia, USA). Cell imaging experiments were performed on a 
Leica DMi8 fluorescence microscope, equipped with an Andor Zyla 4.2+ sCMOS 
detector.  
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H2S Electrode Experiments. Scintillation vials containing 20.00 mL of phosphate buffer 
(140 mM NaCl, 3 mM KCl, 10 mM phosphate, pH 7.4) were prepared in an N2-filled 
glovebox. The Unisense electrode was inserted into the vial and the vial was capped with 
a split-top septum to minimize oxidation. The current was allowed to equilibrate prior to 
starting the experiment. With moderate stirring, the CA stock solution (50 µL) was 
injected, followed by subsequent injections of TCA stock solution (50 µL) and PLE stock 
solution (100 µL). H2S release was monitored until leveling off.  
CCK-8 Cell Viability Experiments. HeLa cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin at 37 °C under 5% CO2. 96-well plates were seeded with 15,000 
cells/well overnight then washed, incubated in FBS-free DMEM containing vehicle 
(0.5% DMSO), TCA (10-100 µM), or carbamate (10-100 µM) for 90 minutes. Cells were 
then washed with PBS and CCK-8 solution (1:10 in FBS-free DMEM) was added to each 
well, and cells were incubated for 1-2 hours at 37 °C under 5% CO2. The absorbance at 
450 nm was measured using a microplate reader and the cell viability was measured and 
normalized to the vehicle group. Results are expressed as mean ± SD (n=6). P values 
were calculated using a Student’s T-test in Excel compared to DMSO alone.  
Cell Imaging. HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin at 37 °C under 5% CO2. Imaging dishes were seeded with HeLa 
cells overnight and then washed and incubated with SF7-AM (5 µM) and Hoechst 33342 
(5 µg/mL) in FBS-free DMEM for 30 min. Cells were then washed with PBS and 
incubated with either Cy-TCM (100 µM) or vehicle (DMSO, 0.5%) in FBS-free DMEM 
for 60 minutes prior to being washed with PBS and imaged.  
 
6.4.2 Syntheses 
General procedure for the synthesis of phenol esters. 4-Hydroxy benzyl alcohol (1.0 
equiv.) was dissolved in anhydrous THF (0.1 M solution), under and atmosphere of N2. 
The solution was cooled to 0 °C, followed by addition of Et3N. The reaction mixture was 
let stir for 5 minutes, after which the carbonyl chloride was added dropwise over 20 
minutes. The resultant mixture was stirred at 0 °C until the completion of the reaction 
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indicated by TLC. The reaction was quenched by adding brine (30 mL), and the aqueous 
solution was extracted with ethyl acetate (3 x 20 mL). The organic layers were combined, 
dried over anhydrous MgSO4, and concentrated under reduced pressure. The crude 
product was purified by silica column chromatography. Full spectroscopic data for each 
compound is reported in Appendix E. The preparation of MeCp-OH is also reported in 
the Appendix E..  
General procedure for preparation of thiocarbamates. The functionalized benzyl alcohol 
(1.0 equiv.) was dissolved in anhydrous THF (0.2 M solution) under an atmosphere of 
N2. Aryl isothiocyanate (1.1 equiv.) was added, followed by DBU (1.25 equiv.) at 0 °C. 
The resultant mixture was warmed to rt and stirred monitored by TLC. The reaction was 
quenched upon observation of by-product formation by TLC by addition of brine (20 
mL), and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried 
over anhydrous MgSO4 or Na2SO4, concentrated under reduced pressure, and purified by 
silica column chromatography. Full spectroscopic data for each compound is reported in 
Appendix E. 
General procedure for preparation of carbamate controls. Functionalized benzyl alcohol 
(1.0 equiv.) was dissolved in anhydrous THF (0.1 M solution) under an atmosphere of 
N2. Aryl isocyanate (0.90 equiv.) was added, followed by DBU (1.25 equiv.) at 0 °C. The 
resultant mixture was warmed to rt and stirred monitored by TLC. The reaction was 
quenched upon observation of by-product formation by TLC by addition of brine (20 
mL), and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried 
over anhydrous MgSO4, concentrated under reduced pressure, and purified by silica 












INVESTIGATIONS INTO THE CARBONIC ANHYDRASE INHIBITION OF 
COS-RELEASING DONOR CORE MOTIFS 
 
This chapter includes previously published and coauthored material from Steiger, A.K; 
Zhao, Y.; Choi, W.J.; Tillotson, M.R.; Crammond, A.; Pluth, M.D. “Investigations into 
the Carbonic Anhydrase Inhibition of COS-Releasing Donor Core Motifs” Biochem. 
Pharmacol. 2017, 149, 124-130.  
 
7.1 Introduction 
Hydrogen sulfide (H2S), now well established as an important gaseous signaling 
molecule, has been implicated in a wide variety of physiological processes since its initial 
recognition in 1996.12, 199, 256 H2S is produced endogenously and maintained at low (mid-
nanomolar) concentrations, and the administration of exogenous sulfide has been shown 
to provide a therapeutic benefit in various applications, including reduction of myocardial 
infarct size, vasodilation, and decrease in inflammation.2, 9 For example, GYY4137 and 
AP39, which undergo slow hydrolysis to release H2S, have been shown to exhibit anti-
inflammatory activity.229, 257 Additionally, appending H2S donor scaffolds to non-
steroidal anti-inflammatory drugs (NSAIDs) has been used to generate a number of H2S-
NSAID hybrids including ATB-346 and NBS-1120, which are based on naproxen and 
aspirin derivatives, respectively (Figure 7.1). Aligned with these positive impacts, new 
H2S donation strategies are emerging rapidly, and a number of H2S-releasing compounds 
are currently in clinical trials.123, 204 Recent goals in improving upon H2S-based 
therapeutics have included triggerable donation in response to specific (and variable) 
stimuli, controllable rates of H2S release, and the ability to append the H2S-releasing 
moiety to a variety of scaffolds to potentially access H2S-drug hybrids.  
 Building from these needs, our lab recently introduced a new strategy for H2S 
donation by using self-immolative carbonyl sulfide (COS)-releasing motifs (Figure 7.2a), 
which leverages the rapid hydrolysis of COS to H2S by carbonic anhydrase (CA), a 
ubiquitous mammalian zinc metalloenzyme that normally catalyzes the hydrolysis of CO2  
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Figure 7.1 Selected examples of H2S-releasing therapeutics currently in various stages of 
clinical development. 
 
under near diffusion-limited rates to regulate blood pH levels and tissue CO2 transport.258, 
259 Since our initial report,131 a number of related COS-donating scaffolds have been 
reported for H2S release.140, 147, 150, 152, 207-209 Complementing slow-release COS donors,150 
a common strategy has been to engineer the triggered self-immolative COS release, 
which can be activated by different stimuli, including ROS,140 esterase,152, 207 light,208, 209 
and bio-orthogonal triggers147 (selected triggered examples are shown in Figure 7.2b). In 
addition to providing functional H2S donor platforms, the availability of such COS 
donors may allow for the investigation of COS chemical biology, which has been largely 
under-studied.205 Because CA is required for the efficient conversion of COS to H2S in 
all of the above scaffolds, it is imperative to not only understand the mechanism of CA 
activity in COS hydrolysis, but to also to determine whether any of the COS-donating 
motifs are functional CA inhibitors. Significant prior research has focused on identifying 
CA inhibitors for therapeutic uses, such as treatment of glaucoma, epilepsy, and 
mountain sickness, and is the topic of numerous recent reviews.108, 111, 259 Because the 
structural scope of active CA inhibitors is broad and includes many sulfur-containing 
molecules, including dithiocarbamates and trithiocarbonates,260, 261 and we wanted to 
determine whether the sulfur-containing cores of possible COS-releasing scaffolds 
(Figure 7.2c) exhibit CA inhibition. If a COS-releasing motif functions as a viable CA 
inhibitor, donor scaffolds built from such motifs are unlikely to find widespread utility as 
functional H2S donors. Because efficient H2S release from COS donors relies on CA 
activity, such investigations are important in understanding the scope of potential COS-
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releasing structural motifs.  
 
 
Figure 7.2 (a) General strategy for H2S generation from COS-releasing molecules. A 
caged thiocarbamate is shown as an example system. (b) Selected examples of triggered 
COS donors with different core structural motifs. (c) Potential thiocarbonate, 
thiocarbamate, and dithiocarbonate motifs that could function as COS/H2S donors. 
 
7.2 Results 
7.2.1 Synthesis of Model Compounds 
The 15 model compounds used in our investigations were prepared using two 
general procedures. In synthetic procedure A (Figure 7.3a), one equivalent of an alcohol, 
thiol, or amine was combined with one equivalent of phenyl isothiocyanate or phenyl 
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isocyanate and base and was stirred until completion of the reaction. Following an 
extraction and purification by column chromatography, compounds 1, 2, 6, 9, and 14-15 
were isolated in 20-88% yield. In synthetic procedure B (Figure 7.3b), one equivalent of 
the alcohol, thiol, or amine starting material was combined with one equivalent of phenyl 
chloroformate and base. When the reaction was complete, the product was washed, 
extracted, and purified by column chromatography. Compounds 3-5, 7-8, and 10-13 were 
isolated in 32-82% yield. 
Our initial report of caged COS release utilized an O-alkyl thiocarbamate 
scaffold, but S-alkyl thiocarbamates and thiocarbonates have also been reported.152, 209 
Depending on the placement of the COS moiety in the caged core, there different 
constitutional isomers that can release COS, which motivated our selection of model 
compounds 1-5 (Figure 7.3c). Similarly, the availability of caged CO2 compounds, which 
generate CO2/H2O rather than COS/H2S, prompted our investigation of control 
compounds 6-8 (Figure 7.3d). Additionally, the recent interest in CS2 donor development 
prompted our inclusion of dithiocarbamates 9-10 (Figure 7.3e).262 Finally, we included 
isomers 11-15 as control compounds, which have similar functional motifs but lack the 
caged COS core (Figure 7.3f). For each of these model compounds, our goal was to 
determine whether the core structures exerted cytotoxicity or cell proliferative effects and 
also to measure the CA inhibition profiles for each compound to better guide future COS 
donor development. 
 
7.2.2 Cytotoxicity Evaluation  
Prior to measuring CA inhibition profiles, we first measured the cytotoxicity of 
each compound in A549 human lung adenocarcinoma cells using the CCK-8 cell 
proliferation assay. We chose concentrations ranging from 10 – 100 µM for each 
compound, which corresponds to the general concentration ranges typically used in 
biological experiments that use H2S-donating compounds. Incubation of A549 with 10, 
25, 50, or 100 µM of each compound did not result in significant cytotoxicity or 
proliferation, suggesting that the inherent core structures from each model compound do 




Figure 7.3 (a), (b) General synthetic procedures to prepare model compounds. Structures 
of the model compounds prepared and investigated in this study include (c) COS donor 
scaffolds (1-5), (d) CO2 donor scaffolds (6-8), (e) CS2 donor scaffolds (9-10), and (f) 
control scaffolds (11-15).   
 
7.2.3 Determination of CA Inhibitors 
To investigate the potential CA inhibition properties of each of the selected 
scaffolds, we used CA-mediated p-nitrophenyl acetate (pNPA) hydrolysis as a model 
system for measuring CA activity / inhibition. The CA-mediated hydrolysis of pNPA is 
slower than the near diffusion-limited hydrolysis of CO2, and the p-nitrophenol (pNP) 
product has a characteristic absorbance at 405 nM, thus providing a simple method to 
measure CA activities by UV-vis spectroscopy (Figure 7.5a)263. For each compound, we 
measured the rate of pNPA hydrolysis to pNP and compared these observed rates to those 
of CA alone, as well as the rate in the presence of the common CA inhibitor 
acetazolamide (AAA). In each case, the rate of production of pNP was then fit directly to 
a first-order exponential equation. Of the 15 compounds tested, 11 failed to produce 
significant changes in the rate of pNPA hydrolysis, suggesting that these compounds do 
not exhibit significant CA inhibition at concentrations typically used in H2S donor 
experiments. Four compounds, however, were found to inhibit CA activity: 2, 9, 12, and 
13. Of these compounds, 2 and 9 were moderate inhibitors and decreased the rate of  
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Figure 7.4 CCK-8 cytotoxicity assay of compounds 1-15. The cytotoxicity of each 
compound was investigated in A549 cells at 10, 25, 50 and 100 µM using the CCK-8 cell 
counting assay and compared to the DMSO vehicle. (a) caged COS scaffolds (1-5), (b) 
caged CO2 (6-8) and CS2 (9-10) scaffolds, and (c) control scaffolds (11-15). 
 
pNPA hydrolysis by about 50%. By comparison, compounds 12 and 13 were much more  
effective CA inhibitors and decreased the rate of hydrolysis to approximately that seen in 
the presence of AAA, which is recognized as a strong CA inhibitor (Figure 7.5b-f).  
 
7.2.4 Inhibition studies with potential decomposition products 
 In addition to the 15 compounds examined above, we also investigated the CA 
inhibition properties of thiophenol and benzyl thiol because these thiols could potential 
be generated as hydrolysis and/or decomposition products of 2, 9, 12, and 13. (vide 
infra). We found both thiophenol and benzyl thiol to inhibit CA (Figure 7.5e). The rate of 
hydrolysis in the presence of thiophenol alone was found to be similar to that of 12 and 
13, both of which, if deprotonated, would decompose to thiophenol. Similarly, the rate of 
pNPA hydrolysis observed in the presence of benzyl thiol is similar to that of 2 and 9, 
which would decompose to benzyl thiol.  
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Figure 7.5 (a) CA-mediated hydrolysis of pNPA to form pNP. pNPA assay of (b) caged 
COS scaffolds, (c) caged CO2 scaffolds, (d) caged CS2 scaffolds, and (e) control 
scaffolds. (f) Absorbance data was fit to a first order exponential to determine rate of 
hydrolysis in the presence of each compound and compared to AAA, PhSH, and BnSH.  
 
7.3 Discussion 
The recent introduction and adoption of triggered COS-releasing compounds for 
H2S donation highlights the potential of this strategy to access a broad class of H2S 
donors with potential therapeutic properties. In addition to providing functional COS/H2S 
donor platforms, the use analogous CO2/H2O-releasing compounds provide key control 
compounds that undergo the same self-immolative chemistry to generate the same 
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organic byproducts as the canonical donors, but which do not release COS/H2S. For all 
such scaffolds, a key component of the COS/H2S donor strategy is the requirement of 
CA-mediated COS hydrolysis to H2S. Because of this requirement, the donor motifs 
should not interfere with CA activity. With these considerations in mind, we wanted to 
measure cytotoxicity profiles and CA inhibition data for these potential COS-releasing 
moieties to help determine the most promising scaffolds for caged COS release. 
We identified a library of 15 compounds that include known and potential caged 
COS scaffolds, caged CO2 and CS2 motifs, and related control compounds as described in 
the Results section. Although each of these compounds represents a scaffold that could be 
used in a donor or control compound, they do not contain triggering moieties to allow for 
decomposition, meaning that they should not release COS spontaneously. By 
investigating the cytotoxicity and CA inhibition profile of each core motif, we hoped to 
identify the core structures with high CA compatibility for future COS/H2S donor design.   
As outlined in the Results section, none of the prepared model compounds were 
found to be cytotoxic in A549 cells at concentrations below 100 µM, suggesting that the  
core motifs are not inherently cytotoxic at concentration ranges typically used in H2S 
donation studies. Of the 15 compounds investigated, however, we did identify four 
compounds that inhibit CA activity: 2, 9, 12, and 13 (Figure 7.6a). At first, the only 
similarity between these compounds appeared to be the presence of a sulfur atom 
adjacent to the thiocarbonyl moiety. We also noticed, however, a unifying characteristic 
of these compounds is that deprotonation of the amide NH could lead to decomposition to 
form a thiol-containing byproduct (benzyl thiol for 2 and 9 or thiophenol for 12 and 13, 
Figure 7.6b). We hypothesized that these thiol byproducts may be responsible for the 
observed inhibitory properties, rather than the carbamate scaffolds themselves. Further 
supporting this hypothesis, we measured the inhibitory effects of benzyl thiol and  
thiophenol. Benzyl thiol exhibited similar CA inhibitory profiles to 2 and 9, and 
thiophenol inhibited CA similarly to 12 and 13. Aside from the shown CA inhibition 
properties, this additionally suggests the instability of these scaffolds at even moderately 





Figure 7.6 (a) Structures of compounds identified as CA inhibitors. (b) Mechanism for 
production of thiophenol or benzyl thiol following deprotonation of 2, 9, 12, or 13. 
 
7.4 Conclusions 
In combination with recent work investigating stability and rate of COS/H2S 
release from different COS-releasing scaffolds,206 the present work provides an important 
resource for selecting the best scaffolds for COS donation in the design of H2S 
therapeutics. Four scaffolds (1, 3, 4, and 5) were identified that have either been reported 
to release COS or are likely to release COS through self-immolation that do not inhibit 
CA. These motifs are likely ideal starting points in the design of new COS/H2S donor 
motifs. Although this work provides the first insights into the potential CA inhibition 
properties of COS/H2S donor scaffolds, any structural modifications could impact the 
extent of inhibition, which will likely require future constructs to be tested for CA 
inhibition directly. Additionally, the identification of thiocarbamate 2 as a CA inhibitor 
should not completely eliminate this S-alkyl thiocarbamate motif from consideration as a 
COS/H2S donor core, because further functionalization of the core structure may impact 
or reduce the CA inhibition profiles. Indeed, similar scaffolds have been shown to be 
successful COS donors in recent reports.152, 209 Future work is required to determine the 
precise consequences of using a COS donor that inhibits CA as an H2S donor, but the 
efficiency, rate of decomposition, and rate of H2S production may all be affected. 
Through the rational selection of COS donor cores that provide efficacious COS/H2S 
release rates, suitable stability in the presence of biological milieu, and minimal CA 
inhibition, we expect the field of COS/H2S donors will continue to expand rapidly and 
provide access to new motifs with pharmacologically-relevant activities. Chapter VIII 
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will summarize the progress made in the development of self-immolative scaffolds for 
COS/H2S delivery reported in this dissertation. 
 
7.4 Experimental Details 
7.4.1 Materials and Methods  
Synthetic Materials. Reagents were purchased from Sigma-Aldrich, Alfa-Aesar, or Tokyo 
Chemical Industry (TCI) and used as received. Compounds 1-15 were synthesized as 
previously reported. Spectroscopic grade, inhibitor-free THF and DCM were 
deoxygenated by sparging with argon followed by passage through a Pure Process 
Technologies solvent purification system to remove water. Deuterated solvents were 
purchased from Cambridge Isotope Laboratories and used as received. Silica gel 
(SiliaFlash F60, Silicycle, 230-400 mesh) was used for column chromatography. 1H, and 
13C{1H} NMR spectra were recorded on a Bruker 500 MHz instrument. Chemical shifts 
are reported in ppm relative to residual protic solvent resonances.  
 
Spectroscopic Materials. Tris-HCl buffer was prepared from Tris hydrochloride (Sigma, 
50 mM) and deionized water obtained from a Synergy UV Millipore Water System and 
adjusted to pH 8.5 with a SevenMulti pH Probe (Mettler Toledo). UV-visible spectra 
were acquired on a Cary 60 UV-vis spectrometer equipped with a Quantum Northwest 
TC 1 temperature controller.  
 
Cell Culture Materials. A549 cells obtained from ATCC were grown in a 5% CO2 
incubator at 37 °C in Dulbecco’s Modified Eagle Medium (Gibco, high glucose, phenol 
red) with 5% FBS (VWR) and 1% penicillin streptomycin (Gibco). Cells were passaged 
(up to p 25) every 1-3 days upon reaching 85-90% confluency. Absorbance 
measurements were acquired using a Tecan Safire2 microplate reader. 
 
Cytotoxicity Assays. Stock solutions of the compounds (20 mM, 10 mM, 5 mM, 2 mM) 
were prepared in DMSO via serial dilution and used to make 100 µM, 50 µM, 25 µM, 
and 10 µM solutions of each compound in DMEM (no phenol red, no FBS). 96-Well 
plates were seeded with ~20,000 cells/well overnight prior to cytotoxicity experiments. 
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Cells were washed with PBS (Gibco) and incubated with the desired compound or with 
vehicle (0.5% DMSO) for one hour prior to being washed with PBS and incubated with 
CCK-8 solution (10% in DMEM). After 1 hour, the absorbance at 450 nm was measured 
on a plate reader, and the cell survival was calculated as a percent of the control and 
normalized to the vehicle group. The results are expressed as mean ± SD (n = 6).   
 
Determination of CA Inhibition. Stock solutions of each compound (20 mM in DMSO), 
acetazolamide (20 mM in DMSO), p-nitrophenylacetate (pNPA, 15 mM in ethanol), and 
CA (7.5 mg/mL in Tris buffer) were prepared and stored at 2-4 °C until immediately 
prior to use. pNPA (20 µL) was injected into the Tris HCl buffer (3 mL) immediately 
followed by the desired compound of interest (7.5 µL) with stirring at 37.00 ± 0.05 °C. 
Data collection began immediately prior to injection of CA (20 µL) and continued until 
the production of pNP was complete, as determined by a plateau in absorbance at 405 
nm. Absorption data was fit to a first-order exponential equation in Origin 8 to obtain 
pseudo first-order rate data, which are reported in units of s-1. All trials were completed in 
triplicate and rates are reported as mean ± SD (n = 3).   
 
7.4.2  Syntheses 
General synthetic procedure A. The alcohol, thiol, or amine starting material (1.0 equiv.) 
was combined with phenyl isothiocyanate or phenyl isocyanate (1.0 equiv.) in anhydrous 
THF (15 mL) at 0 °C, followed by the addition of base (1.2 equiv.). The resultant mixture 
was stirred at 0 °C for 20 min, after which the ice bath was removed, and the reaction 
mixture was stirred at r.t. until the completion of the reaction as indicated by TLC. The 
reaction was quenched by adding brine (30 mL), and the aqueous solution was extracted 
with ethyl acetate (3 × 15 mL). The organic layers were combined, dried over MgSO4, 
and evaporated under vacuum. The crude products from each reaction were purified by 
column chromatography. 
Compound 1 was prepared from benzyl alcohol and phenyl isothiocyanate in the 
presence of NaH. (yield: 75%). The characterization data match the reported data.140 
Compound 2 was prepared from benzyl mercaptan and phenyl isocyanate in the presence 
of NaH. (yield: 38%). The characterization data match the reported data.264 Compound 6 
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was prepared from benzyl alcohol and phenyl isocyanate in the presence of TEA (yield: 
20%) The characterization data match the reported data.265 Compound 9 was prepared 
from benzyl mercaptan and phenyl isothiocyanate in the presence of NaH. (yield: 75%). 
The characterization data match the reported data.266 Compound 14 was prepared from 
benzyl amine and phenyl isocyanate in the presence of TEA. (yield: 88%). The 
characterization data match the reported data.267 Compound 15 was prepared from benzyl 
amine and phenyl isothiocyanate in the presence of TEA. (yield: 64%). The 
characterization data match the reported data.268  
 
General synthetic procedure B. The alcohol, thiol, or amine starting material (1.0 equiv.) 
was combined with the phenyl chloroformate reagent (1.0 equiv.) in anhydrous DCM (15 
mL) at 0 °C, followed by the addition of base (1.0 equiv.). The resultant solution was 
stirred at 0 °C for 20 min, after which the ice bath was removed, and the reaction mixture 
was stirred at r.t. until the completion of the reaction as indicated by TLC. The reaction 
was quenched by adding brine (30 mL), and the aqueous solution was extracted with 
ethyl acetate (3 × 15 mL). The organic layers were combined, dried over MgSO4, and 
evaporated under vacuum. The crude products from each reaction were purified by 
column chromatography. 
 Compound 3 was prepared from benzyl alcohol and phenyl chlorothionoformate 
in the presence of pyridine. (yield: 57%). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.55 (m, 
7H), 7.33 (t, J = 10.0 Hz, 1H), 7.16 (d, J = 10.0 Hz, 2H), 5.60 (s, 2H). 13C{1H} NMR 
(125 MHz, CDCl3) δ (ppm): 195.0, 153.5, 134.2, 129.6, 128.8, 128.7, 128.6, 126.6, 
122.0, 75.6. Compound 4 was prepared from benzyl mercaptan and phenyl chloroformate 
in the presence of TEA. (yield: 73%). The characterization data match the reported 
data.269 Compound 5 was prepared from benzyl mercaptan and phenyl thiochloroformate 
in the presence of TEA (yield: 71%). 1H NMR (500 MHz, DMSO-d6) δ (ppm): 7.53 (m, 
5H), 7.32 (m, 4H), 7.27 (m, 1H), 4.25 (s, 2H). 13C{1H} NMR (125 MHz, DMSO-d6) δ 
(ppm): 188.6, 137.3, 135.8, 131.1, 130.2, 129.4, 129.1, 127.9, 126.5, 34.9. Compound 7 
was prepared from benzyl alcohol and phenyl chloroformate in the presence of TEA. 
(yield: 62%). The characterization data match the reported data.270 Compound 8 was 
prepared from benzyl alcohol and phenyl thiochloroformate in the presence of NaH. 
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(yield: 32%). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.57 (m, 2H), 7.44 (m, 3H), 7.39 (m, 
5H), 5.29 (s, 2H). 13C{1H} NMR (125 MHz, CDCl3) δ (ppm): 167.9,135.0, 134.9, 129.6, 
129.2, 128.6, 128.5, 127.7, 69.4. Compound 10 was prepared from benzyl mercaptan and 
phenyl chlorothionoformate in the presence of pyridine. (yield: 43%). The 
characterization data match the reported data.271 Compound 11 was prepared from benzyl 
amine and phenyl chloroformate in the presence of TEA. (yield: 82%). The 
characterization data match the reported data.272 Compound 12 was prepared from benzyl 
amine and phenyl thiochloroformate in the presence of pyridine. (yield: 57%). 1H NMR 
(500 MHz, DMSO-d6) δ (ppm): 8.85 (s, 1H), 7.46 (m, 2H), 7.41 (s, 3H), 7.35 (t, J = 5.0 
Hz, 2H), 7.26 (d, J = 10.0 Hz, 3H), 4.32 (s, 2H). 13C{1H} NMR (125 MHz, DMSO-d6) δ 
(ppm): 164.6, 139.3, 135.4, 129.4, 129.3, 129.1, 128.8, 127.8, 127.5, 44.7. Compound 13 
was prepared from benzyl amine and phenyl chlorodithioformate in the presence of TEA. 
(yield: 49%). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.61 (m, 2H), 7.50 (m, 3H), 7.32 (m, 
3H), 7.17 (d, J = 10.0 Hz, 2H), 6.86 (br, 1H), 4.86 (d, J = 5.0 Hz, 2H). 13C{1H} NMR 






















 The significant interest in H2S as the newest gasotransmitter has motivated 
chemists and chemical biologists to develop a suite of chemical tools to study 
physiological H2S. These tools are can be broadly classified into two main categories: 
scaffolds to detect H2S (H2S probes) and small molecules that release H2S (H2S donors). 
Significant progress has been made in the design of H2S probes that are sensitive and 
selective for H2S as well as in the development of H2S donors that are well-controlled 
and contain a variety of functional groups. Several key challenges remain, however, 
including irreversible consumption of sulfide during detection in living systems and the 
use of donors that are poorly representative of enzymatic production of H2S. The work 
reported in this dissertation addresses many of the concerns and limitations that are 
commonly encountered in the development of chemical tools for H2S. An analyte-
replacement fluorescent probe for H2S was reported that can simultaneously detect H2S 
and release an equivalent of sulfide in the form of COS to help maintain homeostasis. 
This was the first report of the triggerable release of COS from self-immolative 
thiocarbamates and the use of COS as a source of sulfide through rapid hydrolysis to H2S 
in the presence of the ubiquitous mammalian enzyme, CA. Today, self-immolative 
thiocarbamates are a robust and highly tunable strategy for H2S delivery. The donors 
reported herein represent only a portion of the COS/H2S donors reported to date, but 
show that this strategy can be modified with ease to produce donors relevant for certain 
research and therapeutic applications. Additionally, the cytotoxicity of some of the 
enzyme-activated donors reported in this dissertation has piqued interest in COS 
chemical biology. While COS biology has been largely ignored in the past, the recent 
introduction of COS delivery agents may allow for more detailed investigations into this 
field. Significant work remains to be done to elucidate the physiological effects of COS 
from those of H2S. The rapid enzymatic consumption of COS and subsequent hydrolysis 
to H2S in mammalian tissues complicates simple experiments that may be done to 
observe the effects of COS. CA inhibition or knockdown experiments may provide some 
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insight into COS biology, however, since CA is responsible for regulation of intracellular 
pH, numerous other variable are likely to influence the results of such investigations. 
Since many CA isoforms exist, and the isoforms that rapidly hydrolyze COS are so far 
unidentified, there are potentially more complex, isoform-specific experiments that can 
be imagined. Finally, since there are currently only very limited methods to detect COS 
in biological milieu (i.e. headspace gas chromatography above tissue samples), the 
development of additional chemical tools, especially selective probes for COS, may be 
necessary to reach an in-depth understanding of COS in physiology. The work in this 
dissertation will hopefully serve as a springboard into a flourishing new field of COS 
























CHAPTER II SUPPLEMENTARY INFORMATION 
 
	
Figure A1. 1H NMR spectra of 1 before (top) and after (bottom) TCEP addition.  
 
 
Figure A2. 13C{1H} NMR spectra of 1 before (top) and after (bottom) TCEP addition. 
 
 
Figure A3. 19F NMR spectra of 1 before (top) and after (bottom) TCEP addition. The 
presence of multiple signals is a result of multiple decomposition products that form 
following self-immolation due to the nucleophilicity of the resulting aniline species and 




Sulfide Electrode Experiments 
 
Figure A4. Addition of COS to PBS buffer results in minimial H2S formation until the 




Figure A5. No H2S is formed from 1 in PBS buffer until TCEP is added. 
 
NMR Spectra 
1H (600 MHz, DMSO-d6), 13C{1H} (150 MHz, DMSO-d6), and 19F NMR (564 MHz, 
DMSO-d6) NMR Spectra of 1 
	










































































1H (600 MHz, DMSO-d6), 13C{1H} (150 MHz, DMSO-d6), and 19F NMR (564 MHz, 
































































CHAPTER III SUPPLEMENTARY INFORMATION 
	
Cytotoxicity of TCO 1 
 
	
Figure B1. N2A cells were cultured in high glucose Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin at 37 °C under 5% CO2. Once confluent, cells were incubated in 
FBS-free DMEM containing vehicle (0.5% DMSO) or TCO 1 (10 – 100 µM) for 3 hours 
in a 96-well plate. CCK-8 solution (10% in FBS-free DMEM) was added to each well, 
and cells were incubated for 3 hours at 37 °C. The absorbance at 450 nm was measured 
by using a microplate reader. The cell viability was measured and normalized to the 










































1H (400 MHz, CDCl3) NMR Spectra of 1. 
	
 












































CHAPTER IV SUPPLEMENTARY INFORMATION 
 
H2S Calibration Curve 
UV cuvettes (1.50 mL capacity) were charged with 0.500 mL of the MB cocktail (vide 
infra) and 0.500 mL of PBS buffer (pH 7.40, 10.0 mM). The resultant solution was mixed 
thoroughly, followed by the addition of an NaSH stock solution (1.00 mM) to make the 
final H2S concentrations of 1.00, 3.00, 5.00, 10.0, 15.0, and 20.0 µM. The MB solution 
was allowed to react with H2S for 1 hour before measuring the absorbance at 670 nm. 
 
Figure C1. H2S calibration curve for the MB assay. 
 
Cys-Triggered H2S Release from OA-CysTCM-1 in the Presence of GSH 
An OA-CysTCM-1 stock solution (0.100 mL, 10.0 mM in DMSO) was added to 
20.0 mL of PBS (pH 7.40, 10.0 mM) containing CA (25.0 µg/mL) in a 25-mL 
scintillation vial. A Cys stock solution (100 µL, 100 mM in H2O) and a GSH stock 
solution (50.0 µL, 100 µL, or 200 µL, 100 mM in H2O) were then added so that the 
working Cys and GSH concentration ratios are 2:1, 1:1, and 1:2, respectively. Next, 
0.300 mL aliquots of the reaction mixture were transferred to UV cuvettes containing 
0.300 mL of MB cocktail (0.0600 mL zinc acetate (1.00% w/v), 0.120 mL FeCl3 (30.0 
mM in 1.20 M HCl), and 0.120 mL N,N-dimethyl-p-phenylene diamine (20.0 mM in 7.20 
M HCl)) at different time points. The absorbance at 670 nm was then measured after 1 
	 111 
hour and was converted to H2S concentration by using the H2S calibration curve as 
shown in Figure C1. 
 
Figure C2. GSH Effects on Cys-triggered COS/H2S release from OA-CysTCM-1 (50 
µM). The Cys concentration was 500 µM in all experiments, and H2S concentrations 
were measured after 2-h incubation. 
 
Fluorescence Imaging of H2S Release from OA-CysTCM-1 
 A stock solution of SF7-AM (1.50 µL, 20.0 mM in DMSO) was added to a vial 
containing PBS (pH 7.40, 3.00 mL), cysteine (250 µM), and carbonic anhydrase (25.0 
µg/mL). Fluorescence measurements (λex = 488 nm, λem = 498-700 nm) were taken either 
immediately upon addition of SF7-AM or after addition of OA-CysCM-1 (15.0 µL, 20.0 
mM in DMSO) or OA-CysTCM-1 (15.0 µL, 20.0 mM in DMSO) and taken periodically 




Figure C3: Fluorescence response of SF7-AM (5.00 µM) with cysteine (250 µM) and 
carbonic anhydrase (25.0 µg/mL) (left); upon addition of OA-CysCM-1 (50.0 µM, 
middle); and upon addition of OA-CysTCM-1 (50.0 µM, right) over the course of 120 









1H (500 MHz, DMSO-d6) and 13C{1H} (150 MHz, DMSO-d6) NMR Spectra of OA-
CysTCM-1. Two sets of NMR resonances showed up in 13C NMR spectrum due to slow 
















CHAPTER V SUPPLEMENTARY INFORMATION 
Mass Spectrometry Data 
 
 
Figure D1. Mass spectrum of the reaction byproducts formed after stirring 1 with PLE in 
PBS buffer (pH 7.4, 1% DMSO) for 48 hours. Structures of potential byproducts have 
been labeled with their respective masses and reaction schemes detailing formation of 








































m/z: [M + H]+= 298.2
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Cytotoxicity of Na2S 
 
 
Figure D2. Cell viability studies of Na2S in BEAS 2B cells using the (a) MTT and (b) 
LDH cell viability assays.  
 
Cytotoxicity of 1 and 2 in HeLa cells 
 
	
Figure D3. Cytotoxicity assay of donor 1 and control compound 2 in HeLa cells using 
the CCK-8 assay. HeLa cells were cultured in a 96-well plate overnight in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin at 37 °C under 5% CO2 and washed with PBS pH 7.4 
prior to incubation in FBS-free DMEM containing vehicle (0.5% DMSO, black bar), 1 
(green bars, 10-100 µM), or 2 (purple bars, 10-100 µM) for 1 hour. CCK-8 solution (10% 
in FBS-free DMEM) was added to each well, and cells were incubated for 3 hours at 37 
°C. The absorbance at 450 nm was measured using a microplate reader. The cell viability 






























































CHAPTER VI SUPPLEMENTARY INFORMATION 
 




Me-OH was prepared with 4-hydroxybenzyl alcohol and acetyl chloride according to the 
general synthetic procedure described above. (324 mg, 48% yield). Spectral data is in 






Cp-OH was prepared with 4-hydroxybenzyl alcohol and cyclopropanecarbonyl chloride 
according to the general synthetic procedure described above. (506 mg, 65% yield). 






iPr-OH was prepared with 4-hydroxybenzyl alcohol and isobutyryl chloride according to 
the general synthetic procedure described above. (423 mg, 54% yield). Spectral data is in 





tBu-OH was prepared with 4-hydroxybenzyl alcohol and pivaloyl chloride according to 
the general synthetic procedure described above. (329 mg, 39% yield). Spectral data is in 















Cy-OH was prepared with 4-hydroxybenzyl alcohol and cyclohexanecarbonyl chloride 
according to the general synthetic procedure described above. (388 mg, 41% yield). 





Ph-OH was prepared with 4-hydroxybenzyl alcohol and benzoyl chloride according to 
the general synthetic procedure described above. (726 mg, 79% yield). Spectral data is in 





Ad-OH was prepared with 4-hydroxybenzyl alcohol and 1-adamantanecarbonyl chloride 
according to the general synthetic procedure described above. (416 mg, 36% yield). 1H 
NMR (500 MHz, CDCl3) δ (ppm): 7.37 (d, J=8.22 Hz, 2H), 7.05 (d, J=8.22 Hz, 2H ), 
4.69 (d, J=1.65 Hz, 2H), 2.86 (bs, 1H), 2.11 (m, 3H), 2.08 (d, J=3.17 Hz, 6H), 1.79 (d, 
J=3.51 Hz, 6H). 13C{1H} NMR (125 MHz, CDCl3) δ (ppm): 176.30, 150.52, 138.15, 
128.01, 121.67, 64.78, 41.03, 38.76, 34.46, 27.92. IR (cm-1) 3515.75, 2903.27, 2853.32, 
1718.00, 1504.69, 1452.47, 1222.53, 1189.10, 1160.28, 1040.92. HRMS m/z [M + H]+ 





Nap-OH was prepared with 4-hydroxybenzyl alcohol and 2-naphthoyl chloride 
according to the general synthetic procedure described above. (660 mg, 59% yield). 1H 
NMR (500 MHz, CDCl3) δ (ppm): 8.83 (s, 1H), 8.23 (dd, J=8.6, 1.7 Hz, 1H), 8.04 (d, 
J=8.1 Hz, 1H), 7.99 (d, J=8.6 Hz, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.67 (ddd, J=8.1, 6.8, 1.3 










2H), 4.78 (s, 2H), 1.66 (bs, 1H). 13C{1H} NMR (125 MHz, CDCl3) δ (ppm): 165.42, 
150.48, 138.57, 135.85, 132.51, 131.97, 129.50, 128.67, 128.42, 128.19, 127.86, 126.87, 
126.69, 125.46, 121.91, 64.88. IR (cm-1) 3319.86, 3058.22, 2867.44, 2360.09, 2341.52, 
1734.43, 1631.12, 1596.86, 1508.04, 1463.36, 1418.26, 1387.99, 1352.95, 1280.24, 
1225.79, 1194.70, 1164.29, 1080.76, 1013.92. HRMS m/z [M + H]+ calcd. For 





MCp-OH was prepared from the corresponding carboxylic acid. MCp-COOH (1.50 g, 
1.0 equiv.) was dissolved in anhydrous dichloromethane (3.0 mL, 5.0 M solution), 
followed by addition of anhydrous DMF (60 µL, 0.05 equiv.). The reaction mixture was 
heated to reflux, and SOCl2 (1.20 mL, 1.1 equiv.) was added dropwise under reflux. The 
reaction mixture was stirred under reflux for two hours, then concentrated under reduced 
pressure. The crude reaction mixture was re-dissolved in a minimum of dichloromethane 
and added dropwise to a stirring solution of 4-(TBS-hydroxymethyl)phenol (2.0 g, 0.56 
equiv.), triethylamine (3.51 mL, 1.68 equiv.), and DMAP (500 mg, 0.28 equiv.) in 
dichloromethane (60 mL, 0.25 M solution). Upon completion (as determined by TLC) the 
reaction was quenched with 20 mL of brine, and extracted with methylene chloride (3 x 
20 mL). The combined organic layers were dried over anhydrous magnesium sulfate, and 
purified by silica column chromatography to yield 1.03 g (21% yield over two steps). 
MCp-OTBS (1.03 g, 1.0 equiv.) was dissolved in anhydrous THF (32 mL, 0.1 M 
solution) under an atmosphere of nitrogen, and cooled to 0 °C. TBAF (3.20 mL 1.0 M in 
THF, 1.0 equiv.) was added dropwise. The reaction was let stir for 30 minutes, quenched 
with brine (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic 
layers were dried over anhydrous MgSO4, concentrated under reduced pressure, and 
purified by silica column chromatography to yield MCp-OH as a white solid (365 mg, 
55% yield). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.37 (d, J=8.40 Hz, 2H), 7.06 (d, J-
=8.40 Hz, 2H ), 4.67 (s, 2H), 1.90 (bs, 1H), 1.44 (m, 5H), 0.86 (m, 2H). 13C{1H} NMR 
(125 MHz, CDCl3) δ (ppm): 174.73, 150.38, 138.25, 127.97, 121.65, 64.73, 19.45, 18.81, 
17.47. IR (cm-1) 3356.76, 2969.77, 1736.30, 1652.94, 1606.43, 1507.08, 1465.16, 
1419.78, 1388.80, 1324.07, 1163.95, 1120.74, 1013.39. HRMS m/z [M + H]+ calcd. For 

























TCM1 was prepared with p-tolyl isothiocyanate and Me-OH according to the general 
synthetic procedure described above. (25 mg, 14% yield).  1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 10.99 (s, 1H), 7.69-6.93 (m, 8H), 5.55 (s, 2H), 2.28 (bs, 6H). 
Broadness is observed in the 1H NMR spectrum due to rotation around the C-N bond of 
the thiocarbamate. 13C{1H} NMR (125 MHz, DMSO-d6, 25 °C) δ (ppm) 187.81, 187.20, 
169.67, 150.82, 136.45, 135.55, 134.86, 134.57, 134.01, 133.63, 130.23, 129.78, 129.69, 
129.35, 123.41, 122.47, 122.38, 71.89, 70.26, 60.23, 21.32, 21.24, 21.00, 20.90, 14.57. 
Splitting of peaks is observed in the 13C{1H} NMR spectrum due to slow rotation around 
the C-N bond of the thiocarbamate, yielding rotamers. IR (cm-1) 3195.71, 3170.76, 
3100.82, 3030.76, 2950.80, 1753.55, 1593.68, 1540.73, 1507.65, 1455.32, 1405.65, 
1365.85, 1342.19, 1218.90, 1206.36, 1186.16, 1173.45, 1162.22. HRMS m/z [M + H]+ 





TCM2 was prepared with p-tolyl isothiocyanate and Cp-OH according to the general 
synthetic procedure described above. (65 mg, 39% yield). 1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 10.97 (s, 1H), 7.65-6.97 (m, 8H), 5.55 (s, 2H), 2.28 (s, 3H), 1.89 (m, 
1H), 1.05 (m, 4H). Broadness is observed in the 1H NMR spectrum due to rotation 
around the C-N bond of the thiocarbamate. 13C{1H} NMR (125 MHz, DMSO-d6, 25 °C) 
δ (ppm): 187.81, 187.19, 173.35, 150.77, 136.46, 135.55, 134.86, 134.57, 134.02, 133.64, 
130.20, 129.78, 129.69, 129.35, 123.42, 122.47, 122.33, 71.88, 70.24, 21.00, 20.90, 
13.06, 9.52. Splitting of peaks is observed in the 13C{1H} NMR spectrum due to slow 
rotation around the C-N bond of the thiocarbamate, yielding rotamers. IR (cm-1) 3231.59, 
3173.53, 3099.77, 3029.41, 2921.09, 1854.61, 1741.51, 1594.89, 1544.77, 1509.09, 
1461.52, 1422.56, 1400.67, 1384.26, 1338.06, 1313.36, 1288.42, 1213.37, 1163.87, 
























TCM3 was prepared with p-tolyl isothiocyanate and iPr-OH according to the general 
synthetic procedure described above. (52 mg, 31% yield). 1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 10.97 (1H, s), 7.67 – 6.94 (bm, 8H), 5.56 (s, 2H), 2.83 (sept, J=7.84, 
1H), 1.25 (d, J=7.84, 6H). Broadness is observed in the 1H NMR spectrum due to 
rotation around the C-N bond of the thiocarbamate. 13C{1H} NMR (125 MHz, DMSO-d6, 
25 °C) δ (ppm): 187.83, 187.21, 175.48, 150.91, 136.47, 135.56, 134.84, 134.57, 134.00, 
133.61, 130.23, 130.21, 129.80, 129.67, 129.34, 123.42, 122.47, 122.27, 71.91, 70.25, 
33.78, 30.83, 20.98, 19.13. Splitting of peaks is observed in the 13C{1H} NMR spectrum 
due to slow rotation around the C-N bond of the thiocarbamate, yielding rotamers. IR 
(cm-1) 3214.13, 3108.42, 3040.44, 2969.4, 2922.05, 1751.35, 1594.68, 1540.86, 1507.24, 
1402.57, 1340.66, 1316.76, 1288.55, 1228.48, 1189.68. HRMS m/z [M + H]+ calcd. For 





TCM4 was prepared with p-tolyl isothiocyanate and MCp-OH according to the general 
synthetic procedure described above. (100 mg, 61% yield). 1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 10.99 (s, 1H), 7.66-6.99 (m, 8H), 5.54 (s, 2H), 2.28 (s, 3H), 1.38 (s, 
3H), 1.34 (q, J=3.84, 2H), 0.92 (q, J=3.84, 2H). Broadness is observed in the 1H NMR 
spectrum due to rotation around the C-N bond of the thiocarbamate. 13C{1H} NMR (125 
MHz, DMSO-d6, 25 °C) δ (ppm): 187.82, 187.18, 174.36, 150.97, 136.46, 135.55, 
134.85, 134.56, 133.93, 133.53, 130.13, 129.77, 129.68, 129.34, 123.43, 122.46, 122.34, 
71.92, 70.24, 21.00, 20.89, 19.43, 18.90, 17.31. Splitting of peaks is observed in the 
13C{1H} NMR spectrum due to slow rotation around the C-N bond of the thiocarbamate, 
yielding rotamers. IR (cm-1) 3208.15, 3172.09, 3102.38, 3034.45, 2969.61, 2924.52, 
2868.84, 1739.32, 1592.23, 1541.25, 1508.68, 1449.58, 1421.32, 1398.13, 1334.24, 
1315.04, 1287.58, 1211.63, 1189.86, 1166.87, 1123.90, 1013.25. HRMS m/z [M + H]+ 





TCM5 was prepared with p-tolyl isothiocyanate and tBu-OH according to the general 
synthetic procedure described above. (109.4 mg, 64% yield). Spectral data is in 

















TCM6 was prepared with p-tolyl isothiocyanate and Ph-OH according to the general 
synthetic procedure described above. (34 mg, 22% yield). 1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 11.00 (s, 1H), 8.15 (m, 2H), 7.75 (m, 1H), 7.64 (m, 2H), 7.58-7.11 
(m, 8H), 5.59 (s, 2H), 2.28 (s, 3H). Broadness is observed in the 1H NMR spectrum due 
to rotation around the C-N bond of the thiocarbamate. 13C NMR (125 MHz, DMSO-d6, 
25 °C) δ (ppm): 187.84, 187.21, 165.06, 150.94, 136.47, 135.57, 134.87, 134.58, 134.31, 
133.96, 133.91, 130.27, 129.90, 129.85, 129.72, 129.70, 129.62, 129.47, 129.36, 129.31, 
123.44, 122.56, 122.50, 71.92, 70.25, 21.01, 20.91. Splitting of peaks is observed in the 
13C{1H} NMR spectrum due to slow rotation around the C-N bond of the thiocarbamate, 
yielding rotamers. IR (cm-1) 3200.22, 3156.21, 3092.37, 3028.96, 2969.84, 2925.83, 
1728.56, 1591.53, 1538.83, 1508.72, 1449.12, 1398.19, 1365.23, 1338.94, 1312.68, 
1263.16, 1249.22, 1225.59, 1209.75, 1188.14, 1174.53, 1079.50, 1056.59. HRMS m/z 




TCM7 was prepared with p-tolyl isothiocyanate and Cy-OH according to the general 
synthetic procedure described above. (46 mg, 29% yield). 1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 10.97 (s, 1H), 7.62 – 7.14 (m, 8H), 5.55 (s, 2H), 2.61 (m, 1H), 2.28 
(s, 3H), 2.00 (d, J=12.2, 2H), 1.75 (m, 2H), 1.64 (2, J=13.1, 1H), 1.52 (m, 2H), 1.36 (m, 
2H), 1.29 (m, 1H). Broadness is observed in the 1H NMR spectrum due to rotation 
around the C-N bond of the thiocarbamate. 13C{1H} NMR (125 MHz, DMSO-d6, 25 °C) 
δ (ppm): 187.82, 187.20, 174.30, 150.91, 136.46, 135.56, 134.85, 134.57, 133.97, 133.58, 
130.22, 129.81, 129.68, 129.61, 129.34, 123.42, 122.47, 122.32, 71.91, 70.25, 42.51, 
28.93, 25.74, 25.18, 21.00, 20.90. Splitting of peaks is observed in the 13C{1H} NMR 
spectrum due to slow rotation around the C-N bond of the thiocarbamate, yielding 
rotamers. IR (cm-1) 3203.91, 3176.67, 3030.10, 2930.06, 2854.13, 1752.75, 1527.52, 
1511.28, 1386.41, 1311.79, 1208.06, 1178.02, 1165.88, 1147.76, 1114.41, 1017.32. 

















TCM8 was prepared with p-tolyl isothiocyanate and Ad-OH according to the general 
synthetic procedure described above. (40 mg, 26% yield). 1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 10.98 (s, 1H), 7.57 – 7.05 (m, 8H), 5.55 (s, 2H), 2.28 (s, 3H), 2.06 
(bs, 3H), 2.01 (bs, 6H), 1.75 (bs, 6H). Broadness is observed in the 1H NMR spectrum 
due to rotation around the C-N bond of the thiocarbamate. 13C{1H} NMR (125 MHz, 
DMSO-d6, 25 °C) δ (ppm): 187.83,187.19, 175.84, 151.07, 136.47, 135.55, 134.86, 
134.57, 133.95, 133.54, 130.21, 129.84, 129.68, 129.35, 123.43, 122.47, 122.29, 71.93, 
70.25, 60.23, 40.85, 40.53, 38.68, 36.31, 34.85, 30.25, 27.73, 27.62, 21.24, 21.15, 21.00, 
20.90, 14.57. Splitting of peaks is observed in the 13C{1H} NMR spectrum due to slow 
rotation around the C-N bond of the thiocarbamate, yielding rotamers. IR (cm-1) 3223.67, 
3181.01, 3109.75, 3039.47, 2917.77, 2904.34, 2848.45, 1743.95, 1595.09, 1535.42, 
1508.71, 1450.52, 1422.61, 1396.44, 1333.48, 1316.48, 1305.39, 1270.40, 1224.40, 






TCM9 was prepared with p-tolyl isothiocyanate and Nap-OH according to the general 
synthetic procedure described above. (112 mg, 76% yield). 1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 11.01 (s, 1H), 8.85 (s, 1H), 8.21 (2, J=8.24, 1H), 8.13 (m, 2H), 8.07 
(d, J=8.24, 1H), 7.73 (t, J=7.79, 1H), 7.68 (t, J=7.79, 1H), 7.63-7.09 (m, 8H), 5.61 (s, 
2H), 2.29 (s, 3H). Broadness is observed in the 1H NMR spectrum due to rotation around 
the C-N bond of the thiocarbamate. 13C{1H} NMR (125 MHz, DMSO-d6, 25 °C) δ 
(ppm): 187.87, 187.23, 165.24, 151.05, 136.48, 135.84, 135.59, 134.88, 134.33, 133.94, 
132.58, 132.05, 130.33, 130.02, 129.93, 129.71, 129.52, 129.36, 129.13, 128.26, 127.67, 
126.56, 125.50, 123.44, 122.57, 71.94, 70.28, 55.38, 21.00, 20.91, 14.57. Splitting of 
peaks is observed in the 13C{1H} NMR spectrum due to slow rotation around the C-N 
bond of the thiocarbamate, yielding rotamers. IR (cm-1) 3216.92, 3160.40, 3084.34, 
3034.41, 2919.03, 2853.89, 1730.67, 1629.73, 1596.74, 1542.65, 1507.24, 1460.72, 
1400.09, 1343.64, 1280.39, 1179.23, 1161.82, 1127.63, 1061.28. HRMS m/z [M + H]+ 

















TCM10 was prepared with 4-biphenylyl isothiocyanate and tBu-OH according to the 
general synthetic procedure described above. (90.9 mg, 45% yield). 1H NMR (500 MHz, 
DMSO-d6, 60 °C) δ (ppm): 11.18 (s, 1H), 7.64 (m, 5H), 7.52 (d, J=8.1 Hz, 2H), 7.45 (t, 
J= 7.6 Hz, 2H), 7.35 (m, 1H), 7.13 (d, J= 8.8 Hz, 2H), 5.61 (s, 2H), 1.34 (s, 9H). 
Broadness is observed in the 1H NMR spectrum due to rotation around the C-N bond of 
the thiocarbamate.13C{1H} NMR (125 MHz, DMSO-d6, 60 °C) δ (ppm): 187.7, 176.8, 
151.3, 140.0, 137.2, 133.8, 129.9, 129.4, 127.8, 127.4, 126.9, 123.2, 122.2, 39.1, 27.2. 
FTIR (ATR, cm-1): 3212.31, 3035.48, 2969.43, 1748.39, 1594.62, 1578.16, 1540.37, 
1509.08, 1401.48, 1335.13, 1115.22, 1098.76, 1001.31, 833.74, 755.88, 685.14. HRMS 
m/z [M + H+] calc. 420.1633; found 420.1595.  
 
 
TCM11 was prepared with phenyl isothiocyanate and tBu-OH according to the general 
synthetic procedure described above. (71.2 mg, 55% yield). 1H NMR (500 MHz, DMSO-
d6, 60 °C) δ (ppm): 11.07 (s, 1H), 7.63-7.42 (m, 4H), 7.33 (m, 2H), 7.16 (m, 1H), 7.35 
(m, 1H), 7.12 (d, J= 8.7 Hz, 2H), 5.58 (s, 2H), 1.32 (s, 9H). Broadness is observed in the 
1H NMR spectrum due to rotation around the C-N bond of the thiocarbamate.13C{1H} 
NMR (125 MHz, DMSO-d6, 60 °C) δ (ppm): 187.9, 176.8, 151.3, 138.8, 133.8, 129.9, 
129.1, 125.4, 123.1, 122.2, 39.1, 27.3. FTIR (ATR, cm-1): 3218.40, 3125.23, 3061.19, 
2973.40, 1746.87, 1595.52, 1545.05, 1494.26, 1406.69, 1309.81, 1202.79, 1163.67, 





TCM12 was prepared with p-fluorophenyl isothiocyanate and tBu-OH according to the 
general synthetic procedure described above. (100.1 mg, 58% yield). 1H NMR (500 
MHz, DMSO-d6, 60 °C) δ (ppm): 11.08 (s, 1H), 7.82-7.31 (m, 4H), 7.21-7.06 (m, 4H), 
5.57 (s, 2H), 1.33 (s, 9H). Broadness is observed in the 1H NMR spectrum due to rotation 


















δ (ppm): 176.8, 160.9, 158.9, 151.2, 133.6, 129.9, 125.5, 122.4, 123.1, 115.7, 39.0, 27.2. 
19F NMR (460.6 MHz, DMSO-d6, 60 °C) δ (ppm): -117.17. FTIR (ATR, cm-1): 3181.22, 
2971.41, 1747.38, 1596.49, 1537.94, 1504.04, 1393.87, 1336.73, 1275.72, 1186.62, 
1151.67, 1069.09, 1014.34, 893.61, 805.78, 684.83. HRMS m/z [M + H+] calc. 362.1226; 





TCM13 was prepared with p-trifluoromethylphenyl isothiocyanate and tBu-OH 
according to the general synthetic procedure described above. (99.9 mg, 51% yield). 1H 
NMR (500 MHz, DMSO-d6, 60 °C) δ (ppm): 11.40 (s, 1H), 7.80 (br s, 2H), 7.68 (d, J= 
8.4 Hz, 2H), 7.52 (d, J= 8.5 Hz, 2H), 7.13 (d, J= 8.5 Hz, 2H), 5.61 (s, 2H), 1.32 (s, 9H). 
Broadness is observed in the 1H NMR spectrum due to rotation around the C-N bond of 
the thiocarbamate. 13C{1H} NMR (125 MHz, DMSO-d6, 60 °C) δ (ppm): 188.1, 176.8, 
151.3, 133.5, 130.0, 126.3, 125.7, 123.4, 122.6, 39.0, 27.2. 19F NMR (460.6 MHz, 
DMSO-d6, 60 °C) δ (ppm): -60.6. FTIR (ATR, cm-1): 3185.58, 2969.83, 1746.81, 
1601.25, 1544.38, 1510.27, 1461.11, 1396.96, 1317.40, 1164.31, 1110.57, 1067.89, 





14S  was prepared with p-nitrophenyl isothiocyanate and tBu-OH according to the 
general synthetic procedure described above. (67.9l mg, 47% yield). 1H NMR (500 MHz, 
DMSO-d6, 60 °C) δ (ppm): 11.60 (s, 1H), 8.19 (d, J= 9.2 Hz, 2H), 7.85 (br s, 2H), 7.52 
(d, J= 6.7 Hz, 2H), 7.13 (d, J= 6.7 Hz, 2H), 5.59 (s, 2H), 1.32 (s, 9H). Broadness is 
observed in the 1H NMR spectrum due to rotation around the C-N bond of the 
thiocarbamate. 13C{1H} NMR (125 MHz, DMSO-d6, 60 °C) δ (ppm): 176.7, 151.3, 
143.6, 133.4, 130.1, 124.9, 122.2, 122.0, 39.0, 27.3. FTIR (ATR, cm-1): 3213.46, 
3075.42, 2969.58, 1746.40, 1595.02, 1548.26, 1507.20, 1393.72, 1333.09, 1162.50, 
1102.61, 1014.04, 893.97, 831.49, 747.03, 681.70. HRMS m/z [M + H+] calc. 389.1171; 

















CM1 was prepared with p-tolyl isocyanate and Me-OH according to the general synthetic 
procedure described above. (65 mg, 36% yield). 1H NMR (500 MHz, CDCl3) δ (ppm) 
7.42 (d, J=8.35, 2H), 7.28 (m, 2H), 7.12 (m, 4H), 6.75 (bs, 1H), 5.19 (s, 2H), 2.32 (m, 
6H). 13C NMR (125 MHz, CDCl3) δ (ppm) 169.45, 153.42, 150.59, 135.15, 133.84, 
133.13, 129.55, 121.76, 118.87, 66.22, 21.13, 20.77. IR (cm-1) 3326.83, 2922.76, 
2360.39, 2341.56, 1762.07, 1704.91, 1597.57, 1524.66, 1508.13, 1451.05, 1406.66, 
1368.20, 1314.74, 1295.48, 1191.34, 1164.63, 1049.44, 1016.58.  HRMS m/z [M + H]+ 





CM2 was prepared with p-tolyl isocyanate and Cp-OH according to the general synthetic 
procedure described above. (96 mg, 57% yield). 1H NMR (500 MHz, CDCl3) δ (ppm) 
7.42 (d, J=8.11, 2H), 7.28 (m, 2H), 7.12 (m, 4H), 6.69 (bs, 1H), 5.19 (s, 2H), 2.33 (s, 
3H), 1.87 (m, 1H), 1.19 (m, 2H), 1.05 (m, 2H). 13C NMR (125 MHz, CDCl3) δ (ppm) 
173.42, 153.39, 150.74, 135.14, 133.63, 133.13, 129.55, 129.50, 121.76, 118.76, 66.26, 
20.76, 13.03, 9.31. IR (cm-1) 3334.74, 3015.89, 2969.69, 2360.04, 2341.58, 1727.03, 
1598.07, 1526.98, 1508.92, 1448.66, 1406.77, 1381.64, 1314.94, 1295.88, 1204.23, 
1165.01, 1138.93, 1049.63, 1017.09. HRMS m/z [M + H]+ calcd. For [C19H20NO4]+ 





CM3 was prepared with p-tolyl isocyanate and iPr-OH according to the general synthetic 
procedure described above. (88 mg, 52% yield). 1H NMR (500 MHz, CDCl3) δ (ppm) 
7.44 (d, J=8.20, 2H), 7.28 (m, 2H), 7.13 (d, J=8.17, 2H), 7.10 (d, J=8.20, 2H), 6.60 (bs, 
1H), 5.20 (s, 2H), 2.83 (hept, J=7.0, 1H), 2.33 (s, 3H), 1.34 (d, J=7.0, 6H). 13C NMR 
(125 MHz, CDCl3) δ (ppm) 175.50, 153.32, 150.84, 135.08, 133.59, 133.19, 129.56, 
129.52, 121.69, 118.86, 66.29, 34.18, 20.76, 18.92. IR (cm-1) 3347.50, 2970.71, 2936.12, 




















1178.37, 1164.49, 1118.47, 1069.53, 1041.40. HRMS m/z [M + H]+ calcd. For 





CM4 was prepared with p-tolyl isocyanate and MCp-OH according to the general 
synthetic procedure described above. (87 mg, 90% yield). 1H NMR (500 MHz, CDCl3) δ 
(ppm) 7.41 (d, J=8.03, 2H), 7.28 (d, J=8.11, 2H), 7.12 (d, J=8.03, 2H), 7.08 (d, J=8.11, 
2H), 6.68 (bs, 1H), 5.18 (s, 2H), 2.33 (s, 3H), 1.45 (bs, 5H), 0.87 (m, 2H). 13C NMR (125 
MHz, CDCl3) δ (ppm) 174.55, 153.40, 150.95, 135.14, 133.51, 133.12, 129.55, 129.47, 
121.74, 118.87, 66.28, 20.76, 19.43, 18.82, 17.49. IR (cm-1) 3336.98, 3042.16, 2969.35, 
1730.15, 1696.57, 1595.43, 1525.80, 1509.41, 1454.78, 1406.03, 1325.66, 1312.51, 
1226.40, 1211.00, 1198.55, 1166.74, 1139.45, 1129.51, 1073.47, 1050.49. HRMS m/z 





CM5 was prepared with p-tolyl isocyanate and tBu-OH according to the general 
synthetic procedure described above. (108 mg, 83% yield). Spectral data is in agreement 




CM6 was prepared with p-tolyl isocyanate and Ph-OH according to the general synthetic 
procedure described above. (246 mg, 79% yield). 1H NMR (500 MHz, CDCl3) δ (ppm): 
8.23 (m, 2H), 7.67 (m, 1H), 7.54 (t, J=7.84, 2H), 7.50 (d, J=8.49, 2H), 7.29 (m, 2H), 
7.26 (d, J=8.49, 2H), 7.14 (d, J=8.16, 2H), 6.63 (bs, 1H), 5.24 (s, 2H), 2.33 (s, 3H). 
13C{1H} NMR (125 MHz, CDCl3) δ (ppm): 165.09, 150.90, 135.09, 133.86, 133.67, 
133.20, 130.20, 129.62, 129.58, 129.44, 128.60, 121.91, 118.90, 66.30, 20.77. IR (cm-1) 





















1269.13, 1235.09, 1193.82, 1162.28, 1062.11, 1015.89. HRMS m/z [M + H]+ calcd. For 
[C22H20NO4]+ 362.1392; found 362.1391. 
 
 
CM7 was prepared with p-tolyl isocyanate and Cy-OH according to the general synthetic 
procedure described above. (640 mg, 79% yield). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.41 (d, J=8.36, 2H), 7.28 (m, 2H), 7.12 (d, J=8.10, 2H), 7.09 (d, J=8.10, 2H), 6.78 (bs, 
1H), 5.18 (s, 2H), 2.59 (m, 1H), 2.33 (s, 3H), 2.09 (m, 2H), 1.85 (m, 2H), 1.73 (m, 1H), 
1.62 (m, 2H), 1.38 (m, 3H). 13C{1H} NMR (125 MHz, CDCl3) δ (ppm): 174.51, 153.45, 
150.84, 135.20, 133.60, 133.08, 129.53, 129.51, 121.74, 118.88, 66.26, 43.21, 28.96, 
25.74, 25.38, 20.77. IR (cm-1) 3357.69, 2963.07, 2934.63, 2858.40, 1740.97, 1701.30, 
1594.02, 1526.50, 1508.57, 1461.03, 1407.81, 1314.55, 1301.71, 1227.85, 1211.49, 




CM8 was prepared with p-tolyl isocyanate and Ad-OH according to the general synthetic 
procedure described above. (78 mg, 53% yield). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.43 (d, J=8.10, 2H), 7.29 (m, 2H), 7.13 (d, J=8.10, 2H), 7.07 (d, J=8.46, 2H), 6.59 (bs, 
1H), 5.20 (s, 2H), 2.33 (s, 3H), 2.11 (bs, 3H), 2.08 (d, J=2.92, 6H), 1.80 (m, 6H). 
13C{1H} NMR (125 MHz, CDCl3) δ (ppm): 176.09, 153.35, 151.09, 135.09, 133.41, 
133.18, 129.57, 129.51, 121.76, 118.81, 66.33, 41.05, 38.75, 36.46, 27.91, 20.77. IR (cm-
1) 3335.00, 2905.92, 2852.06, 2360.58, 2341.57, 1728.80, 1598.69, 1528.20, 1508.60, 
1452.54, 1407.35, 1315.33, 1217.92, 1195.02, 1165.11, 1051.05. HRMS m/z [M + H]+ 




CM9 was prepared with p-tolyl isocyanate and Nap-OH according to the general 
synthetic procedure described above. (302 mg, 71% yield). 1H NMR (500 MHz, CDCl3) 




















1H), 7.95 (d, J=8.18, 1H), 7.66 (m, 1H), 7.61 (m, 1H), 7.52 (m, 2H), 7.30 (m, 3H), 7.14 
(d, J=8.12, 2H), 6.63 (bs, 1H), 5.26 (s, 3H), 2.34 (s, 3H). 13C{1H} NMR (125 MHz, 
CDCl3) δ (ppm): 165.27, 151.00, 135.86, 135.10, 133.89, 133.21, 132.51, 131.99, 129.65, 
129.59, 129.51, 128.69, 128.43, 127.86, 126.88, 126.62, 125.44, 121.97, 118.87, 66.32, 
20.77. IR (cm-1) 3275.44, 2915.16, 1731.08, 1697.51, 1631.77, 1598.64, 1406.97, 
1353.34, 1314.70, 1281.60, 1260.92, 1218.37, 1197.35, 1129.82, 1065.23. HRMS m/z 
[M + H]+ calcd. For [C26H22NO4]+ 412.1549; found 412.1529. 
 
 
CM10 was prepared with 4-biphenylyl isocyanate and tBu-OH according to the general 
synthetic procedure described above. (161.9 mg, 56% yield). 1H NMR (500 MHz, CDCl3, 
rt) δ (ppm): 7.57-7.54 (m, 4H), 7.46-7.40 (m, 6H), 7.34-7.30 (m, 1H), 7.09-7.05 (m, 2H), 
5.21 (s, 2H), 1.36 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3, rt) δ (ppm): 176.9, 151.1, 
140.5, 137.0, 136.5, 133.4, 129.6, 128.7, 127.7, 127.0, 126.8, 119.0, 66.5, 39.1, 27.1. 
FTIR (ATR, cm-1): 3313.48, 2969.35, 1746.36, 1689.12, 1592.73, 1509.58, 1480.26, 
1405.51, 1314.67, 1195.27, 1164.21, 1112.53, 1062.14, 896.62, 828.77, 784.19, 695.36. 
HRMS m/z [M + H+] calc. 404.1862; found 404.1845.  
 
 
CM11 was prepared with phenyl isocyanate and tBu-OH according to the general 
synthetic procedure described above. (122.6 mg, 78% yield). 1H NMR (500 MHz, CDCl3, 
rt) δ (ppm): 7.41-7.37 (m, 4H), 7.32-7.28 (m, 2H), 7.08-7.03 (m, 3H), 6.66 (s, 1H), 5.18 
(s, 2H), 1.36 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3, rt) δ (ppm): 176.9, 151.1, 137.7, 
133.4, 129.5, 129.1, 123.6, 121.7, 118.7, 66.4, 39.1, 27.1. FTIR (ATR, cm-1): 3306.13, 
2970.18, 1746.49, 1693.12, 1595.72, 1529.13, 1508.09, 1395.71, 1314.76, 1195.33, 
1163.48, 1112.67, 1053.18, 1015.91, 896.33, 759.44, 694.14. HRMS m/z [M + H+] calc. 
328.1549; found 328.1553.  
 
 
CM12 was prepared with p-fluorophenyl isocyanate and tBu-OH according to the 
general synthetic procedure described above. (124.3 mg, 75% yield). 1H NMR (500 


















6.98 (m, 2H), 6.63 (br s, 1H), 5.17 (s, 2H), 1.36 (s, 9H). 13C{1H} NMR (125 MHz, 
CDCl3, rt) δ (ppm): 177.0, 151.1, 133.3, 129.6, 121.7, 120.5, 115.8, 115.6, 66.5, 39.1, 
27.1. 19F NMR (460.6 MHz, CDCl3, rt) δ (ppm): -119.4. FTIR (ATR, cm-1): 3323.18, 
2967.74, 1744.75, 1691.02, 1589.24, 1527.64, 1508.77, 1406.82, 1314.52, 1194.09, 
1164.68, 1111.68, 1062.02, 897.11, 827.95, 704.67, 695.28. HRMS m/z [M + Na+] calc. 
368.1274; found 368.1271.  
 
 
CM13 was prepared with p-trifluoromethylphenyl isocyanate and tBu-OH according to 
the general synthetic procedure described above. (171.7 mg, 90% yield). 1H NMR (500 
MHz, CDCl3, rt) δ (ppm): 7.55 (d, J= 9.1 Hz, 2H), 7.49 (d, J= 7.4 Hz, 2H), 7.41 (d, J= 
9.1 Hz, 2H), 7.07 (d, J= 7.4 Hz, 2H), 6.87 (s, 1H), 5.19 (s, 2H), 1.36 (s, 9H). 13C{1H} 
NMR (125 MHz, CDCl3, rt) δ (ppm): 177.0, 152.9, 151.2, 140.9, 133.0, 129.7, 126.3, 
125.5, 125.2, 123.1, 121.8, 118.1, 66.7, 39.1, 27.1.19F NMR (460.6 MHz, CDCl3, rt) δ 
(ppm): -62.0. FTIR (ATR, cm-1): 3328.25, 2969.45, 1745.17, 1692.87, 1589.14, 1528.07, 
1508.84, 1314.86, 1256.64, 1215.86, 1194.32, 1164.25, 1110.81, 1062.66, 895.70, 
831.85, 700.40, 694.55. HRMS m/z [M + H+] calc. 396.1423; found 396.1410.  
 
 
CM14 was prepared with p-nitrophenyl isocyanate and tBu-OH according to the general 
synthetic procedure described above. (142.6 mg, 80% yield). 1H NMR (500 MHz, CDCl3, 
rt) δ (ppm): 8.19 (d, J= 7.3 Hz, 2H), 7.54 (d, J= 7.3 Hz, 2H), 7.41 (d, J= 8.5 Hz, 2H), 
7.08 (d, J= 8.5l Hz, 2H), 5.21 (s, 2H), 1.36 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3, rt) 
δ (ppm): 177.1, 152.5, 151.3, 143.8, 143.1, 132.7, 129.8, 125.2, 121.9, 117.8, 66.1, 39.1, 
27.1. FTIR (ATR, cm-1): 3327.31, 2971.82, 1729.89, 1691.69, 1598.33, 1507.95, 
1407.53, 1335.48, 1276.09, 1216.16, 1195.58, 1164.38, 1112.36, 1051.41, 1016.71, 


















































































































































































































































































































































































































































































































































































1H (500 MHz, DMSO-d6, 60 °C), 13C (125 MHz, DMSO-d6, 60 °C), and 19F (470 MHz, 





































1H (500 MHz, DMSO-d6, 60 °C), 13C (125 MHz, DMSO-d6, 60 °C), and 19F (470 MHz, 
























































































































































































































































































































































































































































































































































































































































































1H (500 MHz, CDCl3, RT), 13C (125 MHz, CDCl3, RT), and 19F (470 MHz, CDCl3, RT) 












































1H (500 MHz, CDCl3, RT), 13C (125 MHz, CDCl3, RT), and 19F (470 MHz, CDCl3, RT) 
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